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     Mood disorders, also referred as affective disorders, belong to a group of diagnoses from the 
Diagnostic and Statistical Manual of Mental Disorder (DSM-IV TR) classification where a disturbance of 
an individual’s mood is the main feature of the disorder (Nettle et al., 2012). Among mood disturbances, 
depression and mania can be seen as opposite ends of the affective spectrum. Classically, mania refers to 
the up pole of the spectrum, where patients experience elevated and irritable mood often associated with 
distractibility, racing thoughts and agitation (e.g. a manic or hypomanic episode). In contrast, depression 
refers to the down pole, where patients suffer from low mood, loss of interest, fatigue, feelings of 
worthlessness and/or suicidal ideation (e.g. major depressive episode). Mania and depression can occur 
simultaneously (e.g. mixed episodes or bipolar disorder). Epidemiological research indicates that mood 
disorders are among the major health problems worldwide due to the high prevalence and recurrence in 
the general population, and the significant burden for individual life quality and the repercussion on 
healthcare systems and society (WHO, 2001). Today, depression is estimated to affect 350 millions 
people, with a lifetime prevalence ranging from 3 percent in Japan to 17 percent in the United states - 
most of the countries showing a prevalence between 8 to 12 percent in the general population - (WHO, 
2012). On the other side, the occurrence of manic episodes during a lifetime has been estimated to only 1 
to 2 percent (Soldani et al., 2005; Merikangas et al., 2004). Moreover, co-morbidity between mood 
disorders and somatic or other psychiatric diseases is often observed in patients. For instance, depression 
frequently co-occurs with anxiety or neuropathic pain, and increases the risk for cardio-vascular problems 
(Kessler et al., 1996; Bair et al., 2003). In addition, major depression represents a considerable risk factor 
for suicide, which has been estimated to lead to more than 1 million deaths every year (WHO, 2012). By 
2030, major depression is expected to become the largest contributor to disease burden (WHO, 2008). 
 
 
 
I – The pathophysiology of mood disorders 
 
Neurotransmitters and circuits in mood disorders: The etiology of mood disorders is still poorly 
understood, and the complexity and heterogeneity of the diseases hamper adequate diagnosis and 
treatment (Phillips et al., 2013; Zajecka et al., 2013). Up to date, three principal neurotransmitters have 
been associated to the pathophysiology and treatment of mood disorders (Krishnan et al., 2008). They are 
dopamine (DA), noradrenaline (NA) and serotonin (5-HT), the so-called monoamine neurotransmitter 
systems, and often act in concert to regulate mood. The mesolimbic dopamine pathway comprises 
neurons projecting from the ventral tegmental area (VTA) in the brainstem to the nucleus accumbens 
(NAc) in the ventral striatum, and is believed to be involved in behavioral expressions like pleasure, 
euphoria, delusions or hallucinations. The mesocortical dopamine pathway projects from the VTA to the 
prefrontal cortex, which is mostly implicated in mediating cognitive and affective functions. 
Noradrenaline has both ascending and descending pathways. The ascending pathway projects from the 
locus coeruleus in the brainstem to multiple brain regions including the amydala, thalamus, striatum, 
hypothalamus, hippocampus and prefrontal cortex. The ascending noradrenergic projections are mainly 
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involved in the regulation of attention, decision-making, arousal and the fight or flight response. 
Serotonin, like noradrenaline, has both ascending and descending projections. The ascending pathway 
arises from the raphe nucleus in the brainstem, and projects to the amydala, thalamus, striatum, 
hypothalamus, hippocampus and prefrontal cortex. In the brain, serotonin is mostly involved in sleep, 
anxiety, appetite and mood. However, clean-cut evidences for changes of monoamine levels in the brain 
of mood disorders patients are still lacking.  
 
Pharmacological treatments: Although there is no clear evidence that dysregulation of the monoamine 
neurotransmitter systems significantly contributes to the etiology of mood disorders, most antidepressant 
drugs mainly act via the monoaminergic pathways by increasing the levels of the neurotransmitters in the 
synaptic cleft, either by blocking the reuptake or by inhibiting the breakdown of the neurotransmitters. 
Tricyclic antidepressants (TCAs) for example, the first class of psychotropic drugs to be clinically used at 
a large scale, mainly act by blocking serotonin and norepinephrine transporters (SERT and NAT). The 
downside of these types of antidepressants is the relatively high toxicity and the numerous side effects. 
Later, more specific reuptake blockers have been developed, like the selective serotonin reuptake 
inhibitors (SSRIs), the serotonin-norepinephrine reuptake inhibitors (SNRIs) and the norepinephrine 
reuptake inhibitors (NARIs) that more specifically act on their respective target transporters and generally 
have fewer side effects. Another way to increase monoaminergic signaling is by inhibiting the breakdown 
of the neurotransmitters in the synaptic cleft. For example, the monoamine oxidase inhibitors (MAOIs) 
have shown to reduce the breakdown of monoamines, by inhibiting the monoamine oxidase enzyme 
family. Thus, MAOIs enhance serotonergic, noradrenergic and dopaminergic transmission.  
However, all currently available antidepressants encounter notable limitations including a delayed 
therapeutic effict (from weeks to months), a low response rate (only two third of the patients respond 
well) and a high relapse rate after treatment termination (Trivedi et al., 2006). 
 
Stress, neurotrophins and depression: Stress has been proposed as a major risk factor to develop 
affective disorders. Stressful stimuli generally activate the hypothalamus resulting in the production of 
corticotropin-releasing factor (CRF), which in turn stimulates the release of adenocorticotropic hormone 
(ACTH) from the pituitary. Finally, ACTH causes the secretion of glucocorticoids, i.e. cortisol 
(corticosterone in rodents), from the adrenal gland. Cortisol in turn terminated the hormonal stress 
response by inhibiting the CRF release from the hypothalamus. However, under pathological conditions, 
such as chronic or excessive stress exposure, the HPA axis fails to exert this negative feedback, resulting 
in abnormally high glucocorticoid levels. Thus, chronic hypercortisolemia can significantly impact on 
structural and functional plasticity in various brain areas (Berton et al., 2006). In particular, prolonged 
stress exposure has been shown to affect the production of growth factors, and among many candidates, 
brain-derived neurotrophic factor (BDNF) has been reported as a key-role player in the deleterious effects 
of stress on the brain (see Figure 1). BDNF is a small neurotrophin secreted by neuronal and glial cells in 
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various regions of the brain, especially in the areas controlling mood and emotions. Upon binding to its 
tropomyosin-related kinase receptor (TrkB), BDNF induces proliferation, differentiation, survival and 
neurite extension, which are essential process in the normal development and functioning of brain cells. 
However, under situations of chronic stress, BDNF gene expression can be repressed. The resulting 
decrease in BDNF protein has been suspected to cause cell loss and synaptic dysfunction in the 
hippocampus and prefrontal cortex of depressed patients (Duman et al., 2012). Antidepressant treatments, 
via monoamine-related signal transduction cascades, have been shown to increase BDNF and other 
trophic factors, and potentially restore neuronal loss and atrophy in hippocampal and cortical areas via 
BDNF (Castren et al., 2008). 
 
 
II – BDNF/TrkB signaling 
 
Neurotrophins in the brain: Neurotrophins are a family of small-secreted proteins that play a key role in 
the development and maintenance of the vertebrate nervous system (Chao, 2003). To mediate their 
effects, neurotrophins can bind to two distinct classes of receptors, displaying opposite effects. The high 
affinity interaction with the “tropomyosin-related kinase” receptor family (Trks) is usually associated 
with cell survival, differentiation and synaptic plasticity, whereas the low affinity interaction with the p75 
(p75NTR) promotes proteolysis and apoptosis (Lu et al., 2005). The neurotrophin tyrosine kinase receptor 
2 (NTRK2), also known as TrkB, is specifically activated by several neurotrophins including BDNF, 
neurotrophin 3 (NT 3) and neurotrophin 4/5 (NT 4/5), thereby exerting their trophic effects (Klein et al., 
1991; Klein et al., 1992; Soppet et al., 1991). Among all the neurotrophins, the interaction of BDNF with 
TrkB has been characterized most thoroughly. The expression of BDNF, as well as of TrkB, is very 
abundant in the cortico-limbic structures of the brain and both are also present at lower levels in different 
peripheral tissues (Maisonpierre et al., 1990; Pruunsild et al., 2007). BDNF/TrkB signaling has been 
reported as critical in various physiological processes such as learning, memory and reward. In particular, 
BDNF is required for the maturation, differentiation and survival of neural progenitor cells, e.g. 
neurogenesis, in the dentate gyrus (DG) of the hippocampus. Abnormal BDNF-mediated activation of 
TrkB has been reported in various neurological and psychiatric disorders (Pezet and Malcangio, 2004). 
 
BDNF-mediated activation of TrkB: The activation of TrkB by BDNF generally follows the common 
pattern associated with tyrosine kinase receptor activation (Friedman and Greene, 1999). Neurotrophins 
exist preferentially as homodimer complexes, and bind to the extracellular interface of a TrkB monomer 
resulting in receptor dimerisation (Jing et al., 1992). The dimerisation increases the catalytic activity of 
the intracellular domain of the receptor enabling the phosphorylation of tyrosine residues inside the 
activation loop (tyrosine Y701, Y705 and Y706) and subsequently the autophosphorylation of tyrosine 
residues situated outside of the activation loop (tyrosine Y515 and Y816) (Cunningham and Greene, 
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1998).  Then, activation and recruitment of partner proteins and adaptators to the different tyrosine sites 
will lead to activation of three main intracellular signaling pathways that are strongly interconnected 
(Huang and Reichardt, 2003). Briefly, phosphorylation of tyrosine Y515 activates 1) the Ras-mitogen-
activated protein kinase (MAPK) signaling cascade, which promotes neuronal differentiation and growth, 
and 2) the phosphatidylinositol 3-kinase (PI3-K) signaling cascade, which promotes neuronal survival and 
growth. Phosphorylation of tyrosine Y816 activates 3) the phospholipase Cγ (PLCγ) pathway generally 
associated with synaptic plasticity and neurotransmission (Minichiello, 2009). The neurotrophin/Trk 
complex is internalized by endocytosis and the intracellular domain of the receptor, present on the outside 
of the endosome, is still phosphorylated and susceptible to binding of signaling molecules (Howe et al., 
2001). However, the exact mechanism underlying TrkB internalization and recycling is still poorly 
understood. In addition, different alternative TrkB mRNA splice variants can lead to the translation of 
different TrkB isoforms including two truncated forms (Middlemas et al., 1991). It has been described 
that the two truncated forms of TrkB (TrkB-T1 and TrkB-T2) lacking the intrinsic tyrosine kinase 
activity, were able to inhibit full-length TrkB (TrkB-FL) signaling via the binding of a truncated form 
with a full form (Dorsey et al., 2006). 
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Figure 1: Schematic representation of epigenetic and neuroplastic mechanisms in the hippocampus of 
depressed patients and antidepressant action.  
 
(A) Stimulation of hippocampal pyramidal neurons by glutamate or monoaminergic neurotransmitters, possibly via 
the activation of cAMP responsive element binding (CREB), is critical for the regulation of BDNF expression. In 
addition, epigenetic mechanisms control the expression of BDNF, and an appropriate epigenetic programming 
during development and adulthood ensures an adequate expression and function of BDNF. (B) Chronic stress 
exposure, as well as genetic variations, can interfere with epigenetic regulation and reduce BDNF-mediated 
plasticity in the hippocampus. (C) Interestingly, it has been shown that antidepressant treatments and physical 
activity can reverse epigenetic alterations and restore a normal expression of BDNF and enhance neuroplasticity in 
hippocampal neurons. Adapted from Berton et al (2006). 
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III – Epigenetic regulation in mood disorders 
 
Definition and basic principles: Epigenetics refers to mechanisms that regulate gene expression 
independently of the DNA sequence. Hence, the modulation of gene expression by epigenetic 
mechanisms is essential during development, where a “cellular memory” is created enabling an 
appropriate pattern of gene expression and a specific cellular phenotype (Probst et al., 2009). Diverse 
stimuli such as life events, behavioral experience or circadian rhythms can induce cellular responses that 
involve epigenetic remodeling, and it is believed that stable epigenetic imprints at particular genetic loci 
may shape neuronal plasticity and thereby influence behavior. The two best-described molecular 
mechanisms of epigenetic regulation are DNA methylation and post-translational histone modifications in 
the cell nucleus.  
 
DNA methylation is the process of chemical addition of a methyl group to the carbon atom at position 5 
of a cytosine residue, which typically occurs at CpG nucleotides (i.e. where a cytosine nucleotide occurs 
next to a guanine nucleotide in the linear sequence of bases, separated by a phosphate). In general, DNA 
methylation in promoter regions disables transcription factors to bind to their recognition sites, thereby 
silencing gene expression. DNA methylation needs the recruitment of specific enzymes called DNA 
methyltransferases (DNMTs), which mediate the addition of the methyl group on cytosine residues. In 
addition to DNMTs, some proteins are able to interact with methyl-CpG sites and increase the repressive 
potential of methylated DNA. These molecules can carry a methyl-CpG binding domain (MBD proteins) 
or other specific domains that recognise methylated DNA. Several pathways leading to DNA 
demethylation have been proposed involving the growth arrest and DNA-damage-inducible protein 45 
alpha (GADD45a) (Barreto et al., 2007). In addition, ten-eleven-translocation (TET) enzymes can oxidize 
the 5-methylcytosine into a 5-hydroxymethylcytosine, which can be further oxidized into 5-
formylcytosine and 5-carboxylcytosine (Tahiliani et al., 2009; Ito et al., 2011).  
 
In the eukaryotic nucleus, DNA is compacted and wrapped around histone and non-histone proteins to 
form a dynamic structure called chromatin. The nucleosome consists of an octamer of core histones (two 
copies of histone H2A, H2B, H3 and H4) around which DNA is wounded, and represents the basic 
repeated unit of chromatin. Two types of chromatin can be distinguished based upon their condensation 
states. Heterochromatin is inactive and condensed, which means that transcription factors are not able to 
approach and recognise their specific DNA-binding sites to activate gene transcription. On the other hand, 
euchromatin reflects an “open” state of chromatin, and is associated with active transcription. Chromatin 
remodelling enables the transition between a permissive and a repressive state, and vice versa, enabling a 
temporal and spatial modulation of gene expression. Post-translational changes encompass covalent 
modification of histones at distinct amino acid residues on their amino-terminal tails, including lysine 
acetylation, methylation, SUMOylation and ubiquitinylation; arginine methylation; serine 
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phosphorylation and proline isomerisation (Berger et al., 2007). The effect of these chemical alterations 
on gene transcription depends on the type of histone modification but also on the amino acid residue 
being modified. Generally, histone acetylation is associated with euchromatin, while histone methylation 
is linked to heterochromatin. The enzymes responsible for acetylation or deacetylation are histone 
acetyltransferases (HATs) and histone deacetylases (HDACs), respectively. Regarding methylation, 
histone methyltransferases (HMTs) catalyse the addition of the methyl group, whereas histone 
demethylases (HDMs) reverse the methylated state. Interestingly, it has been shown that HDACs and 
HMTs were associated with MBDs and act as co-repressor molecules to form complexes that further 
repress gene transcription (Jones et al., 1998). All these findings support a link between DNA methylation 
and chromatin remodelling in transcriptional regulation. 
 
Clinical and preclinical evidence of epigenetic mechanisms in mood disorders: The episodic nature of 
mood disorders suggests that they are unlikely to be pure genetic diseases, which generally are 
responsible for the genesis of life-long illnesses. Genome-wide association studies have revealed 
hundreds of potential candidates for severe mental illness, but the effective contribution of each 
individual gene appears to be very small. Epidemiological evidence also links environmental factors, 
especially early life events, with an increased risk for mood disorders (Hammen et al., 2005; Kessler et 
al., 1997). Hence, the notion of gene x environment (GxE) interaction has emerged as a prevalent theory 
to explain the inter-individual variations underlying susceptibility and resilience to mental disorders. As a 
possible mediator of GxE interactions, epigenetic reprogramming during brain development may be of 
critical importance. A multitude of clinical studies have investigated epigenetic signatures in blood-
derived lymphocytes and post-mortem brain tissues from mood disorder patients. For example, post-
mortem brain analysis revealed a decreased expression of G9a histone methyltransferase, HDAC2 and 
H3K9 methylation, all pointing toward a permissive state of chromatin, in the NAc of depressed patients 
(Covington et al., 2009; Covington et al., 2011). In the periphery, mRNA profiling in white blood cells 
revealed a decrease of HDAC2 and HDAC5 in the depressive state of major depressive disorder (MDD), 
and a decrease of HDAC6 and HDAC8 in the depressive state of bipolar disorder (BPD) (Hobara et al., 
2010). Interestingly, the alterations at HDAC2 and HDAC5 were normalized in the remitted state. 
Similarly, the mRNA expression in peripheral white blood cells of the HDACs Sirt1, Sirt2 and Sirt6 was 
decreased in the depressed state of MDD and BPD, whereas no differences were observed in the remitted 
state (Abe et al., 2011). In addition, a recent study showed that monozygotic twins affected with MDD 
have greater variance in methylation in white blood cells as compared to their unaffected siblings (Byrne 
et al., 2013). Next to the above-mentioned clinical evidence, various animal studies have brought further 
support for the involvement of epigenetics in the vulnerability to stress and mood disorders. Meaney and 
colleagues were the first to demonstrate a mechanism of epigenetic regulation for stress vulnerability in 
rodents. They found that variation in maternal care could regulate the expression of the glucocorticoid 
receptor (GR) in the hippocampus by inducing changes in DNA methylation and histone acetylation, an 
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effect that seemed to be stable into adulthood. Offspring who received higher levels of maternal care 
showed less anxiety-like behavior and better recovery from stressful situations (Weaver et al., 2004). This 
result was the first to indicate the importance of early life events in epigenetic programming and 
susceptibility for mood disorders later in life. Moreover, using a model of adult stressful life events, 
Nestler and colleagues showed that an inbred population of mice could be separated into susceptible and 
unsusceptible subpopulations after exposure to social defeat stress (Krishnan et al., 2007), and that the 
molecular signature underlying the resistance to stress seems to reside in epigenetic regulations. Direct 
evidence for a possible role of epigenetic mechanisms in the development of mood disorders is further 
supported by the work on the Circadian Locomotor Output Cycles Kaput (Clock) gene. Clock has been 
shown to display histone acetyl transferase properties, and is critical in regulating circadian rhythms 
(Nakahata et al., 2008). Interestingly, mutations in the Clock gene resulted in manic-like behavior in mice 
(Roybal et al., 2007), and strongly support the implication of circadian rhythms and associated epigenetic 
regulations in the pathophysiology of BPD (Milhiet el al., 2011). Altogether, clinical and preclinical 
studies suggest that the interplay between life events and genetic variation might play a critical role in 
epigenetic reprogramming, and may be one of the most plausible explanations underlying differential 
susceptibility towards mood disorders. 
 
Epigenetic mechanisms in the treatment of mood disorders: Antidepressants are known to increase 
levels of monoamine neurotransmitters at the synapse, and, after prolonged exposure, to induce 
neuroplastic changes. Hence, the modulation of monoamine-related signaling cascades might trigger 
various cellular events involving epigenetic remodeling and subsequent gene transcription. Fluoxetine, 
one of the most prescribed SSRI antidepressants, was shown to directly induce the expression of MBDs 
(MeCP2 and MBD2) in adult rat brain (Cassel et al., 2006). In addition, chronic treatment with fluoxetine 
could significantly upregulate H3 acetylation at the BDNF gene in the hippocampus of a mouse model of 
depression (Onishchenko et al., 2008).  Similarly, escitalopram - another SSRI antidepressant - could 
decrease DNMT expression and reduce the excessive DNA methylation at the P11 gene in the frontal 
cortex of the Flinders Sensitive Line genetic rodent model of depression (Melas et al., 2011). Imipramine, 
a TCA, was shown to reverse the decreased H3 acetylation levels in the hippocampus induced by chronic 
stress in rodents (Covington et al., 2011; Hollis et al., 2011; Hollis et al., 2010). Furthermore, imipramine 
treatment reversed the large majority of histone methylation changes in the NAc induced by social defeat 
stress in mice (Wilkinson et al., 2009). Additional experiments further supported the notion that 
imipramine exerts its therapeutic effects by increasing BDNF levels, at least partly through 
downregulation of HDAC5 (Tsankova et al., 2006). Moreover, electroconvulsive shock therapy (ECT), 
still the most effective treatment for refractory depressed patients, has been shown to increase H3 
acetylation at the BDNF gene in naïve rats (Tsankova et al., 2004). Regarding mood stabilizers, valproate, 
an effective treatment for mania and bipolar disorders, was shown to act as an HDAC inhibitor (Phiel et 
al., 2001). Interestingly, administration of HDAC inhibitors directly into the NAc exerted antidepressant 
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properties in mice (Covington et al., 2009). This same study showed that HDAC inhibiton produced a 
similar pattern of gene expression in the NAc as compared to fluoxetine (Covington et al., 2009). 
Moreover, infusion of DNMT inhibitors such as RG108 and zebularine into the NAc could reverse the 
depressive-like behaviors induced by chronic stress in mice (LaPlant et al., 2010). 
Altogether, the current literature indicates that epigenetic remodeling might be necessary for the 
therapeutic action of antidepressants. 
 
 
IV – Aim and outline of the thesis 
 
     The research presented in this thesis aims to explore the role of BDNF signaling and its downstream 
epigenetic regulations in the pathophysiology and treatment of mood disorders.  
 
First of all, an overview of current literature is provided in the first part of this dissertation. Chapter 2 
gives an overview about epigenetic regulations at the BDNF gene in psychiatric phenotypes, and 
discusses potential implications for psychiatric neuroscience and development of novel psychotropic 
drugs. Further, Chapter 3 summarizes the literature about the impairment of neuroplasticity in depression 
and potential implications for the development of novel antidepressant drugs. In particular, a detailed 
overview of the different trophic factors (including BDNF) and intracellular signaling pathways 
implicated in the pathophysiology of depression is presented. In addition, the neurotrophic actions of 
current antidepressant medications are reviewed. Finally, Chapter 4 describes the upregulation of TrkB 
signaling in brain disorders and proposes different methods and approaches to model BDNF/TrkB 
interaction and develop novel TrkB modulators. 
 
Further, the original research of this thesis explored the involvement of BDNF/TrkB signaling and 
epigenetic regulations in the pathophysiology and treatments of mood disorders. Chapter 5 provides 
further insights into the epigenetic and neuroplastic regulations of a novel TrkB inhibitor cyclotraxin-B. 
In Chapter 6, the effect of developmental exposure to fluoxetine was investigated using a model of 
prenatal stress in rats. In particular, the effects of maternal fluoxetine on affective behavior and epigenetic 
regulations at BDNF/TrkB signaling were addressed. Chapter 7 brings further evidence on the 
requirement of TrkB in the anxiolytic effects of the new generation antidepressant agomelatine in a 
transgenic mouse model of depression, while Chapter 8 focusses on the effects of agomelatine in a mouse 
model of hyperactivity and manic-like behavior. More specifically, the ability of agomelatine to restore 
stress-induced alterations at histone modifications, intracellular signaling cascades and plasticity-related 
gene expression was investigated.  
 
Finally, Chapter 9 summarizes and discusses the main findings of this dissertation, while also providing 
future directions and perspectives. 
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Abstract 
 
 
 
     Abnormal brain-derived neurotrophic factor (BDNF) signaling seems to play a central role in the 
course and development of various neurological and psychiatric disorders. In addition, positive effects of 
psychotropic drugs are known to activate BDNF-mediated signaling. Although the BDNF gene has been 
associated with several diseases, molecular mechanisms other then functional genetic variations can 
impact on the regulation of BDNF gene expression and lead to disturbed BDNF signaling and associated 
pathology. Thus, epigenetic modifications, representing key mechanisms by which environmental factors 
induce enduring changes in gene expression, are suspected to participate in the onset of various 
psychiatric disorders. More specifically, various environmental factors, particularly when occurring 
during development, have been claimed to produce long-lasting epigenetic changes at the BDNF gene, 
thereby affecting availability and function of the BDNF protein. Such stabile imprints on the BDNF gene 
might explain, at least in part, the delayed efficacy of treatments as well as the high degree of relapses 
observed in psychiatric disorders. Moreover, BDNF gene has a complex structure displaying differential 
exon regulation and usage, suggesting a subcellular- and brain region-specific distribution. As such, 
developing drugs that modify epigenetic regulation at specific BDNF exons represents a promising 
strategy for the treatment of psychiatric disorders. Here, we present an overview of the current literature 
on epigenetic modifications at the BDNF locus in psychiatric disorders and related animal models. 
 
 
 
Keywords: BDNF gene, environmental factors, epigenetic, psychiatric disorders, treatments 
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I – Introduction  
 
     BDNF is a small secreted protein that is a member of the neurotrophin family of growth factors1. Its 
action depends on two distinct receptors differing in their respective downstream signaling pathways. The 
p75 neurotrophin receptor is activated by all neurotrophins and, upon activation, has various effects, 
which are dependent on e.g. the ligand bound to it and the type of cell it is expressed in2, 3. Further, its 
action depends on the presence of the tropomyosin-related kinase receptor B (TrkB), the other receptor 
for BDNF, and neurotrophin-4/54. BDNF-dependent activation of TrkB is essential for the proper 
development of the vertebrate nervous system and impairment of its associated signaling pathways is 
likely to be at the origin of many neurological and psychiatric disorders5-7. Activation and subsequent 
phosphorylation of the different tyrosine residues in the catalytic domain of the TrkB receptor has been 
associated with at least three intracellular signaling cascades, which are widely interconnected8. Briefly, 
the mitogen-activated protein kinase (MAPK) pathway is primarily implicated in neuronal differentiation 
and neurite outgrowth, the phosphoinositide-3 kinase (PI3K) pathway mainly enables cell survival, and 
the phospholipase-gamma (PLC-γ) pathway is particularly involved in synaptic plasticity and facilitates 
neurotransmission9-12. As such, BDNF plays an important role in normal neural development13. BDNF is 
highly expressed in limbic structures and cerebral cortex, and is important for long-term potentiation 
(LTP) and neurogenesis, making this trophic factor a key player in learning and memory as well as in 
reward-related processes14-16.  BDNF is meticulously regulated in the brain and modifications of neuronal 
BDNF expression or release are thought to induce abnormal functioning of some brain areas17, 18. Recent 
interest has been directed to the epigenetic regulation of BDNF that mediates the effects of environmental 
factors on the BDNF gene resulting in enduring changes of its expression19. Epigenetics refers to 
processes such as DNA methylation, histone acetylation or nucleosome sliding, which are dynamic events 
controlling the expression of genes without affecting the DNA sequence (for reviews, see20, 21).  
    This review gives an overview of recent findings on epigenetic mechanisms associated with BDNF 
gene regulation in psychiatric disorders and animal models. The origin of such modifications, i.e. risk 
factors such as neurodevelopmental stress exposure, in these pathologies is not under focus here because 
it has already been the matter of an extensive recent review elsewhere19. Our objective here is to provide 
an overview of new insights into the potential role of the epigenetic regulation of BDNF in the 
pathophysiology of these disorders. Further, we will discuss some pharmacological perspectives, focusing 
on drugs that can modify BDNF gene expression by affecting epigenetic regulation. 
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II – Regulation of the BDNF gene expression 
 
The BDNF gene: BDNF has a complex gene structure, which has been documented and revisited 
extensively22-28. A number of studies have presented substantial similarities in rodents and humans 
(Figure 1). Briefly, the human BDNF gene consists of several untranslated 5’ exons with independent 
promoters. These can be connected to a 3’ coding exon to form a bipartite or tripartite transcript providing 
different splice variants of BDNF mRNA24. The 3’ coding exon (exon IX) contains the sequence that 
codes for the pro-BDNF protein. In addition, the 3’ untranslated region (UTR) of exon IX is composed of 
two alternative polyadenylation (polyA) sites, so as to generate one short splice variant and one long 
splice variant22. The use of distinct BDNF mRNA splice variants differing either by the 5’ or 3’ extremity 
allows for temporal and spatial regulation of BDNF expression which appears to be critical in the 
modulation of synaptic plasticity and spine development in dendrites29-31. This temporo-spatial regulation 
depends largely on the various promoters of the BDNF gene, which are differentially targeted in response 
to diverse stimuli and signaling events32-34. In addition to regulation at the promoter level, BDNF gene 
expression is also controlled at the posttranscriptional level. In particular, all Bdnf mRNAs are translated 
into pro-BDNF and are further cleaved into mature BDNF by several mechanisms35. The balance between 
pro-BDNF and mature BDNF levels in the synaptic cleft is controlled by tissue plasminogen activator 
(tPA) and is essential for neuronal plasticity36. While pro-BDNF binds specifically to p75 and primarily 
promotes cell death and long-term depression (LTD), mature BDNF binds more readily to TrkB, 
particularly enabling long-term potentiation and cell survival37, 38. Therefore, the balance between pro- 
and mature BDNF on the one hand, and between the p75 and TrkB receptors on the other, is of critical 
importance in determining the functional characteristics of the BDNF signal39. Moreover, a common 
single nucleotide polymorphism (SNP) within the BDNF gene causes a valine (Val) to methionine (Met) 
substitution at codon 66 of the prodomain. This SNP is thought to alter BDNF mRNA and protein 
trafficking, and has been widely implicated in psychiatric disorders40-43. 
 
Epigenetic control of BDNF gene expression: Various epigenetic mechanisms have been associated with 
repression or activation of the rodent Bdnf gene (Figure 2). For example, the methyl-CpG binding protein 
2 (MeCP2) is known for its repression of Bdnf gene transcription44, 45. MeCP2 binds selectively to 
methylated DNA at the rat’s Bdnf promoter IV, where it is associated with the co-repressor molecules 
Sin3a and histone deacetylase 1 (HDAC1) to form a complex that maintains the repressed state of the 
Bdnf gene46. It has been shown that increased Bdnf transcription after membrane depolarization in 
cultured neurons correlates with the phosphorylation and dissociation of MeCP2 from Bdnf promoter 
IV46, 47. Other proteins such as the Growth arrest and DNA-damage-inducible protein b (Gadd45b) have 
been shown to be required for activity-induced DNA demethylation at Bdnf promoter IX, which is 
associated with increased hippocampal neurogenesis in mice48. In addition to changes in DNA-
methylation, post-translational modifications of histones at distinct amino acid residues on their amino-
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terminal tails have been reported at the Bdnf gene. Some of these covalent modifications have been shown 
to modulate Bdnf gene expression. For example, methylation at lysine (K) 27 on histone H3 (H3K27) is 
usually associated with transcriptional repression, whereas acetylation on histone H3 and H4 is associated 
with transcriptional activation49. Rodent studies have revealed that some promoters are preferentially 
targeted by epigenetic regulation. This is notably the case for promoter IV, that contains a specific 
binding site for the cyclic-AMP responsive element binding protein (CREB)32, 50, 51. CREB is known to 
have a specific binding domain for CREB binding protein (CBP), which plays a central role in the 
regulation of gene activity and influences chromatin remodeling due to its histone acetyl-transferase 
(HAT) properties52. 
 
 
III – BDNF, epigenetics and psychiatric disorders 
 
     A prevailing current theory posits that multiple genetic and environmental factors contribute to the 
development of most neurological and psychiatric disorders54, 55. In particular, diverse environmental 
stressors have been shown to modulate BDNF availability and function in rodents56-58. Importantly, stress-
induced changes in Bdnf mRNA expression have been shown to depend upon the timing, type, duration 
and frequency of the stressor59. Indeed, some risk factors may cause persisting changes in BDNF gene 
regulation, underlying a lasting epigenetic imprint on the genome, thereby increasing susceptibility to 
psychopathology. In this section, the epigenetic regulation of BDNF in psychiatric disorders and related 
phenotypes will be discussed. 
 
Epigenetic regulation of BDNF in learning and memory: BDNF has been shown to mediate synaptic 
plasticity, known to be critically important in learning and memory processes60, in particular for the 
consolidation and extinction of fear memory61-63. It has been shown that the BDNF val66met 
polymorphism affects memory and extinction learning in rodents and humans, which may have its 
importance in anxiety-related behavior41, 42, 64. Recent data about BDNF protein levels led to the 
suggestion that this trophic factor is required for consolidation and extinction of fear memory in the 
prelimbic cortex as well as in the amygdala in rodents65, 66. Expression of Bdnf exons I and III was 
significantly upregulated in the amygdala of fear-conditioned rats, whereas extinction of conditioned fear 
in the prefrontal cortex (PFC) was accompanied by a significant increase in Bdnf exons I and IV67, 68. 
Interestingly, Bdnf exon IV upregulation was associated with hyperacetylation of histone H4 near its 
concurrent promoter, suggesting a relationship between long-lasting extinction learning and histone 
modifications at Bdnf gene promoters in the PFC68. Another study has shown that consolidation of fear 
learning was associated with a transcriptional upregulation of Bdnf exon IV, whereas context exposure 
alone leads to increased levels of Bdnf exons I and VI69. These data suggest differential exon usage in the 
hippocampus in response to distinct cognitive tasks such as learning a novel environment versus 
Chapter II 
	  28	  
associating an emotion with that same environment. Interestingly, increased levels of Bdnf exon IV-
containing transcripts correlated with the decrease in DNA methylation at the corresponding promoter, 
which was directly linked to an overall increase in total Bdnf mRNA (exon IX) in the hippocampus during 
fear memory consolidation69. Moreover, there is increasing evidence that DNA methylation at the Bdnf 
gene represents a crucial mechanism that regulates associated changes in hippocampal synaptic 
plasticity70. Regarding recognition memory, it has been shown that performance in the novel object 
recognition task correlates with increased Bdnf expression and methylation state at the Bdnf promoter I in 
the hippocampus of mice71. Nevertheless, although epigenetic regulation of the Bdnf gene seems to play a 
crucial role in the dynamic process of learning, memory and related pathological disorders, compelling 
evidence from human studies to support findings observed in animal models is lacking. 
 
Epigenetic regulation of BDNF in depression: Some studies on human patients suffering from major 
depression have shown reduced hippocampal volumes72 and decreased circulating levels of BDNF, which 
normalize after chronic antidepressant treatment73, 74. Post-mortem analyses have shown decreased BDNF 
levels in the brains of suicide victims and depressed patients75, 76. Regarding rodent models of depression, 
mounting evidence indicates that BDNF is implicated in stress-induced hippocampal alterations77, 78. 
Reduced levels of BDNF have been shown to contribute to impaired neuronal differentiation in the 
dentate gyrus and depression-related behavior in rodents79. In contrast, infusion of BDNF into the 
hippocampus has antidepressant properties in rodent models of depression80. In addition, antidepressants 
such as selective serotonin reuptake inhibitors (SSRIs) are known to activate BDNF-mediated signaling 
and reverse neuronal atrophy and cell loss induced by chronic stress in rodents, whereas Bdnf +/- mice 
showed an impaired response to antidepressants81, 82. Altogether, these findings have spurred researchers 
to further investigate the involvement of chromatin remodeling at the BDNF gene in depression and 
antidepressant action. Indeed, in chronic social defeat stress, a rodent model of depression, levels of Bdnf 
mRNA IV and V were decreased in the hippocampus of stressed mice83. Interestingly, this robust 
decrease in expression was associated with long-lasting H3K27 hypermethylation at the corresponding 
promoters. A similar study, using perinatal exposure to methylmercury in mice as a model for depressive-
like behavior has demonstrated that this developmental exposure was associated with long-lasting 
changes at Bdnf promoter IV in the hippocampus84. Onishchenko and colleagues84 showed that the 
observed decrease in hippocampal Bdnf mRNA levels was mediated by H3K27 hypermethylation and H3 
hypoacetylation at this specific promoter.  
     Taken together, these studies underscore the importance of BDNF gene expression in the 
pathophysiology of depression and in the mechanisms of antidepressant treatments. Further, animal 
models of stress and depression induce specific epigenetic changes at the Bdnf gene within the 
hippocampus, possibly contributing to the onset of associated behavioral disorders. However the role of 
epigenetic modifications of the BDNF gene in depressed patients has yet to be investigated.  
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Epigenetic regulation of BDNF in addiction: Both BDNF and the mesolimbic dopamine system are 
known to play a central role in addiction87-89. In the mesolimbic system, dopaminergic neurons in the 
ventral tegmental area (VTA) project to the nucleus accumbens (NAc). In this respect, BDNF has been 
shown to mediate long-term neuronal adaptation in pathological conditions by controlling dopamine 
receptor expression, thereby inducing behavioral sensitization90. Changes in Bdnf mRNA and protein 
have been examined in multiple brain regions such as the VTA and NAc following administration and/or 
withdrawal of many addictive compounds91-93. A recent study found that acute cocaine administration 
induces a transient increase in BDNF protein levels and activates TrkB-mediated signaling in the NAc of 
rats94. Furthermore, BDNF infusions in the NAc are known to increase cocaine self-administration as well 
as relapse to cocaine seeking in withdrawal94. These authors suggest that BDNF release during cocaine 
use is important for the development and persistence of addictive behavior. In the VTA, an increase of 
BDNF induces a transition to an opiate-dependent motivational state in naïve rats95. Previous findings 
showed that changes in BDNF levels following cocaine administration are persistent96, suggesting that 
epigenetic modifications could be implicated in drug-induced modifications in gene expression. However, 
only few studies have focused on epigenetic regulation at the BDNF gene in relation to addictive 
disorders. A recent study has revealed that chronic administration of cocaine increases H3 acetylation at 
Bdnf promoter II in the rat striatum, whereas no significant changes have been observed in H4 acetylation 
at the same promoter97. Interestingly, this hyperacetylation significantly increased after one week of 
withdrawal from cocaine. However the increase in H3 acetylation did not immediately correlate with an 
increase in Bdnf mRNA and protein levels, which progressively increased during cocaine withdrawal96. 
Similar results have shown that chronic administration of cocaine in rats caused a robust induction of H3, 
but not H4, acetylation at Bdnf promoters II and III in the NAc shell, which was reverted by HDAC4 
overexpression in this same region102. Moreover, cocaine self-administration increased acetylation of 
histone H3 and reduced MeCP2 occupancy at Bdnf promoter IV in the PFC of rats, leading to decreased 
levels of Bdnf exon IV mRNA103. Another study has focused on the effects of cocaine abstinence on the 
endocrine and molecular response to stress, reporting that stress exposure resulted in an increase of Bdnf 
mRNA in the NAc only in mice subjected to prolonged cocaine abstinence104. The increase in Bdnf 
mRNA was associated with H3 hyperacetylation at BDNF promoter I. Regarding human findings, it has 
been shown that prenatal exposure to maternal smoking is associated with higher rates of DNA 
methylation at BDNF promoter VI in white blood cells of adolescents, but only in those that are 
homozygous for the Val allele of the Val66Met polymorphism101. Interestingly, adolescents whose 
mothers smoked during pregnancy also showed an increase in drug experimentation101. Altogether, these 
studies support the notion that drug-induced plasticity may be partially caused by persistent epigenetically 
regulated changes in BDNF expression. 
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Epigenetic regulation of BDNF in schizophrenia: Human studies have revealed that the val66met 
polymorphism within the BDNF gene may be associated with schizophrenia and may be one of the major 
factors affecting brain volume reductions associated with this disorder105. Furthermore, analysis of human 
post-mortem brains has shown that BDNF mRNA as well as BDNF protein synthesis and availability are 
significantly reduced in layer III, V and VI of the dorsolateral PFC (DLPFC) of schizophrenic patients106. 
In addition, it has been shown that levels of BDNF were significantly reduced in the serum of 
schizophrenic patients107, 108. However, these findings should be interpreted with caution due to the 
heterogeneity across the different studies and the complex etiology of the schizophrenic spectrum. 
Further, the TrkB receptor is widely expressed in γ-aminobutyric acid (GABA) neurons, and impairment 
of BDNF/TrkB signaling might contribute to a change in GABAergic interneuron functioning observed in 
schizophrenic patients109. GABAergic neurons can be divided in different subpopulations including the 
parvalbumin-positive cells, which exert a powerful negative control on pyramidal cells, by high frequency 
firing and fast-spiking action potentials110. A recent study has demonstrated that mice mutant for Bdnf 
promoter IV show a significant deficit in GABAergic signaling by interneurons in the PFC, particularly 
those expressing parvalbumin111. These data suggest that decreased levels of BDNF in the brain may 
relate to alterations in the GABAergic system within the PFC of schizophrenic patients. Although that 
BDNF plays a crucial role in many neurodevelopmental processes and that schizophrenia is strongly 
linked to aberrant neurodevelopment112, only few studies have addressed epigenetic changes at BDNF 
gene promoters induced by developmental perturbations113, 114. Whether epigenetic mechanisms are 
responsible of the abnormal levels of BDNF observed in post-mortem brains of schizophrenic patients 
remains unclear. A recent observation has suggested a link between the BDNF Val66Met polymorphism 
and abnormal DNA methylation levels at CpG islands at the BDNF locus in the frontal cortex of 
schizophrenic patients100. More specifically, it was shown that there was a decrease in DNA methylation 
at exonic CpG islands of the BDNF gene in the frontal cortex of individuals carrying the Met allele. All in 
all, these data support the notion that genetic variations in BDNF are associated with a distinct epigenetic 
regulation of BDNF gene expression, which may be important in the pathophysiology of schizophrenia.    
 
 
IV – Pharmaceutical drugs targeting BDNF gene expression 
 
     Since aberrant BDNF signaling might play a critical role in the pathophysiology and/or treatment of 
various psychiatric disorders, directly targeting epigenetic modifications at the BDNF gene promoters 
might represent a promising strategy to enduringly reverse abnormal BDNF expression and engender 
long-lasting clinical benefits. In the next section we will present recent findings demonstrating that 
common psychotropic drugs (such as antidepressants and mood stabilizers) interfere with epigenetic 
processes at the BDNF gene, and discuss the potential use of other emerging drugs.  
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Antidepressants: Chronic defeat stress is commonly used to model depressive-like behavior in rodents. 
Whereas chronic treatment with antidepressants is able to restore a normal phenotype in socially defeated 
animals83, 122, chronic imipramine administration could not reverse the enduring H3K27 hypermethylation 
at Bdnf promoters IV and V induced by chronic social defeat in mice. Interestingly, it did reverse the 
repression of Bdnf expression at promoter IV and V by inducing H3-K9 and H3-K14 acetylation resulting 
in an activation of Bdnf gene transcription83. Additional experiments further supported the notion that 
imipramine exerts its therapeutic effects by increasing BDNF levels, at least partly through 
downregulation of HDAC583. Another study showed that chronic treatment with fluoxetine did not alter 
the methylation state of H3K27 induced by perinatal exposure to methylmercury in mice, but significantly 
upregulated H3 acetylation at Bdnf promoter IV84. Moreover, electroconvulsive shock therapy (ECT), still 
the most effective treatment for refractory depressed patients85, is thought to be mediated by enduring 
changes in gene expression, including that of neurotrophic factors like BDNF. Acute ECT results in 
increased H4 acetylation at Bdnf promoter II and correlates with increases in total Bdnf mRNA in rats86. 
On the other hand, chronic ECT in healthy rats has been shown to increase H3 acetylation at Bdnf 
promoters IV and V and to result in an upregulation of the corresponding Bdnf mRNA86. These data 
suggest that antidepressant drugs as well as other antidepressant therapies reverse environmentally 
induced reductions in BDNF expression through changes in covalent modifications at histones tails. 
 
HDAC inhibitors: HDACs, which are classified in four different classes and generally associated with 
transcriptional repression123, represent interesting therapeutic targets for a wide range of human 
disorders124, 125. Many HDAC inhibitors are currently being tested in clinical trials and the FDA has 
already approved some of them for the treatment of specific types of cancer126. A possible role for HDAC 
inhibitors in treating certain mental disorders has emerged from the observation that valproic acid (VPA), 
a commonly used antiepileptic and mood stabilizing drug, is a non-specific inhibitor of class I and II 
HDACs127. Interestingly, VPA has been shown to modulate the expression of BDNF protein and 
mRNA128. Bdnf exon IV mRNA expression was increased within the PFC of mice treated with VPA 
during a fear extinction paradigm, the effect of which was mediated by H4 hyperacetylation at the 
corresponding gene promoter68. Another interesting study has demonstrated that the VPA-induced 
increase in Bdnf expression depends upon a novel responsive region in the neighborhood of promoter 
IV128. In addition, other HDAC inhibitors such as sodium butyrate and trichostatin A (TSA) have been 
shown to induce an up-regulation of Bdnf gene transcription in both cortical neuronal and astrocyte 
cultures, although the exact mechanisms involved have not been elucidated yet128, 129.  
 
DNA methylation modulators: Several proteins belonging to the DNA methyltransferase (DNMT) family 
are implicated in regulating the maintenance methylation and de novo methylation at CpG dinucleotides21. 
Many clinical trials with DNMT inhibitors such as the nucleoside analogue 5-aza-cytidine (5-azaC) and 
its deoxy analogue 5-aza-deoxycytidine (5-aza-dC) have been investigated in the treatment of 
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hematological malignancies130. Further, 5-aza-dC has been shown to reduce the degree of methylation at 
Bdnf promoter I in mouse neuroblastoma cells131. Additionally, other DNMT inhibitors such as zebularine 
have been shown to induce a decrease in DNA methylation at the Bdnf gene69, 113. Infusion of zebularine 
in the hippocampus of mice significantly increased the levels of Bdnf exons I, IV and VI mRNA. In that 
study, demethylation at Bdnf promoters I, IV and VI was associated with enhanced consolidation of 
conditioned fear memories69. Zebularine has been shown to decrease DNA methylation at Bdnf promoter 
IV in the PFC of rats subjected to early-life adversity113. Apart from targeting DNMTs, inhibition of 
MeCP2, which selectively binds to BDNF promoter IV to enhance DNA methylation47, could represent 
an interesting target to increase Bdnf expression.  
 
 
V – Preclinical and clinical perspectives 
 
     There is growing evidence that BDNF plays a central role in psychiatric disorders owing to its action 
on neuronal and synaptic plasticity7. Various environmental factors, particularly when exposure occurs 
during early development, have been shown to produce disturbances in BDNF availability and function, 
thus increasing vulnerability to mental illness. As outlined in this review, long-lasting changes in 
epigenetic processes such as DNA methylation and histone modifications, thereby regulating BDNF gene 
expression, seem to play a crucial role in this respect.  
 
Relevance to psychiatric neuroscience: The proper regulation of BDNF expression is critical for key 
regulatory processes related to e.g. learning, memory and reward. In addition, animal studies have 
revealed a major role for abnormal BDNF signaling in the pathophysiology of many psychiatric 
phenotypes. While memory formation and drugs of abuse are able to increase levels of Bdnf mRNA and 
protein in various brain areas, chronic stress exposure and associated negative emotional responses are 
generally linked to decreased levels of BDNF mainly in the hippocampus and PFC. In various animal 
models, different long-lasting epigenetic changes at the Bdnf gene are associated with abnormal Bdnf 
mRNA and protein levels.  
 
     While most studies have focused on chromatin remodeling, particularly involving histone tail 
modifications, relatively few studies have assessed DNA methylation changes. Interestingly, aberrant 
DNA methylation seems to be critically involved in developmental programming of adult health and 
disease. In fact, DNA methylation footprints are relatively stable and may even be transmitted to the next 
generation, suggesting an important role for BDNF in the transgenerational inheritance of emotional 
traits113. Regarding human studies, it has been shown that DNA methylation at the BDNF gene was 
indeed increased in the Wernicke area of suicide patients as well as in the white blood cells of healthy 
adolescents prenatally exposed to maternal smoking99, 101. On the other hand, decreased DNA methylation 
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levels at the BDNF gene were observed in the PFC of schizophrenic patients carrying the Met allele as 
compared to patients homozygous for the Val allele100.  
 
     Whereas both aberrant DNA methylation and histone modifications at the BDNF gene have been 
implicated in the pathophysiology of psychiatric disorders and related phenotypes, it is yet to be 
determined whether these epigenetic changes are the cause or the consequence of the associated 
pathology. The fact that epidemiologically relevant environmental risk factors for psychiatric disorders 
(e.g. chronic stress in major depression) modulate BDNF levels in animal models through epigenetic 
modifications, and that pharmacological interventions (e.g. antidepressants) are able to restore BDNF 
levels via changes in the epigenome, suggest that epigenetic changes at the BDNF gene are rather causal 
in the pathology than merely being an epiphenomenon. Along similar lines, it is tempting to speculate that 
the effects of repetitive administration of drugs of abuse that modulate BDNF levels, thereby enduringly 
modifying the neuronal network and changing local plasticity in reward circuits, are mediated by 
epigenetic modifications.  
 
Differential BDNF transcript regulation: BDNF expression is tightly regulated at the level of 
transcription with differential exon usage, resulting in the specific involvement of the various transcripts 
in different functions and related processes. Among other things, it has been reported that long and short 
Bdnf transcripts are differentially engaged in protein synthesis29. Furthermore, the use of distinct Bdnf 
mRNA splice variants differing in either their 5’ or 3’ extremity allows a temporal and spatial regulation 
of BDNF expression. For example, the various BDNF transcripts display a tissue-specific expression 
pattern within the human body, as well as a region-specific distribution within the central nervous 
system24. The expression of BDNF protein at local sites of action depends upon restricted regulation of 
Bdnf mRNA trafficking, which is controlled by the 5’ non-coding exon, defining the distinct subcellular 
target areas of the different transcripts134. In rodent primary neuronal cultures, it has been shown that Bdnf 
exon IV was restricted to the soma, whereas Bdnf exon II and VII were predominantly observed in 
dendrites, and Bdnf exon I was distributed in both soma and dendrites40, 135. It is suggested that transcripts 
localized in the dendrites are most likely to participate in local synthesis of BDNF protein and modulate 
morphological and biochemical changes related to synaptic plasticity136, 137. Similarly, Bdnf transcripts 
primarily expressed in the soma would be particularly involved in processes related to the synthesis of 
neurotransmitters or hormones138. Bdnf exon II seems to be particularly involved in mediating synaptic 
plasticity within the reward circuitry, as well as in the molecular and cellular changes underlying drug 
abuse in the striatum97, 102. Furthermore, Bdnf exon VI is likely to be involved in cognitive processes 
related to learning and memory primarily in the hippocampus and PFC of rodents139. Bdnf exon IV, the 
promoter of which contains specific binding sites for CREB and MeCP2, making it a preferential 
epigenetic target, displays a ubiquitous repartition in the brain and seems to play a key role in many 
processes related to mood, emotion, reward, learning and memory. Evidently, the exact role of the various 
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BDNF transcripts and the complex regulation of BDNF mRNA and protein processing await further 
research. 
 
     In relation to the differential functions of the various BDNF transcripts, modulation of the expression 
of specific BDNF exons in a targeted fashion may represent a promising strategy to restore enduring 
changes in gene expression induced by e.g. repeated environmental insults. In particular, HDAC 
inhibitors and DNMT inhibitors represent potentially powerful agents for the treatment of psychiatric 
disorders through regulation of e.g. BDNF gene expression. Conversely, these molecular agents are 
expected to exert their effects on a substantial proportion of the genome, thereby most likely inducing 
numerous negative side effects. More specifically, inhibitors of DNA methylation have been suggested to 
promote cancer metastasis, lupus or autoimmune diseases126. In view of the region-specific distribution of 
BDNF transcripts in the brain and their functionally distinct roles, developing compounds that modulate 
the transcription of specific BDNF exons will provide considerable advantages and possibly avoid 
undesirable side effects. 
 
Perspectives in psychiatric research: Another promising approach may be to directly target TrkB 
signaling, whose abnormal regulation may underlie lasting epigenetic changes influencing the 
transcription of many genes important in brain functioning. Directly targeting TrkB has the capacity to 
modulate the functional balance between p75 and TrkB signaling so as to avoid the possible negative 
effects mediated by the pro-apoptotic p75 receptor. Recent findings have described new specific TrkB 
agonists and antagonists140-144. Chronic administration of such agents might induce, through epigenetic 
modifications, lasting changes in the expression of TrkB target genes. Finding molecules that target 
specific brain regions and/or genetic loci, thus limiting their impact on non-specific adverse epigenetic 
processes in these areas, is a major challenge in psychiatric drug discovery.  
 
     In order to gain more insight into the exact role of epigenetic regulation at the BDNF locus in 
psychiatric disorders, future studies should focus on human post-mortem brain material to assess whether 
epigenetic modifications in the human brain are comparable to those observed in rodent models. A recent 
study has suggested that DNA methylation patterns at gene promoters are preserved up to a post-mortem 
delay of at least 48 hours, enabling researchers to reliably study DNA methylation in human post-mortem 
brains145. Moreover, further studies should address the regulation of BDNF gene expression in blood cells 
and assess whether and, if so, to what extent, changes observed within peripheral blood mononuclear cells 
(PBMCs) reflect those as observed within the brains of patients suffering from psychiatric disorders. This 
would indicate whether or not PBMCs represent a suitable surrogate tissue to examine epigenetic 
processes relevant to brain disorders146, 147. Adverse environmental exposures occurring during the various 
stages of brain development are known risk factors for developing psychopathology, including affective 
disorders and schizophrenia112, 148. To further elucidate the role of BDNF in this respect, the impact of 
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such environmental factors on epigenetic changes at the Bdnf locus should be examined in animal models, 
both in relevant brain regions and peripheral blood cells, while simultaneously assessing possible 
associations between epigenetic states and intermediate behavioral phenotypes. Monitoring such changes 
in humans might be helpful to identify individuals at risk for pathology and/or predict transition from 
subclinical symptoms to disease. Finally, it is also important to understand the impact of the BDNF 
val66met polymorphism on DNA methylation and/or histone modifications at the BDNF gene. If it is 
confirmed that this genetic variation indeed can influence DNA methylation at CpG islands within the 
human BDNF promoter region64, this would add to the evidence of the BDNF gene being a vulnerability 
substrate for psychiatric disorders, thus implicating a novel −epigenetic− mechanism in the effect of the 
polymorphism. 
 
     In conclusion, enduring epigenetic changes at the BDNF gene seem to underlie various 
neurobiological and behavioral phenotypes in animal models of psychiatric disorders. Recent evidence 
suggests that such epigenetic modifications are also present in human patients. A better understanding of 
the exon-specific regulation of the BDNF gene and associated epigenetic remodeling in psychiatric 
disorders and related phenotypes might open new therapeutic perspectives for these disorders. 	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Table 1. Major findings on epigenetic modifications at the BDNF gene in humans 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BDNF, epigenetics and psychiatric diseases 
	   45	  
 
 
 
 
 
 
 
 
Table 2. Major factors influencing epigenetic regulation of the Bdnf gene in rodents 
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Table 3. Treatments and medications modulating epigenetic regulation of the Bdnf gene 
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Fig 1. Structure of the human and rodent BDNF gene.  
 
Exons are represented as boxes and the introns as lines. Numbers of the exons are indicated in roman numerals and 
the size of exons and introns is indicated in Arabic numerals.  The 3’ coding exon (exon IX) contains 2 
polyadenylation sites (poly A). The red boxes represent the start codon ATG that marks the initiation of 
transcription. The green box shows the region of exon IX coding for the pro-BDNF protein, including the rs6265 
genetic variant implicated in the Val66Met polymorphism. Some exons, like exon II and IX, contain different 
transcript variants with alternative splice-donor sites (A, B, C, D). CpG islands were predicted with Methprimer 
software and determined as sequences of at least 200 pairs of bases with a GC percentage greater than 50%. Adapted 
from Aid et al., 200723, and Pruunsild et al., 200724. 
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Fig 2. Epigenetic mechanism associated with repression and activation of Bdnf exon IV transcription.  
 
The BDNF exon IV displays twelve distinct CpG sites, which can be methylated and interact selectively with 
MeCP2 to form complexes that repress gene transcription. Histone methyltransferases (HMTs) are responsible of 
adding methyl groups at histone tails (H3K27), whereas histone deacetylases (HDACs) remove acetylation at 
histone tails, both processes that repress gene transcription. Moreover, low levels of nicotinamine adenine 
dinucleotide (NAD) promote DNA methylation at BDNF locus53. Conversely, Bdnf gene activation is associated 
with an increased histone H3 and H4 acetylation, which is mediated by histone acetyl transferase (HAT) activity. 
Derepression of BDNF exon IV can be observed after membrane depolarization or NMDA receptor activation, both 
inducing the dissociation of MeCP2 from methylated DNA33, 47. In addition, NMDA receptor stimulation has also 
been shown to reduce HDAC1 occupancy of BDNF promoter IV33. DNA demethylation might be facilitated by 
growth arrest and DNA damage proteins such as Gadd45b48. An increased binding of CREB to its specific binding 
protein CREB binding protein (CBP) is also associated with an increase in BDNF gene transcription. Membrane 
depolarization has been shown to increase this CBP-mediated regulation via calcium/calmodulin-dependent protein 
kinase (CaMK) signaling49. Hypothetically, TrkB, whose signaling is known to activate the CaMK pathway, might 
induce CREB phosphorylation and subsequent binding to CPB, thereby increasing BDNF expression. See text for 
more details. 
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Abstract 
 
 
     Depression is considered as a major health problem with a high prevalence and a heavy economic 
burden in western societies. At the anatomical level, major depression corresponds to atrophy or impaired 
functioning of cortico-limbic regions involved in mood and emotions including the hippocampus and the 
prefrontal cortex. Especially, it is suspected that alterations in growth factors and associated signaling 
pathways might underlie neuronal loss and synaptic dysfunction in cortico-limbic structures, which may 
be causally related to the development and course of depression. Accordingly, mounting evidences 
suggest that antidepressant treatments may exert their therapeutic effects by enhancing trophic signalling 
and their downstream neuroplastic signaling. However, current therapies still have significant limitations 
including a delayed onset of action, as well as a considerable lack of efficacy. Hence, a deeper 
understanding about the molecular and cellular mechanisms involved in the pathophysiology, as well as 
in the action of antidepressants might lead to the identification of key-role effectors, and provide further 
insight into the development of novel fast-acting and more effective therapies. Here, we summarized the 
current literature about the involvement of growth factors and associated signalling in the 
pathophyisology and treatment of depression, and provide future directions for the development of novel 
antidepressant drugs.  
 
 
Key words: growth factors, neurocircuits, plasticity, antidepressant, neurotrophic signalling, mood 
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I – Introduction  	  
     Depression has emerged over the past decades as a major debilitating disease with a high prevalence in 
occidental populations, resulting in profound social and economic burden (Kessler et al., 2003; Lopez and 
Murray, 1998; Pincus and Pettit, 2001). The molecular and cellular mechanisms underlying the 
pathophysiology of depression remain poorly understood. Furthermore, the development and course of 
the illness are likely to be mediated by a complex interaction between genetic and environmental factors, 
and the associated heterogeneity of the disease makes it difficult to develop effective therapeutic 
treatments (Keers and Uher, 2012). So far, many classes of antidepressant medication have been 
discovered and marketed for the treatment of depression. However, currently available antidepressants 
display significant limitations, including low response rates and relapse after treatment cessation, which 
remain major drawbacks for a disease where suicide rate are relatively high (Angst et al., 2002). Up to 
date, clinical and preclinical studies have revealed that depression could be linked to alterations in 
cortico-limbic structures controlling mood and emotions, including neuronal loss and synaptic 
dysfunction (Duman and Aghajanian, 2012). Among many candidates, growth factors and related 
signalling pathways constitute major players in neuroplasticity, and current evidence indicate that 
impairment of such regulations might be associated with depressed mood (Pittenger and Duman, 2008). 
Interestingly, currently prescribed antidepressants, predominantly functioning via monoaminergic 
signalling cascades, have been shown to modulate neuroplastic signalling to exert their therapeutic effects 
(Tardito et al., 2006). Hence, a deeper understanding of the exact molecular and cellular mechanisms 
involved in antidepressant action might lead to the identification of key effectors, and provide further 
insight into the development of novel fast-acting and more effective therapies. Here, we summarized the 
current literature on the implication of trophic factors and associated signalling pathways in depression 
and antidepressant treatments. First, a brief overview of brain regions and circuits implicated in the 
pathophysiology of depression, and in the response to antidepressant is highlighted. Further, evidences for 
the involvement of growth factors and associated signalling pathways in depression and its treatment are 
described. Finally, perspectives and future directions for the development of new antidepressant drugs are 
suggested. 
 
II – Brain region and neurocircuits 	  
Neuroanatomical evidences: Many brain regions, especially within the limbic system, has been 
associated with mood and emotions, and the impairment in those areas might play a role in the 
pathophysiology of depression. For instance, the prefrontal cortex (PFC) has many functional connections 
within the brain, processing sensory input and mediating executive motor functions, and its links with the 
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limbic system (e.g. hippocampus and amygdala) form an integral part of memory consolidation and 
retrieval (Ongur and Price, 2000; Price, 1999). Especially, the prefrontal cortex has been associated with 
decision-making, personality expression and social behaviour. Neuroimaging studies found a reduction in 
size of multiple areas of the PFC in subjects diagnosed with major depression (Bremner et al., 2002; 
Drevets, 2000). In line with those studies, post mortem brain analysis of depressed patients revealed 
reduced neural cell size and neural and glial cell densities in the dorsolateral and subgenual PFC (Cotter 
et al., 2002; Öngür et al., 1998; Rajkowska et al., 1999). In rodents, chronic restraint stress caused a 
significant reduction in number and length of apical dendritic branches in some areas of the PFC (Cook 
and Wellman, 2004). Similar results were observed after chronic administration of corticosterone, where 
drastic dendritic reorganization of pyramidal neurons was reported in the medial PFC (mPFC) (Wellman, 
2001). Dendritic arborisation in the mPFC induced by stress in rats was found to be predictive of 
impaired attentional set-shifting performance, a measure of cognitive performance related to mPFC 
functioning (Liston et al., 2006).  	  
Further, the amygdala is an integrant part of the limbic system implicated in cognitive and emotional 
processing, especially involving fear response (Aggleton, 1993; LeDoux, 2000). Volumetric MRI studies 
so far revealed contrasting results, with studies showing both an increase in volume (Frodl et al., 2003; 
Lange and Irle, 2004; Vassilopoulou et al., 2013) as well as a decrease in amygdala volume in depressed 
patients (Bellani et al., 2011; Kronenberg et al., 2009; Lorenzetti et al., 2009). Functional magnetic 
resonance imaging (fMRI) studies in depressed patients have shown exaggerated amygdala activity when 
confronted with emotional facial expressions (Canli et al., 2005; Sheline et al., 2001), and increased 
memory sensitivity to negative stimuli (Hamilton and Gotlib, 2008). Depressed patients also showed an 
overall increased activity of the left amygdala (Drevets et al., 1992). Similarly, Drevets and colleagues 
used PET imaging to find an increase in amygdala activation and metabolism in MDD patients (Drevets, 
2003). A reduction in glial cell number, probably due to a decrease in oligodendrocytes, was discovered 
in post-mortem amygdala tissues of major depressive disorder (MDD) patients (Bowley et al., 2002; 
Hamidi et al., 2004). Increased fractional anisotropy suggesting improved connectivity was observed 
mainly from the left amygdala to the brain stem, cerebellum and hippocampus (Arnold et al., 2012). 
Accordingly, experiments using rats exposed to chronic stress showed enhanced dendritic arborisation, 
elongation and spine density, providing evidence for increased synaptic connectivity in this brain region 
(Vyas et al., 2006; Vyas et al., 2002).  However, functional coupling was reduced between the amygdala 
and the supragenual PFC (Matthews et al., 2008). The heterogeneity of the depressed subjects used in the 
aforementioned studies is likely to be the cause of the contrasting results with factors such as medication, 
gender and onset and disease development. The data however strongly support the notion that disease 
severity correlates with more pronounced neurological alterations (Bellani et al., 2011; Lorenzetti et al., 
2009), so there is no doubt that amygdala functioning is of particular interest in view of major depression. 
 
Neuroplasticity impairment and depression 
	   53	  
Next to the PFC and amygdala, a preponderant role for the ventral striatum has been reported in major 
depression. The basic fundamentals of the natural reward system are attributed to the dopaminergic 
connections between the ventral tegmental area (VTA) and the nucleus accumbens (NAc). In this respect, 
the NAc and the VTA may play a role in the hedonic symptoms of depression (Nestler and Carlezon Jr, 
2006; Yadid and Friedman, 2008). Depressed patients show an attenuated activation of the VTA-NAc 
pathway or the NAc itself when compared to normal patients using fMRI analysis (Epstein et al., 2006; 
Furman et al., 2011; Pizzagalli et al., 2009; Smoski et al., 2009). Deep brain stimulation (DBS) targeting 
the NAc was shown to have antidepressant, anxiolytic and hedonic effects, most notably in treatment 
resistant depression (Bewernick et al., 2010; Giacobbe et al., 2009; Schlaepfer et al., 2008). These effects 
have been proven to be long lasting and stable up to four years (Bewernick et al., 2012; Malone Jr et al., 
2009). Rat models indicate that NAc DBS influences the neurobiology of efferent projections of the NAc 
to the hippocampus. In response to NAc DBS, more neuronal precursors were found in the dentate gyrus 
of the hippocampus, hinting at an enhanced adult neurogenesis (Schmuckermair et al., 2013). DBS may 
also alter the morphology of the PFC, with increased apical and basilar dendrite length (Falowski et al., 
2011). Both the alteration of the PFC and hippocampus in response of NAc DBS show the influence of 
the NAc in depression over the long term.  
 
Finally, the hippocampus is a major part of the limbic system known to be highly vulnerable to stress and 
environmental variations. This region is critical in mood and cognition. MRI analyses revealed reduced 
hippocampal volumes in patients suffering from both recurrent and first episode depression (Bremner et 
al., 2000; Cole et al., 2011; Frodl et al., 2007), and a correlation between volume reductions and total 
duration of major depression has been reported (Sheline et al., 1996). It has also been proposed that 
reductions in hippocampal volume may not antedate illness onset, but volume may decrease at the 
greatest rate in the early years after illness onset (MacQueen et al., 2003). Post mortem analysis in MDD 
patients suggested an increase in the density of pyramidal, granule and glial cells combined with a 
decrease of soma size of pyramidal cells (Stockmeier et al., 2004). This might indicate a decrease in 
cellular neuropil which might provide an explanation for the reduced hippocampal volumes found in 
depressed subjects. In rodents, chronic stress caused atrophy of apical dendrites of pyramidal neurons in 
the CA3 region of the hippocampus (Magarinos et al., 1996; Vyas et al., 2002; Watanabe et al., 1992). 
Exposure to excess glucocorticoids in rats showed decreased apical branching numbers and apical 
dendrite length (Woolley et al., 1990), suggesting a role of the activation of the hypothalamic-pituitary-
adrenal (HPA) axis in the remodelling of hippocampal morphology and neural cell loss associated with 
depression. Accordingly, various models of chronic stress exposure in rodents have indicated a decrease 
of neurogenesis in the dentate gyrus, involving a reduced proliferation, survival and differentiation of 
neural stem cells (Eisch and Petrik, 2012). Moreover, evidence that adult hippocampal neurogenesis is 
required for the behavioural effects of antidepressants (Sahay and Hen, 2007; Santarelli et al., 2003) 
provides further proof of the crucial role of the hippocampus in depression.  
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Hippocampal plasticity and neurogenesis: Hippocampal neurogenesis is believed to be required in the 
therapeutic action of antidepressant drugs (David et al., 2009; Djavadian, 2004; Klempin et al., 2013; 
Santarelli et al., 2003). Accordingly, chronic treatment with the selective serotonin reuptake inhibitor 
(SSRI) fluoxetine increased hippocampal neurogenesis, involving the generation of newborn cells in the 
DG (Malberg et al., 2000; Santarelli et al., 2003; Surget et al., 2011) (Boldrini et al., 2009; Encinas et al., 
2006). In addition, chronic fluoxetine administration increased the dentate connectivity and synaptic 
plasticity in naive rats (Stewart and Reid, 2000). A report proving that serotonin depletion reduced 
neurogenesis in the DG and SVZ in adult rats also supports the theory linking antidepressant treatment to 
neurogenesis (Brezun and Daszuta, 1999). The different serotonin receptors in the brain showed 
differential region specific neurogenesis patterns. Activation of 5-HT1A resulted in increased neurogenesis 
in the SGL and SVZ whereas activation of 5-HT2A increased proliferation in the SGL but not the SVZ. 
The opposite was the case regarding 5-HT2C activation, with an increased neurogenesis in the SVZ but 
not the SGL of the DG (Banasr et al., 2004). Further, serotonin and noradrenaline reuptake inhibitor 
(SNRI) antidepressants, like SSRIs, have been shown to modulate neurogenesis and plasticity. 
Neurogenesis in the DG of the hippocampus was increased following chronic venlafaxine administration 
to rats (Mostany et al., 2008). Similarly, chronic venlafaxine treatment proved to be efficient in 
preventing the deleterious effects of restraint stress on hippocampal neurogenesis and BDNF protein 
expression (Xu et al., 2006). However, a recent study reported that duloxetine treatment did not 
significantly increase the number of new cells in the hippocampus of mice (Marlatt et al., 2010). Finally, 
tricyclic antidepressants (TCA) have also proved to modulate hippocampal neurogenesis. Analysis of 
post-mortem brains of MDD patients treated with nortryptiline and clomipramine showed an increase of 
neural progenitor cells and dividing cells in the DG, as compared to healthy controls (Boldrini et al., 
2009). In animal models, clomipramine was able to counteract the stress-induced inhibition of 
proliferation in the hippocampus (Liu et al., 2008). Chronic imipramine and desipramine treatment 
increased cell proliferation in multiple brain regions of the hippocampus of rodents (Pechnick et al., 2011; 
Santarelli et al., 2003; Schiavon et al., 2010). 5-HT1A knockout in mice abolished the antidepressant 
effects of fluoxetine but not desipramine and imipramine (Santarelli et al., 2003). In addition, imipramine 
could restore the decrease in neurogenesis caused by chronic stress and chronic corticosteroid 
upregulation (Diniz et al., 2013; Doi et al., 2010; Hitoshi et al., 2007; Kitamura et al., 2011; Van 
Bokhoven et al., 2011).  
 
 
III – Neurotrophins and growth factors 
BDNF: Brain-derived neurotrophic factor (BDNF) is involved in the growth, differentiation and survival 
of neurons (McAllister et al., 2001) and is also an important factor in the regulation of neurogenesis 
(Rossi et al., 2006) and synaptic plasticity (McAllister et al., 1999). BDNF is abundantly expressed in the 
mammalian brain, with the highest concentrations found in the hippocampus and cortex (Hofer et al., 
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1990). Reduction of BDNF and its tropomyosin-related kinase receptor B (TrkB) expression in the 
hippocampus and PFC has been reported in post-mortem brain analysis of suicide victims (Dwivedi et al., 
2003b; Pandey et al., 2008), and lowered serum concentration of BDNF has been associated with MDD 
(Karege et al., 2005; Karege et al., 2002; Sen et al., 2008). Interestingly, serum concentration could be 
largely restored with antidepressant treatment (Aydemir et al., 2005; Gonul et al., 2005; Piccinni et al., 
2008; Sen et al., 2008; Shimizu et al., 2003), indicating that serum BDNF levels could perhaps provide an 
indication of antidepressant response (Gass and Hellweg, 2010). One of the most common functional 
single nucleotide polymorphism (SNP) in the BDNF gene is the val66met. This polymorphism affects the 
activity-dependent secretion of BDNF (Egan et al., 2003) and negatively influences hippocampal volume 
(Frodl et al., 2007), and may in this way increase susceptibility to MDD. Expression of BDNF was also 
increased in the post mortem brain of depressed patients treated with antidepressant drugs as compared to 
non-treated patients (Chen et al., 2001b; Dunham et al., 2009). In rodents, direct infusion of BDNF 
protein in the hippocampus (Deltheil et al., 2008; Deltheil et al., 2009; Shirayama et al., 2002; Sirianni et 
al., 2010) and midbrain (Siuciak et al., 1997) showed antidepressant-like effects. Contrastingly, the 
opposite effect was reported after infusion of BDNF in the VTA of the NAc (Eisch et al., 2003). The 
same disparity was present using region specific knockdown of BDNF expression. The impairment of 
BDNF signalling in the DG of the hippocampus (Taliaz et al., 2010) elicited pro-depressive behaviour 
whereas knockdown of BDNF in the NAc had an anti-depressive effect (Berton et al., 2006). Conditional 
knockout in the forebrain resulted in an increase in depressive behaviour in female but not male mice 
(Monteggia et al., 2007) and decreased the efficacy of the antidepressant desipramine (Monteggia et al., 
2004). A conditional knockout of BDNF in the forebrain displayed the same gender-specific incongruity 
in stress-induced depressive-like behaviour (Autry et al., 2009). A different study using adeno-associated 
viral mediated knockout of BDNF in the DG and CA1 of the hippocampus proved that a loss of BDNF 
function in the hippocampus attenuated antidepressant drug treatment efficacy (Adachi et al., 2008). Lee 
and colleagues developed a val66met mouse analogue (Chen et al., 2006) and subsequent experiments 
showed that the val66met genetic variant decreased fluoxetine efficacy through impaired synaptic 
plasticity in the DG (Bath et al., 2012; Ninan et al., 2010) and PFC (Pattwell et al., 2012). In addition, 
BDNF expression in the brain of rats was upregulated after chronic antidepressant drug and 
electroconvulsive therapy (ECT) (Altar et al., 2003; Balu et al., 2008; Jacobsen and Mørk, 2004; Nibuya 
et al., 1995). 
 
FGF: The fibroblast growth factor (FGF) family has been described as a major player in proliferation and 
maturation of neurons in the main neurogenic areas of the brain, the subgranular (SGZ) and 
subventricular (SVZ) zone of the dentate gyrus in the hippocampus. In addition, these growth factors 
(FGF1 and FGF2) were evidenced to play a critical role in the regulation of synaptic plasticity (Reuss et 
al., 2003). Post mortem brain analysis revealed a lowered expression of FGF1 and FGF2 in the 
dorsolateral PFC and the anterior cingulate cortex of patients with MDD (Evans et al., 2004). In addition, 
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FGF2 was decreased in the hippocampus of depressed patients, whereas fibroblast growth factor receptor 
1 (FGFR1) was increased (Gaughran et al., 2006). In rodents, Turner and colleagues reported reduced 
mRNA expression of FGF2 and its main receptor FGFR1 in the CA1, CA2, CA3 and DG following social 
defeat stress, a well-established model of depression (Turner et al., 2008a). Moreover, 
intracerebroventricular (ICV) injection of FGF2 induced neurogenesis in both the SVZ and SGZ (Jin et 
al., 2003; Mudo et al., 2009; Rai et al., 2007), and was also shown to improve depressive-like behaviour 
in rats (Turner et al., 2008b). A more recent study also reported that increased neural proliferation in the 
PFC following FGF2 infusions might also be involved in the antidepressant actions of FGF2 (Elsayed et 
al., 2012). Functional FGF2 knockout mice showed a significant decrease in newly generated neurons but 
no reduction in proliferating cells (Werner et al., 2011). The additional increase in cell death in the 
hippocampus indicated a faulty neurogenesis following FGF2 knockout (Werner et al., 2011). 
Conditional knockout experiments with FGFR1-null mice show defective long-term potentiation (LTP) 
and neurogenesis (Zhao et al., 2007), suggesting that the FGF2/FGFR1 interaction might represent an 
important foundation of neurogenesis.  
 
VEGF: Vascular endothelial growth factor (VEGF) is primarily known for its induction of angiogenesis 
and modulation of vascular permeability during embryogenesis and growth, as well as pathological events 
such as tumorigenesis (Ferrara et al., 2003). In addition, mounting evidence suggests that VEGF can be 
considered as a potent neurotrophic factor as well (Nowacka et al., 2012, Storkebaum et al., 2003). A 
multitude of studies have investigated the plasma concentrations of vascular endothelial growth factor 
(VEGF) in MDD patients, but the data and interpretation remain conflicting possibly due to the 
differences in study design (Clark-Raymond and Halaris, 2013). However, experimental studies showed 
that VEGF displayed robust neuroprotective effects in cell models of ischemia and hypoxia (Jin et al., 
2000) as well as a positive effect on neuronal growth, maturation and proliferation under normoxic 
conditions (Khaibullina et al., 2004; Rosenstein et al., 2003; Silverman et al., 1999; Sondell et al., 1999; 
Zhu et al., 2003). A role in the development of dendrites and axons has also been described for VEGF 
(Khaibullina et al., 2004; Licht et al., 2010; Rosenstein et al., 2003; Sondell et al., 1999). Chronic stress 
in rats decreased the expression of VEGF and its receptor in the hippocampus (Heine et al., 2005). 
Moreover, ICV administration of VEGF increased neuroprotection and neurogenesis in the adult rat brain 
after ischemia (Sun et al., 2003). More specifically, ICV administration of VEGF increased neurogenesis 
in both the SVZ and the SGZ of the DG with enhanced proliferation of neurons, astroglia and endothelial 
cells (Jin et al., 2002), while VEGF-B knockout mice showed impaired neurogenesis (Sun et al., 2006). 
Hence, the overexpression of VEGF in the hippocampus using an adeno-associated viral vector in rats 
resulted in increased neurogenesis and was associated with improved learning and memory (Cao et al., 
2004; During and Cao, 2006). Furthermore, VEGF is required for the proliferation of neural stem-like 
cells in the hippocampus following electroconvulsive therapy (ECT) treatments (Elfving and Wegener, 
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2012; Segi-Nishida et al., 2008). In a similar manner, VEGF also seems to be required for the behavioural 
action of various antidepressants drugs in rodent models of depression (Greene et al., 2009; Sun et al., 
2012; Warner-Schmidt and Duman, 2007; Warner-Schmidt and Duman, 2008).  
GDNF: Glial cell line-derived neurotrophic factor (GDNF) is a neurotrophic factor first discovered in a 
glial cell line, and is expressed in many brain regions (Golden et al., 1998). It is a member of the 
transforming growth factor β (TGF-β) superfamily and is important for neuronal survival (Pascual et al., 
2008). Only a few clinical studies investigating the role of GDNF in depression have been reported, and 
contrasting findings between brain and blood expression remain. A recent post-mortem brain analysis 
showed an increased of (GDNF) expression in the parietal cortex of depressed patients (Michel et al., 
2008). In contrast, decreased GDNF serum levels have been associated with depression (Diniz et al., 
2012b; Pallavi et al., 2013; Zhang et al., 2008), and negatively correlated with disease severity in 
adolescents (Pallavi et al., 2013). Similarly, lowered expression of GDNF was also reported in peripheral 
white blood cells of depressed patients (Otsuki et al., 2008). Interestingly, antidepressant treatment 
significantly increased the serum concentration of GDNF in depressed patients (Zhang et al., 2008), as 
well as ECT in patients with drug-resistant depression (Zhang et al., 2009). Experimental studies in 
animal models evidenced a neuroprotective role of GDNF, and ICV infusion of GDNF increased 
progenitor cell proliferation in the DG (Dempsey et al., 2003) and SVZ (Kobayashi et al., 2006). 
Similarly, infusion of GDNF in the striatum of rats increased progenitor cell proliferation in the 
hippocampus and substantia nigra (Chen et al., 2005). Moreover, GDNF induced differentiation of DG-
derived neural precursors into astrocytes in vitro (Boku et al., 2013). Further, adeno-associated viral 
vector-induced overexpression of GDNF in the rat cortex provided neuroprotection against ischemia-
induced injury (Tsai et al., 2000). In addition, antidepressant treatment increased GDNF release in a rat 
C6 glioblastoma cell line (Hisaoka et al., 2001), whereas lithium treatment in rats resulted in increased 
GDNF concentration in the PFC and occipital cortex but a decrease in the hippocampus (Angelucci et al., 
2003b). Thus far, the exact involvement of GDNF in the aetiology of depression is not fully understood, 
but its neuroprotective capacity might make it an interesting future target for antidepressant treatment.  
 
IGF-1: Insulin-like growth factor (IGF-1) has been designated as a potential therapeutic target for 
neurodegenerative disease such as depression (Carro et al., 2003, Paslakis et al., 2012). IGF-1 is a growth 
factor for many tissues and IGF-1 and its receptor IGF-1R are produced in many body tissues including 
the brain (Bondy et al., 1993). Decreased serum concentrations of IGF-1 have been associated with 
increased neurodegeneration (Busiguina et al., 2000). Studies using selective knockout mice showed that 
a decrease in both systemic and hippocampal IGF-1 levels could increase susceptibility to depression 
(Mitschelen et al., 2011). IGF-1 induced differentiation of neuronal precursors (Anderson et al., 2002; 
Arsenijevic and Weiss, 1998), and proved to be neuroprotective in cerebellar granule neurons in vitro 
(D'Mello et al., 1993). IGF-1 knockout mice showed a decrease in total brain size and DG granular cell 
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layer volume, further supporting the importance of IGF-1 in neurodevelopment (Beck et al., 1995). 
Developmental research in mice has revealed the importance of IGF-1 in hippocampal neurogenesis and 
synaptogenesis (O'Kusky et al., 2000). ICV infusion of IGF-1 ameliorated the age-related decline in 
hippocampal neurogenesis (Lichtenwalner et al., 2001), and peripheral administration of this growth 
factor could selectively induce hippocampal neurogenesis in rat (Åberg et al., 2000). Interestingly, since 
IGF-1 can readily pass the blood brain barrier (Pan and Kastin, 2000), its effects on the brain can be 
achieved by direct injection in the blood circulation. Intranasal administration has been proposed in order 
to provide a shorter path for IGF-1 to enter the brain (Paslakis et al., 2012), avoiding unwanted effects of 
IGF-1 in peripheral tissues. In addition, increase of peripheral IGF-1 concentration by direct injection of 
IGF-1 or inhibition of IGF-1 binding protein displayed anxiolytic and antidepressant effect in rodents 
(Duman et al., 2009; Hoshaw et al., 2005; Malberg et al., 2007; Park et al., 2011), which might be 
attributed in part to increased serotonin levels in the brain (Hoshaw et al., 2008). 
 
VGF: VGF nerve growth factor inducible (non-acronymic) is a small neuropeptide that plays a role in 
energy homeostasis, metabolism and synaptic plasticity. VGF expression is regulated by neurotrophin 
signalling. A recent study showed that depressed patients displayed lower expression of VGF in 
leukocytes, which could be reversed by antidepressant treatment (Cattaneo et al., 2010). Moreover, VGF 
expression in the hippocampus and PFC, like the neurotrophins described above, is decreased in animal 
models of depression (Cattaneo et al., 2010; Thakker-Varia and Alder, 2009). Interestingly, infusion of 
VGF in the hippocampus (Thakker-Varia et al., 2007) or lateral ventricle (Hunsberger et al., 2007) had an 
antidepressant behavioural effect in rats. This effect may be related to increased neurogenesis, which 
occurs after only 7 days of VGF administration to the hippocampus (Thakker-Varia and Alder, 2009). 
VGF expression can be increased by exogenous BDNF administration (Alder et al., 2003) and BDNF 
might even be a requirement for regional VGF expression (Eagleson et al., 2001). VGF is important in 
synaptic plasticity (Alder et al., 2003) and it is indicated that it increases synaptic plasticity in a BDNF-
dependent manner (Bozdagi et al., 2008). The requirement of BDNF in VGF expression and the necessity 
of BDNF in VGF-induced synaptic plasticity show that VGF is heavily intertwined in the BDNF 
pathway. In addition, VGF expression can be upregulated by exercise (Hunsberger et al., 2007) and ECT 
(Altar et al., 2004; Newton et al., 2003). Antidepressant treatment also increased VGF expression in the 
hippocampus and PFC of rats (Cattaneo et al., 2010). 
 
NGF: Nerve growth factor (NGF) is a growth factor first described as a neurite outgrowth factor (Olson, 
1967). Later, NGF proved to be involved in neuron repair and survival (Kromer, 1987; Shigeno et al., 
1991; Sofroniew et al., 2001; Zhao et al., 2004). More recently, NGF has been implicated in neurogenesis 
in the striatum (Frielingsdorf et al., 2007; Zhu et al., 2011), hippocampal plasticity (Conner et al., 2009) 
and proliferation and differentiation of neuronal stem cells (Cattaneo and McKay, 1990). However, only 
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few studies have investigated the role of this trophic factor in depression. Serum levels of NGF are 
lowered in elderly MDD patients (Diniz et al., 2012a). Interestingly, antidepressant treatment using 
duloxetine, a serotonin-norepinephrine reuptake inhibitor (SNRI), could restore altered levels of NGF in 
major depressed patients (Martino et al., 2013). However, this effect was not found in a clinical study 
using selective serotonin reuptake inhibitors (SSRI) antidepressant (Hellweg et al., 2008). In the Flinders 
Sensitive Line (FSL) rat model of depression, it was found that ECT increased NGF levels in the 
hippocampus (Angelucci et al., 2003a), and that NGF injections had antidepressant effects (Overstreet et 
al., 2010).  
 
IV – Intracellular signalling cascades 
MAPK/PI3K: The mitogen-activated protein kinase (MAPK) cascade is activated by a G-protein called 
Ras (Schaeffer and Weber, 1999). Ras is activated following ligand binding to tyrosine kinase receptors 
and neurotrophins may exert their proliferative and neurogenic action via the Trk/Ras/MAPK pathway 
(Chao, 2003; Guan, 1994; Kaplan and Miller, 2000). MAPK signalling, via the induction of extracellular 
signal-regulated kinase (ERK), has been implicated in neuronal survival (Cavanaugh, 2004; Hetman et 
al., 1999; Klesse et al., 1999; Xia et al., 1995) and neurotrophin induced survival (Creedon et al., 1996; 
Wang et al., 2007), in a way that most likely requires the involvement and activation of myocyte-
enhancer factor 2C (MEF2C) (Wang et al., 2007). Multiple lines of evidence point towards MAPK 
signalling as an important pathway in the action of neurotrophins in the brain (Kaplan and Miller, 2000). 
Several growth factors, including BDNF (Cavanaugh et al., 2001; Obrietan et al., 2002), NFG (Learish et 
al., 2000) and EGF (Learish et al., 2000) are known to increase the activity of MAPK. For example, 
MAPK activation was required for VEGF, EGF or FGF induced hippocampal proliferation (Abe and 
Saito, 2000a, b; Learish et al., 2000; Lu et al., 2011). In the PC12 cell line, p38 MAPK activation was 
required for the induction of neuronal differentiation by both NGF and epidermal growth factor EGF 
(Morooka and Nishida, 1998). BDNF promoted survival in neural cell cultures via a MAPK dependant 
activation of CREB (Bonni et al., 1999; Hetman et al., 2002). Decreased levels of ERK were found in the 
post-mortem brain of patients suffering from mood disorders (Yuan et al., 2010). Administration of 
mitogen-activated protein kinase kinase (MEK) inhibitors was associated with increased depressive-like 
behaviour, suggesting the participation of the MAPK signalling cascade in the pathophysiology of 
depression (Qi et al., 2009). Interestingly, a decrease of MAPK phosphorylation were found in the 
hippocampus and PFC of rats following chronic stress (First et al., 2011; Gourley et al., 2008; Qi et al., 
2006), and could be normalized successfully by chronic antidepressant treatment (First et al., 2011; 
Gourley et al., 2008; Hisaoka et al., 2007). Furthermore, the Ras/MAPK pathway is known to be tightly 
intertwined with the phosphatidylinositide 3-kinase (PI3K) and its target kinase Akt (a serine/threonine 
kinase, also known as protein kinase B) in order to regulate neuronal survival (Klesse et al., 1999). The 
activation of the PI3K/Akt pathway seems to play a role in growth factor response, including NGF, 
BDNF and FGF (Chen et al., 2007; Peltier et al., 2007; Yao and Cooper, 1995), and is implicated in LTP 
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and neurogenesis in the hippocampus (Bruel-Jungerman et al., 2009). The mammalian target of 
rapamycine (mTor) has also been described as a key-role mediator of the PI3K pathway, and many 
studies reported that the fast-acting and robust antidepressant-like properties of N-Methyl-D-aspartate 
(NMDA) antagonist might be assigned to the plasticity-related signalling underlying mTor activation 
(Autry et al., 2011; Li et al., 2010). 
 
Wnt/β-catenin/GSK3: The main course of action of Wnt is executed via the canonical pathway involving 
Frizzled receptors and dishevelled (Dsh) proteins, leading to the activation of β-catenin, possibly via the 
inhibition of glycogen synthase kinase 3 (GSK3) by phosphorylation (Miller et al., 1999). Wnt/β-catenin 
signalling is involved in cerebral development and stimulates proliferation and neurogenesis in the 
telencephalon (Gulacsi and Anderson, 2008). Wnt2 has been shown to be a key-role regulator of 
dopaminergic neuron proliferation in the developing ventral midbrain (Sousa et al., 2010) and a 
conditional β-catenin knockout in the ventral midbrain of mice significantly reduced dopaminergic 
neurogenesis (Tang et al., 2009). The overexpression of Wnt3 was sufficient to increase hippocampal 
neurogenesis of adult hippocampal progenitor cells both in vitro and in vivo (Lie et al., 2005). 
Pharmacological blockade and genetic invalidation of Wnt pathway could attenuate adult hippocampal 
neurogenesis in rodents (Jessberger et al., 2009). Moreover, Dickkopf-1 (Dkk-1), an inhibitor of the Wnt 
canonical pathway, caused neuronal cell death when injected in rat brains (Scali et al., 2006), and a Dkk-1 
knockout abolished the stress-related hippocampal atrophy in mice (Matrisciano et al., 2011). It is 
interesting to note that Wnt2, Wnt5a and Wnt7a are involved in the β-catenin dependant synaptic 
plasticity by increasing synaptogenesis and dendritic arborisation (Ciani et al., 2011; Sahores et al., 2010; 
Varela-Nallar et al., 2010; Varela-Nallar et al., 2012; Wayman et al., 2006; Yu and Malenka, 2003). 
Interestingly, post-mortem β-catenin levels were decreased in the ventral PFC of depressed patients as 
compared to healthy subjects (Karege et al., 2012) and conditional knockout of β-catenin resulted in an 
increase in depressive-like behaviour in mice (Gould et al., 2008). Further, BDNF proved to specifically 
increase the expression of Wnt1 and β-catenin in mouse neural stem cell cultures (Chen et al., 2013). 
Chronic ECT and antidepressant treatment increased β-catenin and Wnt2 expression in the hippocampus 
of rats (Madsen et al., 2003; Okamoto et al., 2010). In addition, viral-mediated overexpression of Wnt2 in 
the hippocampus of rat caused antidepressant-like effects (Okamoto et al., 2010). Viral-vector-induced 
knockdown of frizzled-6 resulted in increased depressive-like behaviour in rats (Voleti et al., 2012). On 
the other hand, chronic antidepressant treatment and ECT decreased frizzled-3 in the rat frontal cortex 
(Yamada et al., 2005). Furthermore, the inhibition of GSK3, an essential player is Wnt signalling, has 
been implicated as a potential therapeutic target for diabetes, neurodegenerative disease (Cohen and 
Goedert, 2004) and mood disorders such as depression (Li and Jope, 2010). Stimulation of neuroblastoma 
and cerebellar granule cells with BDNF led to increased phosphorylation of GSK3β, resulting in the 
inhibition of its function (Foulstone et al., 1999; Mai et al., 2002). Similarly, NGF induced hippocampal 
axon growth required the inactivation of GSK3β (Kim et al., 2006; Zhou et al., 2004). A post-mortem 
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study of depressed patients showed an increase in GSK3 kinase activity in the PFC of MDD patients, as 
compared to healthy controls (Karege et al., 2007). It is interesting to note that inhibitors of GSK3 
augmented neurogenesis of neural progenitor cells via the Wnt/βcatenin pathway in vitro (Lange et al., 
2011; Valvezan and Klein, 2012), and deletion of GSK3 α and β resulted in hyperproliferation of neural 
cells (Kim et al., 2009). On the other hand, overexpression of GSK3β induced neuronal death and atrophy 
of the DG (Sirerol-Piquer et al., 2011). In rats, intraperitoneal administration of GSK3 inhibitor produced 
antidepressant-like effects (Gould et al., 2004). Hence, the inhibition of GSK3 has been hypothesized as 
the mechanism by which lithium may exert influence on mood disorders such as depression (Wexler et 
al., 2007). Accordingly, administration of antidepressant drugs like fluoxetine and imipramine that 
increase extracellular serotonin concentrations resulted in increased phosphorylation on GSK3β in rodents 
(Beaulieu, 2007; Li et al., 2004). 	  
CREB: The cyclic AMP response element binding protein (CREB) is activated by various kinase 
signalling pathways (Adams et al., 2000), and has been evidenced to participate in neural survival, as well 
as axon and dendrite outgrowth (Lonze et al., 2002; Redmond et al., 2002; Walton et al., 1999). Post-
mortem brain analysis of depressed suicide patients showed that CREB was decreased in the temporal 
cortex, hippocampus and PFC (Dowlatshahi et al., 1998; Dwivedi et al., 2003a). In addition, a decreased 
CRE-DNA binding activity in the hippocampus and PFC in suicide victims has been observed (Dwivedi 
et al., 2003a). Similarly, a reduction in CREB and a significantly larger decrease in phospho-CREB were 
reported in the orbitofrontal cortex of MDD patients (Yamada et al., 2003). In contrast, other studies 
indicated a higher expression of phospho-CREB in the PFC (Odagaki et al., 2001) and in the amygdala of 
patients suffering from mood disorders (Young et al., 2004). In animal models, mice modified to express 
constitutively active CREB showed increased BDNF expression and facilitated LTP in the hippocampus 
(Barco et al., 2002). Further, viral-mediated overexpression of CREB in the hippocampus had an 
antidepressant effect (Chen et al., 2001a), whereas overexpression in the basolateral amygdala increased 
depression and anxiety related behaviour (Wallace et al., 2004). In a similar manner, viral-mediated 
expression of a dominant-negative mutant of CREB (mCREB) effectively blocked CREB activity in the 
NAc and produced an antidepressant effect (Newton et al., 2002; Pliakas et al., 2001), whereas 
overexpression in the NAc increased depressive behaviour (Pliakas et al., 2001). Furthermore, a growing 
body of literature indicate a critical role for CREB in the mechanism of action of antidepressants. Chronic 
administration of SSRI and SNRI antidepressants and ECT in rats increased the transcription of CREB 
mRNA, as well as CRE-DNA binding activity, in the CA1 and CA3 pyramidal layer and granule layer of 
the DG after 10 days of treatment (Blom et al., 2002; Nibuya et al., 1996). An increase of phospho-CREB 
but not CREB was found in the PFC after chronic antidepressant treatment (Laifenfeld et al., 2005). On 
the other hand, CREB deficient mice treated with desipramine and fluoxetine showed the same 
antidepressant-like effects as wild type mice, indicating that CREB is not required for the antidepressant 
actions of SNRIs and SSRIs (Conti et al., 2002). Administration of desipramine in NAc tissue dissected 
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from rat brains were reported to decrease pCREB (Chartoff et al., 2009). In addition, in CREB deficient 
mice, treatment with desipramine neither increased neurogenesis (Gur et al., 2007), nor induced the 
BDNF upregulation normally seen after desipramine administration (Conti et al., 2002) indicating that 
CREB may be necessary for the increase in BDNF following antidepressant treatment. Altogether, the 
current literature indicates that CREB has a central role in depression, but its exact involvement in the 
aetiology and treatment of depression remains to be further elucidated.  
 
V – Concluding remarks 
 
Growth factors and associated neuroplasticity signalling play an essential role in the development and 
maintenance of the central nervous system (Anlar et al., 1999; Ford-Perriss et al., 2001; Greenberg et al., 
2009). Accordingly, there is growing evidences that abnormal trophic support in cortico-limbic regions 
regulating mood and emotions might account in the pathophysiology of depression (Krishnan and Nestler, 
2008). In addition, clean-cut evidences also showed that antidepressants require neuroplasticity pathways 
to rescue the deficits in synapse density, dendritic arborization and neuronal functioning often associated 
with mood disorders (Pittenger and Duman, 2008). However, several limitations about the neurotrophic 
hypothesis of depression remain. Current knowledge makes it difficult to conclude whether 
neuroplasticity and neurogenesis represent a cause or only a consequence of the pathological processes 
associated with depression. Hence, future research should focus on elucidating the exact involvement of 
neurotrophic signalling in the onset and aetiology of major depression. Furthermore, mounting evidences 
seems to indicate that neurogenesis might not be required for the therapeutic action of antidepressants 
(Bessa et al., 2009). In line with this hypothesis, the usage of N-methyl-D-Aspartate (NMDA) receptor 
antagonists showed that rapid induction of neurplasticity pathways such as BDNF and mTor signalling 
pathways was sufficient to produce a robust and prolonged antidepressant effect (Autry et al., 2011; Li et 
al., 2010). Hence, the rapid enhancement of hippocampal neuroplasticity – involving dendritic growth, 
spine density and synaptic transmission - represent an original strategy to circumvent the delayed efficacy 
of current antidepressant drugs. Finally, the use of drugs that specifically target neurotrophic signalling 
should provide more insights about the involvement of neuroplasticity pathways in the mediation of 
antidepressant response. Nevertheless, growth factors and neurotrophins have considerable limitations, 
including a poor blood-brain barrier penetration and a short half-life in plasma, making these small 
proteins difficult to use in animal models or in the clinic (Nave et al., 1985; Ochs et al., 2000; Poduslo 
and Curran, 1996). Hence, identification of small non-peptidic neurotrophin mimetics remains a current 
challenge in neuroscience research, and may represent an interesting target for the development of a new 
class of therapeutic agents for mood-related disorders. 	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Abstract 
	  
	  
	  	  	  	  	  The interaction of brain-derived neurotrophic factor (BDNF) with its tropomyosin-related kinase 
receptor B (TrkB) is involved in fundamental cellular processes including neuronal proliferation, 
differentiation and survival as well as neurotransmitter release and synaptic plasticity. TrkB signaling has 
been widely associated with beneficial, trophic effects and many commonly used psychotropic drugs aim 
to increase BDNF levels in the brain. However, it is likely that a prolonged increased TrkB activation is 
observed in many pathological conditions, which may underlie the development and course of clinical 
symptoms. Interestingly, genetic and pharmacological studies aiming at decreasing TrkB activation in 
rodent models mimicking human pathology have demonstrated a promising therapeutic landscape for 
TrkB inhibitors in the treatment of various diseases, e.g. central nervous system (CNS) disorders and 
several types of cancer. Up to date, only a few selective and potent TrkB inhibitors have been developed. 
As such, the use of crystallography and in silico approaches to model BDNF-TrkB interaction and to 
generate relevant pharmacophores represents powerful tools to develop novel compounds targeting the 
TrkB receptor.  
 
 
Key words:  BDNF, Cancer, CNS disorders, TrkB inhibitors, Treatments 
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I – Introduction  
 
     Neurotrophins are a family of small-secreted proteins that play a key role in the development and 
maintenance of the vertebrate nervous system (Chao, 2003; Lewin and Barde, 1996). To mediate their 
effects, neurotrophins can bind to two distinct classes of receptors, displaying opposite effects. The high 
affinity interaction with the “tropomyosin-related kinase” receptor family (Trks) is usually associated 
with cell survival, differentiation and synaptic plasticity, whereas the low affinity interaction with the p75 
(p75NTR) promotes proteolysis and apoptosis (Lu et al., 2005). The neurotrophin tyrosine kinase receptor 
2 (NTRK2), also known as TrkB, has been shown to be specifically activated by several neurotrophins 
including brain-derived neurotrophic factor (BDNF), neurotrophin 3 (NT 3) and neurotrophic 4/5 (NT 
4/5), thereby exerting its trophic effects (Klein et al., 1991; Klein et al., 1992; Soppet et al., 1991). In 
addition to the classical activation of TrkB, other mechanisms have been described to activate this 
receptor independently to the binding of neurotrophins (Lee et al., 2002; Nagappan et al., 2008). These 
transactivations occur at cell membrane and are able to induce TrkB phosphorylation within a few hours. 
However, the physiological relevance of such mechanisms is not yet elucidated. Among all the 
neurotrophins, the interaction of BDNF with TrkB has been characterized most thoroughly. The 
expression of TrkB, as well as of BDNF, is very abundant in the brain and both are also present at lower 
levels in different peripheral tissues (Maisonpierre et al., 1990; Pruunsild et al., 2007; Yamamoto et al., 
1996). TrkB signaling has been reported as critical in various physiological processes such as learning, 
memory and reward. Abnormal BDNF-mediated activation of TrkB has been reported in various 
neurological and psychiatric disorders (Andero et al., 2011; Baydyuk et al., 2011; Beckinschtein et al., 
2008; Mao et al., 2010; Pezet and Malcangio, 2004). Although the trophic effect of TrkB activation is 
mainly associated with a positive outcome, increasing evidence suggests that an upregulation of TrkB 
signaling in specific brain areas can underlie the molecular and cellular changes responsible for the 
induction and persistence of pathophysiological processes. For instance, an increase in TrkB receptor 
expression has been observed in different types of cancer, neuropathic pain, drug abuse and epilepsy 
(Douma et al., 2005; Heinrich et al., 2011; Lu et al., 2010; Wang et al., 2009). As such, TrkB inhibitors 
can represent promising drugs for the treatment of a wide range of diseases in which over-activation of 
TrkB has been reported. Up to date, only few compounds that act as specific TrkB inhibitors have been 
described. The development of small agents displaying high affinity and specificity for TrkB can 
represent a useful tool to better understand TrkB signaling and its possible implication in pathophysiology 
providing new therapeutic avenues.  
 
     After reviewing the different mechanisms leading to the activation of TrkB, we will focus on 
pathological conditions where an upregulation of TrkB signaling has been reported. Further, we will 
consider some important pharmacological issues regarding emerging compounds that act as TrkB 
inhibitors. 
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II – Mechanisms of TrkB activation 
 
     Trk receptors are cell-surface receptors belonging to the tyrosine kinase receptor  (RTK) family (Klein 
et al., 1989). In addition to the classical activation by endogenous ligands, increasing evidence supports 
the notion that RTKs can be activated by other mechanisms involving various intracellular pathways 
(Fergusson et al., 2003; Flajolet et al., 2008). 
 
Activation by neurotrophins: The activation of TrkB by neurotrophins, namely BDNF, NT 4/5 and NT 3, 
generally follows the common pattern associated with RTK activation (Friedman and Greene, 1999). 
Neurotrophins exist preferentially as homodimer complexes, and bind to the extracellular interface of a 
TrkB monomer resulting in receptor dimerisation (Jing et al., 1992). The dimerisation increases the 
catalytic activity of the intracellular domain of the receptor enabling the phosphorylation of tyrosine 
residues inside the activation loop (tyrosine Y701, Y705 and Y706) and subsequently the 
autophosphorylation of tyrosine situated outside of the activation loop (tyrosine Y515 and Y816) 
(Cunningham and Greene, 1998).  Then, activation and recruitment of partner proteins and adaptators to 
the different tyrosine sites will lead to activation of three main intracellular signaling pathways that are 
strongly interconnected (Huang and Reichardt, 2003). Briefly, phosphorylation of tyrosine Y515 activates 
1) the Ras-mitogen-activated protein kinase (MAPK) signaling cascade, which promotes neuronal 
differentiation and growth, and 2) the activation of phosphatidylinositol 3-kinase (PI3-K) signaling 
cascade, which promotes neuronal survival and growth. Phosphorylation of tyrosine Y816 activates 3) the 
phospholipase Cγ (PLCγ) pathway generally associated with synaptic plasticity and neurotransmission 
(Minichiello, 2009). The neurotrophin/Trk complex is internalized by endocytosis and the intracellular 
domain of receptor, present on the outside of the endosome, is still phosphorylated and susceptible to bind 
to signaling molecules (Grimes et al., 1996; Howe et al., 2001). However, the exact mechanism 
underlying TrkB internalization and recycling is still poorly understood. In addition, different alternative 
TrkB mRNA splice variants can lead to the translation of different TrkB isoforms including two truncated 
forms (Middlemas et al., 1991). It has been described that the two truncated forms of TrkB (TrkB-T1 and 
TrkB-T2) lacking the intrinsic tyrosine kinase activity, was able to inhibit full-length TrkB (TrkB-FL) 
signaling via the binding of a truncated form with a full form (Biffo et al., 1995; Dorsey et al., 2006; Eide 
et al., 1996). 
 
Activation in absence of neurotrophins: There are several ways to activate TrkB signaling independent 
from the binding of neurotrophins. Although this phenomenon is not clearly described, TrkB receptor 
may show a basal activity induced by a local increase in receptor density within intracellular vesicles and 
lipid rafts of the plasma membrane, sufficient to enhance biological responses usually associated with 
neurotrophin signaling (Cazorla et al., 2010, Swift et al., 2010). In addition to this basal TrkB activity, 
another mechanism known as transactivation has been extensively documented. Chao and colleagues 
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have shown that the pharmacological activation of the adenosine 2a receptor (A2aR) was able to promote 
TrkB phosphorylation and activation of PLCγ and PI3K pathways in hippocampal neuronal cultures (Lee 
and Chao, 2001). Furthermore, several studies have indicated that a wide range of G protein-coupled 
receptors (GPCRs) including the dopamine receptor 1 (D1R), the pituitary adenylate cyclase-activated 
polypeptide receptor (PACAPR) and the cannabinoid receptor 1 (CB1R) were also able to transactivate 
the TrkB receptor upon respective stimulation (Berghuis et al., 2005; Iwakura et al., 2008; Lee et al., 
2002; Wiese et al., 2007). This alternative mode of TrkB activation in the absence of neurotrophin 
binding is mediated by intracellular proteins belonging to the Src kinase family (Huang and McNamara, 
2010; Lee and Chao, 2001; Rajagopal and Chao, 2006). This process seems to occur at the cell membrane 
and may persist in intracellular vesicles inside neuronal cells (Rajagopal et al., 2004).  Interestingly, the 
response is similar to the effects of neurotrophins on the TrkB receptor, but the temporal pattern of 
activation is longer (Nagappan et al., 2008). In contrast with this long delayed activation of TrkB by 
GPCRs, a newly identified mechanism of TrkB transactivation involving zinc has been described. Intense 
neuronal activity results in the release of large amounts of zinc along with glutamate at nerve terminals 
(Vogt et al., 2000). These zinc ions are able to penetrate postsynaptic neurons via voltage-dependant 
calcium channels (VDCCs) and the N-methyl-D-aspartate (NMDA) glutamate receptor and indirectly 
activate Src kinases by inhibiting C-Src tyrosine kinase (CSK) (Huang et al., 2008; Hwang et al., 2005). 
Such process leads to phosphorylation of TrkB as well as the activation of the three associated pathways 
within only a few minutes, playing an important role in mossy fiber related long-term potentiation within 
the hippocampus (Nagappan et al., 2008). More recently, also glucocorticoids have been shown to be able 
to transactivate TrkB receptors (Jeanneteau et al., 2009).  Acute dexamethasone administration promotes 
TrkB phosphorylation and activates the corresponding signaling pathways within both the rat brain and in 
primary neuronal cell cultures resulting in a neuroprotective effect (Jeanneteau et al., 2009). However, the 
exact mechanism by which glucocorticoids transactivate TrkB remains to be elucidated. Finally, various 
types of antidepressant including Fluoxetine, citalopram, roboxetine and imipramine were shown to 
induce TrkB phosphorylation, independently of BDNF and monoamine transporter blockade in the rat 
brain (Rantamaki et al., 2011). 
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Fig. 1. Neurotrophin -dependent and -independent activation of TrkB receptor and associated signaling 
pathways.  
 
The binding of neurotrophins to TrkB induces the phosphorylation of the different tyrosines in the intracellular 
domain leading to three main signaling pathways (i.e. MapK. PI3K and PLCγ).  The activation of NMDA receptor 
(NMDAR) by glutamate allows zinc to penetrate in the cells via voltage-dependent calcium channels (VDCC), 
which inhibits C-terminal Src Kinase (CSK) usually implicated in the inhibition of Src kinases proteins. This 
indirect activation of Src kinases can lead to the phosphorylation of tyrosine residues of TrkB intracellular domain 
within a few minutes. In contrast, a longer mechanism of TrkB activation can be observed upon stimulation of many 
GPCRs including A2aR, D1R, PACAPR or CB1R. The activation of such receptors can promote the 
phosphorylation of Src kinases and lead to the subsequent phosphorylation of tyrosine residues of TrkB intracellular 
domain within few hours. Diverse classes of antidepressants, as well as glucocorticoids, have been shown to 
transactivate TrkB. However, the exact mechanisms remain unclear. This illustration was realized with “Servier 
medical art” (http://www.servier.fr/servier-medical-art). 
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III – Upregulation of TrkB signaling in CNS-related disorders 
 
1 – Neurological and psychiatric diseases  
 
     The proper regulation of TrkB levels and their activation is critically important in cell functioning. 
Downregulation of TrkB signaling is often observed in various brain regions in relation to 
neurodegenerative diseases, as well as in some psychiatric disorders (Bernard et al., 2011; Pezet and 
Malcangio, 2004; Weickert et al., 2005). On the other hand, upregulation of TrkB signaling seems to have 
important implications in the pathogenesis of a broad range of illnesses including CNS-related diseases, 
metabolic diseases and cancer. 
 
TrkB signaling in epilepsy: Many experimental models and post-mortem brain analyses of epileptic 
patients have revealed that BDNF mRNA and proteins levels were increased after epileptic seizures (Gall, 
1993; Humpel et al., 1993; Isackson et al., 1991; Jankowsky and Petterson, 2001; Schmidt-kastner et al., 
1996; Takahashi et al., 1999;). TrkB mRNA is also increased in the striatum and cortical regions after 
seizures in rodents (Merlio et al., 1993; Salin et al., 1995; Wyneken et al., 2001). Hence, TrkB signaling 
has been suspected to participate in the molecular mechanism underlying epileptogenesis, e.g the process 
by which a normal brain becomes epileptic. Early reports showed that phosphorylation of TrkB within the 
mossy fiber pathway and CA3 region of the mouse hippocampus is associated with seizure induction in 
the kindling model (He et al., 2002). The selective inhibition of TrkB using intraventricular 
administration of TrkB antibodies showed a decrease in kindling development (Binder et al., 1999). Then, 
using genetic disruption in the kindling model, a modest impairment in epileptogenesis was detected in 
conditional BDNF -/- mice, whereas conditional TrkB -/- mice showed reduced electrographic seizure 
duration and no behavioral evidence of limbic epileptogenesis (He et al., 2004).  More specifically, mice 
carrying the Y186F mutation that disrupts the PLCγ mediated pathway, showed impaired long-term 
potentiation in the mossy fiber pathway and decreased kindling development indicating a key role for 
TrkB-dependent activation of PLCγ signaling in epileptogenesis (He et al., 2010). In ex vivo rat 
hippocampal cultures, the excessive activation of L-type Ca2+ channels was shown to lead to the 
extracellular release of BDNF, thus stimulating TrkB receptors in the mossy fibers to induce axonal 
branching (Koyama et al., 2004). This phenomenon induces hyperexcitable reentrant circuits in the 
dentate gyrus, and might play a role in the cellular basis at the origin of recurrent epileptic seizures 
(koyama et al., 2004). Increasing BDNF levels in the brain using transgenic mice models or acute 
intrahippocampal infusion revealed that this trophic factor could increase seizure severity (Croll et al., 
1999; Scharfman et al., 2002). The convulsant drug cyclothiazide can induce robust epileptiform activity 
in rat hippocampal neurons both in vitro and in vivo (Qi et al., 2006). Inhibition of TrkB before 
administration of cyclothiazide in rat hippocampal neurons or cerebral ventricles suppressed the 
epileptiform activity of this convulsant drug (Wang et al., 2009). In Bassoon mutant mice, a genetic 
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model for epilepsy, higher levels of TrkB and altered distribution of BDNF were found in the striatum in 
response to seizures, which were normalized after chronic treatment with the anticonvulsant drug valproic 
acid (Ghiglieri et al., 2010). Transgenic mice overexpressing the truncated form of TrkB, associated with 
decreased of TrkB signaling, show reduced hippocampal epileptogenesis after induction of status 
epilepticus by kainate acid (Heinrich et al., 2011; Lahteinen et al., 2002).  All in all, genetic and 
pharmacological inhibition of TrkB signaling clearly showed that TrkB activation is implicated in the 
induction of seizures in rodent models of epilepsy. The PLCγ pathway seems to be specifically 
responsible in this pro-epileptic effect. However, the exact mechanism underlying TrkB activation and the 
spatiotemporal pattern of BDNF release in the physiopathology of epilepsy still needs to be further 
clarified.  
 
TrkB signaling in addiction: Changes in BDNF mRNA and protein have been observed in many brain 
regions, especially in relation to the mesolimbic dopaminergic system, following administration or 
withdrawal of different classes of addictive compounds in rodents (Russo et al., 2009). In addition, NT-4 
mRNA and proteins levels was also shown to be increased in distinct brain areas such as the brain stem, 
cerebellum and cerebral hemisphere in rats after chronic treatment with ecstasy (Hatami et al., 2010). 
BDNF is particularly implicated in the regulation of dendrite structure and neuronal plasticity (including 
dopamine receptor expression) indicating a key role in the molecular and cellular adaptations leading to 
addictive behavior (Guillin et al., 2001; Russo et al., 2010). Moreover, the stimulation of dopamine 
receptors in striatal neurons in the adult rat brain leads to increased BDNF production (Hasbi et al., 2009). 
Acute opiate administration in rodents increases BDNF mRNA levels in many regions such as the nucleus 
accumbens (NAc), medial prefrontal cortex (mPFC), ventral tegmental area (VTA), and orbitofrontal 
cortex (Chu et al., 2007; Russo et al., 2009). Withdrawal after chronic exposure to opiates led to a rapid 
and prolonged increase in BDNF mRNA and TrkB mRNA in the locus coeruleus (Numan et al., 1998), 
while infusion of BDNF into the VTA induces an opiate-dependant-like reward state in naïve rats 
(Vargas-Perez et al., 2009). Regarding psychostimulants (e.g., cocaine, amphetamine and alcohol), many 
studies have been performed that suggest an increase in BDNF protein and/or mRNA in many areas 
following acute or chronic administration (Russo et al., 2009). More specifically, both acute and chronic 
cocaine administration have been shown to increase BDNF mRNA and protein levels in the rodent 
striatum (Graham et al., 2007; Liu et al., 2006; Zhang et al., 2002). Long-term cocaine withdrawal is also 
correlated with increased BDNF protein levels in the NAc, VTA and amygdala (Grimm et al., 2003; Pu 
and Poo, 2006). Infusion of BDNF directly in the NAc caused enduring increases in cocaine self-
administration and facilitated relapse in rats, which was neutralized by infusions of BDNF antibodies 
(Graham et al., 2007). In a similar manner, TrkB protein levels are increased in the rodent NAc after 
chronic cocaine administration (Graham et al., 2009; Sadri-Vakili et al., 2010; Toda et al., 2002). A recent 
study suggests that cocaine induced BDNF activation of TrkB in the NAc is essential for the onset of 
addictive states (Graham et al., 2009). Moreover, a single injection of cocaine is sufficient to increase the 
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phosphorylation of TrkB in the NAc of rats after 9 hours (Crooks et al., 2010). The reduction of TrkB 
signaling in the NAc, using non-specific Trk inhibitors or conditional TrkB deletion, was able to prevent 
behavioral sensitization, conditioned place preference and ultrasonic vocalization induced by cocaine 
administration in rats (Crooks et al., 2010, Williams et al., 2010). Altogether, these data support the 
notion that BDNF-dependent activation of TrkB plays a key role in cellular and molecular adaptations 
leading to the development and persistence of addictive behavior in rodents. However, compelling 
evidence from human studies to support findings observed in animal models is lacking. 
 
TrkB signaling in neuropathic pain: Immunocytochemistry and in situ hybridization studies have 
revealed that BDNF and its receptor TrkB are abundantly distributed within nociceptive pathways of 
adult animals (Merighi et al., 2008). As such, BDNF-dependent activation of TrkB signaling has been 
suspected to play a pivotal role in the mediation of pain processes, at least in part, through a possible 
modulation of glutamatergic excitatory and GABAergic inhibitory systems in the spinal cord (Kerr et al., 
1999; Pezet et al., 2002). Additionally, both TrkB and BDNF are increased during inflammation (known 
as a mediator of neuropathic pain) preferentially in the dorsal root ganglions (Apfel et al., 1996; Cho et 
al., 1997). One of the first arguments for the implication of BDNF in neuropathic pain came with the 
observation that L5 spinal nerve ligation in rats, a neuropathic pain model, increased both BDNF 
immunoreactivity and BDNF mRNA in the ipsilateral L4 dorsal root ganglia neurons (Fukuoka et al., 
2001). Additionally, intrathecal injections of BDNF can produce enduring thermal hyperalgesia and 
tactile allodynia in normal mice, suggesting a direct link for this trophic factor in the induction of 
neuropathic pain (Yajima et al., 2005). Furthermore, pharmacological studies aiming at reducing BDNF 
levels showed a direct role of TrkB signaling in the development of neuropathic pain. Intrathecal injection 
of BDNF antibodies at third day after surgery could attenuate thermal hyperalgesia induced by L5 spinal 
nerve ligation in rats (Fukuoka et al., 2001). Similarly, sequestration of endogenous BDNF levels using 
TrkB-Fc chimera injections suppressed the thermal hyperalgesia and tactile allodynia induced by sciatic 
nerve ligation in mice (Yajima et al., 2005). The use of the non-specific tyrosine kinase inhibitor K252a 
was shown to block early pain behavior induced by sciatic nerve ligation in rats  (Miletic and Miletic, 
2008), and likewise, to reduce the hyperalgesia and allodynia induced by intrathecal injection of BDNF in 
normal mice (Yajima et al., 2005). The blockade of TrkB phosphorylation within the spinal cord of adult 
mice using 1NM-PP1 was able to prevent the development of nerve injury-induced persistent pain (Wang 
et al., 2009). At the cellular level, BDNF, which is a crucial signaling molecule between microglia and 
neurons, is suspected to participate in neuronal sensitization to neuropathic pain transmission. Functional 
inhibition of BDNF-TrkB signaling using TrkB-Fc reverses the allodynia and the depolarizing shift in 
Eanion that follows both nerve injury and administration of ATP-stimulated microglia in the lumbar dorsal 
horn of peripheral-injured rats (Coull et al., 2005). Regarding genetic manipulations, antisense treatments 
directed against TrkB attenuates inflammation-induced hyperalgesia in rats (Groth and Aanonsen, 2002). 
Moreover, in BDNF +/- mice, a significant decrease in hyperalgesia and allodynia after nerve ligation was 
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observed as compared to wild-type mice (Yajima et al., 2005). Taken together, these data support the 
notion that BDNF, probably released from microglia, is crucial for neuronal TrkB activation underlying 
neuropathic pain. Blocking microglial–induced TrkB signaling in neurons may represent a promising 
strategy for the treatment of neuropathic pain in this respect. 
 
TrkB signaling in depression: BDNF-mediated TrkB signaling has been extensively studied in relation to 
mood disorders in both human and animal models (Boulle et al., 2011; Duman and Monteggia, 2006; 
Martinowich et al., 2007). TrkB and BDNF expression in the hippocampus, as well as circulating BDNF 
in peripheral blood, are decreased in depressed patients, suggesting that BDNF can represent a valuable 
biomarker in major depression (Dwivedi et al., 2003; Hashimoto, 2010). Additionally, in animal models 
of stress and/or depressive-like behavior, BDNF-TrkB signaling is downregulated in many brain regions 
including the hippocampus and prefrontal cortex (PFC), and antidepressant action is mediated at least in 
part through an elevation of BDNF levels in the hippocampus (Duman and Monteggia, 2006; Shirayama 
et al., 2002; Taliaz et al., 2010; Tsankova et al., 2006). While TrkB signaling in these regions plays a 
critical role in depression, only limited research has been carried out regarding its activity in other brain 
structures related to depression such as the striatum. BDNF and TrkB are abundantly expressed in the 
nucleus accumbens (NAc) and ventral tegmental area (VTA), two critical structures of the mesolimbic 
dopamine pathway involved in reward, pleasure and aversion (Baydyuk et al., 2011; Freeman et al., 2003; 
Hung and Lee, 1996; Yu and Chen, 2011). As such, anhedonia, reduced motivation and lethargia have 
been suspected to be modulated by BDNF-mediated TrkB signaling in the striatum. A first line of 
evidence came with the observation that infusions of BDNF into the VTA exerted a depressive-like effect 
in the forced-swim test in mice (Eisch et al., 2003). In this same study, a viral-mediated overexpression of 
a truncated form of TrkB (TrkB-T1) produced an antidepressant-like effect in the forced-swim test (Eisch 
et al., 2003). In the social defeated stress model, a mouse model of depression displaying several features 
of anhedonia, an upregulation of BDNF-TrkB signaling in the striatum has been reported. Viral-mediated 
specific knockdown of BDNF in the VTA showed that BDNF was critically important for the 
development of long-lasting aversion to social contact in mice (Berton et al., 2006). Moreover, increased 
BDNF levels in the NAc seem to mediate the susceptibility towards social defeat in mice (Krishnan et al., 
2007). However, no changes were observed in TrkB and Phospho-TrkB levels in the NAc of susceptible 
versus control mice (Krishnan et al., 2007). In this same study, the authors showed that BDNF levels in 
the NAc are significantly higher in depressed patients as compared to controls (Krishnan et al., 2007). 
Clearly, BDNF-TrkB signaling in depression is complicated and brain region dependent. This questions 
whether therapeutic interventions targeting TrkB may be a useful approach. Interestingly, a newly 
developed TrkB antagonist, Ana 12, showed preferential distribution in the striatum as well as 
antidepressant-like properties in the forced-swim test and tail-suspension test in mice (Cazorla et al., 
2011; see section 4.2. for more details).  It would be of interest to test the ability of such compounds to 
reverse aversive behavior and anhedonia in rodent models of depression. Additionally, further studies 
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measuring BDNF levels as well as TrkB expression/activation in post-mortem brain analysis of depressed 
patients should be carried on. 
 
 
2 – Other diseases 
 
TrkB signaling in cancer: BDNF-dependent and -independent activation of TrkB represent a critical 
transduction pathway in tumor cell survival and proliferation.  Overexpression of TrkB, a hallmark of 
many tumors, results in activation of autocrine and paracrine survival pathways, promoting survival of 
cancerous cells, but also resistance to anticancer drugs and facilitation of angiogenesis (Thiele et al., 
2009). More specifically, TrkB-expressing neuroblastoma tumors treated with BDNF are less sensitive to 
cytotoxic drugs, and patients with tumors expressing high levels of TrkB and BDNF have a poor 
prognosis (Asgharzadeh et al., 2006; Nakagawara et al., 1994; Scala et al., 1996). Many types of human 
cancer (melanoma, lung adenocarcinoma and colorectal tumors) have been founded with TrkB mutations, 
although a real gain-of-function has not been elucidated yet (Geiger et al., 2011). Similarly, BDNF and 
NT-4 was shown to be increased in many types of cancers (Lam et al., 2011; Vanhecke et al., 2011). 
Moreover, a first line of evidence suggested that TrkB mediated PI3-K activation is responsible of the 
anoikis (process by which the loss of cell-matrix interaction leads to apoptosis) resistance and induction 
of metastasis in rat intestinal epithelial cells (Douma et al., 2004). Further studies have confirmed the 
implication of TrkB signaling in anoikis resistance and induction of metastasis in many other types of 
cancerous cells (Sclabas et al., 2005; Yu et al., 2008; Zhang et al., 2008). More recently, a couple of 
pharmacological studies assessing the potential therapeutic effects of Trk inhibitors have been carried out. 
The inhibition of TrkB with either a soluble TrkB ectodomain or the Trk receptor inhibitor K252a was 
shown to restrain proliferation and to enhance apoptosis in cultured choriocarcinoma cells (Kawamura et 
al., 2010). Similarly, K252a was able to increase anoikis sensitization in nasopharyngeal carcinoma cells 
(Ng et al., 2010). The Trk inhibitor AZ623 can inhibit BDNF-induced TrkB phosphorylation and 
subsequent proliferation of neuroblastoma cells and potentiates the effects of topotecan (a topoisomerase-
I inhibitor, commonly used in the treatment of various cancers) on the regrowth of human neuroblastoma 
xenographs (Zage et al., 2011). A phase I clinical trial also suggest that high doses of lestaurtinib, a potent 
Trk inhibitor, can reduce phospho-TrkB levels in the plasma of patient with refractory neuroblastoma 
(Minturn et al., 2011). Lestaurtinib was well tolerated in those patients suggesting that further 
investigation should be pursued especially regarding the clinical relevance of reduced phospho-TrkB 
levels in the remission of the patients. Altogether, preclinical and clinical studies showed a major role for 
TrkB signaling in angiogenesis and metastatic processes, pointing out the necessity to develop new potent 
TrkB antagonists for the treatment of a broad range of cancers. 
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TrkB signaling in eating disorders: BDNF and its receptor TrkB are highly expressed in the 
hypothalamus, a key region controlling neuroendocrine regulated functions such as food intake and 
energy balance homeostasis (Berg von ver Emde et al., 1995; Marmigere et al., 1998; Yan et al., 1997).  
BDNF +/- heterozygous mice, in which BDNF levels are reduced, display abnormalities in eating 
behavior and locomotor activity resulting in weight gain (Kernie et al., 2000). Moreover, a selective 
deletion of BDNF in the ventromedial and dorsomedial hypothalamus in adult mice was associated with a 
stimulation of appetite leading to hyperphagic behavior and obesity (Unger el al., 2007). Similarly, a de 
novo mutation in the gene encoding TrkB, reducing receptor autophosphorylation and downstream 
MAPK signaling, was associated with hyperphagic obesity in an 8-year-old patient (Yeo et al., 2004). In 
mice, a single intrahypothalamic application of agonist TrkB antibody was able to reduce food intake and 
body weight (Tsao et al., 2008). In non-human primates, administration of BDNF or NT4 had 
anorexigenic effects when applied centrally, and on the contrary, orexigenic effects when applied 
peripherally (Lin et al., 2008). All together, these studies bring evidence that BDNF has an important 
implication in the control of appetite in the central nervous system. As reduced BDNF/TrkB signaling in 
hypothalamic areas stimulates appetitive behaviors, developing drugs that specifically activate TrkB can 
represent promising therapy for the treatment of obesity. Additionally, the use of TrkB inhibitors to 
modulate the energy balance towards an orexigenic effect might also be an interesting approach for the 
treatment of eating disorders such as anorexia and bulimia. 
 
 
IV – Development of TrkB inhibitors 
 
     Currently, only few TrkB inhibitors are available. The use of different strategies to better understand 
BDNF-TrkB interaction, the identification of new pharmacophores and the development of selective and 
potent TrkB inhibitors are promising pharmacological challenges.  
 
Modeling BDNF – TrkB interaction: Crystallography studies modeling BDNF-NT3 and BDNF-NT4 
heterodimers have enabled researchers to better characterize the molecular conformation of the BDNF 
protein (i.e. folding of the protein and mapping of the surface residues) and identify key-role regions 
implicated in the binding to TrkB (Robinson et al., 1995, 1999). The use of BDNF/NGF chimeric 
molecules encompassing site-directed mutagenesis revealed that structural elements determining the 
biological activity of BDNF were similar to those found in NGF (Ibanez et al., 1991, 1993). Further, it 
was shown that some residues in loop II, loop IV and β-strands of BDNF were critical in the binding to 
TrkB (Fletcher et al., 2008; O’Leary et al., 1998; Pattarawarapan and Burgess, 2003). Loop IV of BDNF 
seems to be also important in p75 binding (Fletcher et al., 2008; Ryden et al., 1995). More recently, using 
the crystal structure of the BDNF-NT3 heterodimer, the structure of BDNF loop II was further unraveled 
to generate a pharmacophore, and subsequent in silico screening was performed to identify multiple small 
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non-peptidic TrkB ligands (Massa et al., 2010). Regarding TrkB structure, it was revealed that the 
Immunoglobulin- like domain 5, connecting the extracellular portion of the receptor to the 
transmembrane domain, was sufficient for binding of BDNF (Urfer et al., 1995). Further, the crystal 
structure of TrkB-D5 in complex with NT-4/5 showed a major role for N-terminal regions of 
neurotrophins in Trk receptor specificity and binding (Banfield et al., 2001; Ultsch et al., 1999). A virtual 
screening using the TrkB-D5-BDNF x-ray structure and focusing on the specific BDNF N-terminal 
region interaction with TrkB-D5 domain has recently led to the development of small non-peptidic TrkB 
antagonists (Cazorla et al., 2011). As such, computational modeling involving structure-based in silico 
screening represents a promising tool in drug discovery and may open new therapeutic strategies to 
develop potent and selective TrkB ligands. 
 
TrkB antagonists: The staurosporine analogue K252a is a potent protein kinase inhibitor (Kase et al., 
1987). This alkanoid is able to penetrate the cell and acts as a potent and selective Trk receptor inhibitor 
at low concentrations making it an interesting tool to explore TrkB signaling (Tapley et al., 1992). 
Nevertheless, the lack of specificity for TrkB, as compared to TrkA and TrkC, constitutes a major 
limitation for the use of K252a. More recently, using distinct approaches, two specific and potent TrkB 
antagonists with different biochemical properties and structures have been developed. The first one, 
cyclotraxin-B, is an 11 amino acid peptide mimicking the reverse turn structure of BDNF region III 
(Cazorla et al., 2010). This compound was shown to specifically bind to TrkB with high affinity as 
compared to TrkA and TrkC (Cazorla et al., 2010). The interaction with p75 is still to be determined. 
Interestingly, cyclotraxin-B is able to inhibit both BDNF-dependent and -independent activation of TrkB 
in cell line models (Cazorla et al., 2010). After a fusion with the “tat” transduction domain of the human 
immunodeficiency virus (HIV), the formed tat-cyclotraxin-B complex is able to cross the blood-brain 
barrier when administrated intravenously and induces anxiolytic effects in the open field paradigm in 
mice (Cazorla et al., 2010). Additionally, using a structure-based in silico screening that models the 
interaction of low-molecular weight compounds with the N-terminal region of TrkB-D5 domain, a new 
TrkB inhibitor, namely Ana-12, has been developed (Cazorla et al., 2011). In vitro studies showed that 
this compound is a selective and potent TrkB antagonist, as compared to TrkA and TrkC (Cazorla et al., 
2011). When administrated peripherally, Ana-12 is able to cross the blood-brain barrier and preferentially 
diffuses into the striatum resulting in an antidepressant and anxiolytic effect in mice (Cazorla et al., 
2011). Together, cyclotraxin-B and Ana-12 represent powerful agents to better explore TrkB signaling 
and investigate the possible therapeutic value of TrkB inhibitors in a broad range of diseases. 
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Fig. 2. Pharmacological agents developed using different strategies targeting BDNF and TrkB epitopes.  
 
The crystal structures of BDNF homodimer and TrkB-D5 in complex with NT 4/5 are represented. The N-terminus 
(N) and C-terminus (C) as well as the different loop (L1, L2 and L4) and the region III of BDNF protein are 
indicated. The table summarizes the different compounds that have been developed with peptidic mimicking or in 
silico screening of either BDNF or TrkB epitopes.  
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V – Concluding remarks 
 
     The activation of TrkB, through e.g. the binding of neurotrophins or other transactivating mechanisms, 
plays an essential role in cell proliferation, differentiation and survival as well as in neurotransmitter 
release and synaptic plasticity. TrkB activation has been widely reported in the mediation of various 
pathophysiological processes, making this receptor an interesting target for many treatment strategies. 
Preclinical studies have demonstrated that the inhibition of TrkB has significant beneficial effects in 
animal models of depression, neuropathic pain, addictive behavior, epilepsy, and cancer. However, given 
the widespread distribution of TrkB throughout the central and peripheral nervous system as well as its 
pivotal role in brain plasticity, the use of TrkB inhibitors may have potential undesirable effects. 
Interestingly, in this respect, it was recently shown that the systemic administration of the TrkB 
antagonist Ana12 at low doses could efficiently alter behavior without affecting the survival of neurons in 
naïve mice (Cazorla et al., 2011). Thus, the development of therapeutic agents that can specifically block 
neurotrophin-dependent overactivation of TrkB preferably restricted to certain brain regions, without 
altering normal physiological function remains a current challenge. 
 
     Developing novel, potent and selective TrkB inhibitors represents a promising approach in drug 
discovery. Peptide-derived ligands are of limited efficacy because of their proteolytical instability and 
their poor blood-brain-barrier penetration. As such, in silico screening of small non-peptidic molecules 
has emerged as a promising method to develop TrkB ligands. Computational techniques directed at 
modeling BDNF-TrkB interaction derived from crystal structures can lead to the identification of novel 
pharmacophores displaying high specificity for TrkB as compared to p75 and other Trk receptors. It is 
also important to use an appropriate in vitro screening assay as a follow-up validation to address the 
functional properties of newly developed compounds. In that respect, the KIRA-ELISA assay was 
described as a rapid, sensitive and quantitative technique to measure TrkB activation in various cell types 
(Cazorla et al., 2010; Sadick et al., 1997).  
 
     In conclusion, increasing evidences suggest that TrkB activation and signaling is implicated in the 
course and development in a broad range of diseases. As such, the use of functional TrkB inhibitors in 
preclinical and clinical studies can considerably advance neurological, psychiatric and cancer research. 
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Abstract 
 
 
 
     Brain-derived neurotrophic factor (BDNF) is a key-role player in structural and functional plasticity, 
especially within the midbrain dopamine neurons that project to the ventral striatum. Recent evidence 
showed that drug abuse and social defeat in rodents could produce lasting epigenetic remodeling as well 
as BDNF upregulation, associated with major reorganizations within the neuronal network of the 
mesolimbic dopaminergic system. In the present study, we wanted to explore to which extent the 
inhibition of the BDNF tropomyosin-related kinase receptor B (TrkB) with the novel antagonist 
cyclotraxin-B could induce epigenetic remodeling at downstream TrkB target genes involved in 
neuroplasticity. As such, we used SH-SY5Y human neuroblastoma cells, known for their ability to 
differentiate into mature dopaminergic cells expressing high levels of activated TrkB. Our data indicate 
that cyclotraxin-B produced enduring downregulation of AKT1 and BCL2 expression, two major players 
in dendritic arborization and neuronal survival. Moreover, we showed that cyclotraxin-B-induced 
persistent changes in gene expression were associated with post-translational modifications at histone 
tails and changes in the machinery controlling DNA methylation. Hence, our findings provide further 
insight into the neuroplastic and epigenetic effects of cyclotraxin-B, and point out that the ability of TrkB 
antagonists to reverse abnormal BDNF-mediated epigenetic remodeling in the dopaminergic system could 
have therapeutic potentialities. 
 
 
 
 
Key words: TrkB inhibitor, gene expression, chromatin, methylation, acetylation, epigenetics, neuronal 
plasticity 
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I – Introduction  
 
     The interaction of brain-derived neurotrophic factor (BDNF) with its tropomyosin-related kinase 
receptor B (TrkB) plays an essential role in the establishment and maintenance of neuronal and synaptic 
plasticity (Chao, 2003). It is well established that chronic stress can lead to reduced BDNF expression 
resulting into neuronal atrophy and cell loss in the hippocampus, which might play an important role in 
the pathophysiology of stress-related diseases including post-traumatic stress disorders (PTSD), anxiety 
disorders and depression (Autry and Monteggia, 2012). In contrast, repeated administration of 
psychostimulants has been associated with increased levels of BDNF in the mesolimbic dopaminergic 
system, a process that is required for both sensitization and dependence to drugs (Graham et al., 2007; 
Russo et al., 2009). In addition, the increased plasticity induced by elevation of BDNF was also shown to 
be important in epileptogenesis, as well as in the induction and maintenance of neuropathic pain 
(Isackson et al., 1991; Wang et al., 2009). Mounting evidence suggests that the variations observed in 
BDNF expression and downstream signaling may rely on epigenetic regulation, conferring a stable 
imprint on gene transcription and susceptibility for disease (Boulle et al., 2012). BDNF has a complex 
gene structure that has been reported to be highly sensitive to environmental variations and concomitant 
epigenetic modifications (Boulle et al., 2012) underlying changes in gene expression. For instance, the 
methyl-CpG binding protein 2 (MeCP2) binds selectively to methylated DNA at BDNF promoter IV to 
repress its transcription (Chen et al., 2003). In addition, stable post-translational modifications at histone 
tails (i.e. H3K9 acetylation and H3K27 methylation) have been reported at the BDNF gene in ventral 
tegmental area (VTA) dopaminergic neurons projecting into the nucleus accumbens (NAc) in response to 
drug administration or withdrawal (Kumar et al., 2005; Sadri-Vakili et al., 2010; Schmidt et al., 2011).  
Hence, the identification and further characterization of drugs that directly target TrkB and its 
downstream neuroplastic effectors represent a promising avenue in neuroscience research. To date, only 
few drugs with TrkB inhibitory properties have been described (Boulle et al., 2012). In our experiments, 
we used a recently developed and innovative TrkB inhibitor, known as cyclotraxin-B. This small peptidic 
compound acts as a selective and potent TrkB antagonist that can block both BDNF-dependent and 
BDNF-independent activation of TrkB (Cazorla et al., 2010). In addition, cyclotraxin-B was shown to 
cross the blood-brain-barrier (BBB), reduce neuropathic pain in rats (Constandil et al., 2011), and 
produce anxiolytic effects in mice (Cazorla et al., 2010). In the present study, we wanted to explore to 
which extent the blockade of TrkB with cyclotraxin-B could involve lasting epigenetic changes at 
downstream plasticity-related genes in an in vitro model of differentiated dopaminergic cells. 
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II – Experimental procedures  
 
Cell culture and treatment: SH-SY5Y cells were obtained from the European Collection of Cell Cultures 
(ECACC, Salisbury, UK) and had undergone between 20 and 30 passages before use in our experiments. 
The cells were cultured in a 1:1 mixture of F-12K Kaighn’s modification nutrient medium and 
Dulbecco’s Modified Eagle Medium (ATCC, Molsheim, France) supplemented with 10% fetal calf 
serum, 10 U/ml penicillin G, 10 mg/ml streptomycin and 2 nM of L-Glutamine. To induce differentiation, 
the cells were treated with 10 µM of retinoic acid (RA) in culture medium for 5 days, and the medium 
was refreshed every 2 days. Pharmacological treatment was performed on 5-days-RA-differentiated SH-
SY5Y cells using the TrkB antagonist cyclotraxin-B (Cazorla et al., 2010). Based on previous reports, a 
dose of 1 µM cyclotraxin-B was used (Cazorla et al., 2010). Cyclotraxin-B was added to the culture 
medium for 6 or 24 hours, while chronic 96 h treatments consisted of 4 successive cyclotraxin-B 
exposures of 24 h each. 
 
Cell survival and differentiation: Cell viability (mitochondrial activity) was measured using a 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction assay. SH-SY5Y cells were 
incubated for 2 h at 37°C in the presence of MTT (0.5 mg/mL) diluted in culture medium. Incubation 
with isopropanol was performed for one additional hour. The absorbance was then measured at 540 nm 
(Victor X3, Perkin Elmer). Cells treated with 10% DMSO 1 h prior to the MTT addition were used as 
blank and the corresponding value was subtracted as background for each sample. For neurite outgrowth 
measurements, images of the cells were taken using an Olympus IX81 phase-contrast microscope 
(Olympus, Hamburg, Germany), and the neurite extensions were traced and quantified using the Neuron J 
plug-in of the Image J software (ImageJ 1.42, NIH, USA). 
 
Western blot:. SH-SY5Y cells were lysed in ice-cold lysis buffer (1% Nonidet P-40, 150 mM NaCl, 1 
mM EDTA, 10 mM Tris, pH 8.0, 10 mM NaF, 1 mM sodium orthovanadate and protease inhibitors 
cocktail) and protein content was loaded on a SDS-PAGE gel for electrophoretic migration and then 
transferred to a nitrocellulose membrane for 1 h at 4°C. Non-specific binding was blocked by incubating 
the membranes in an Odyssey blocking buffer (LI-COR Biosciences, NE, USA) for 1 h at room 
temperature. Rabbit anti-TrkB (Merck Millipore, MA, USA) and rabbit anti-phospho-TrkB Y817 
(Epitomics Inc, CA, USA) were used as primary antibodies for the detection of endogenous TrkB and its 
activated form. The membranes were incubated with the primary antibodies overnight at 4°C in the 
Odyssey blocking buffer. Then, after extensive washing, the membranes were incubated with the 
appropriate fluorescent secondary antibodies (Alexa Fluor 488 goat anti-rabbit; Molecular Probes, OR, 
USA) for 1 h at room temperature. Finally, the membranes were washed, dried and scanned using the 
Odyssey® infrared imaging system (Westburg, Leusden, The Netherlands). 
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Reverse transcription and real-time quantitative PCR (RT-qPCR): Total mRNA extraction was 
performed using Trizol® (Invitrogen, CA, USA), after which, cDNA synthesis was performed using a 
First Strand cDNA synthesis kit (Fermantas International Inc. Canada) according to the manufacturer’s 
protocol. Amplification was made with SYBR green I Master Mix (Roche Diagnostic, IN, USA). Primer 
sequences are indicated in Table S1. Gene expression was normalized using HPRT and RS27A as 
reference genes. Gene expression analysis was performed with the LightCycler 480 Real-Time PCR 
System (Roche Applied Science, IN, USA) and the conditions for the reaction involved 35 cycles in a 
fixed sequence of 95°C for 30 s, 62°C for 15 s, and 72°C for 15 s. 
 
Chromatin immunoprecipitation (ChIP): Briefly, cells were fixed in a 1% formaldehyde solution, after 
which they were lysed in ice-cold SDS lysis buffer containing protease inhibitors (Roche, Meylan, 
France). The chromatin was sheared in order to obtain DNA fragments that were approximately between 
400 and 800 base pairs. The solution of chromatin was pre-cleared with a mixture of protein A-agarose 
(Pierce, Thermo-Fischer, Illkirch, France) and salmon sperm (Agilent technologies, CA, USA), and then 
immunoprecipitated overnight at 4°C with 2 µg of rabbit anti-H3K9ac, mouse anti-H3K27me3 
(Millipore, Molsheim, France) or rabbit anti-MeCP2 (Sigma Aldrich, MO, USA) antibodies. After 
intensive washes, the immunoprecipitate was eluted from the beads using a 1 % SDS elution buffer and 
the protein-DNA cross-links were reversed by incubating the samples overnight at 65°C in the presence 
of 5 M NaCl. DNA fragments were then treated with proteinase K in order to digest the proteins, and 
DNA was isolated using phenol/chloroform/isoamyl alcohol and then precipitated with 100% ethanol and 
20 µg of glycogen. Fragments of promoter regions of target genes were quantified by quantitative PCR 
(see Table S2 for primer sequences and design). Ct values of immunoprecipitated samples were 
normalized to Ct values obtained from Input DNA. The specificity of the antibodies used in the 
experiments was determined by immunoprecipitation of the sample with non-specific HA-probe (Y-11) 
antibody (Santa Cruz Biotechnology Inc, CA, USA).  
 
Statistical analysis: Data are presented as mean + SEM. Statistical significance was determined using a 
two-tailed Student’s t test for comparison between two groups and, when necessary, a Welsh’s correction 
was used (Prism 5.0, GraphPad software, USA). The level of significance was set as P <0.05.  
 
 
III – Results  
 
Effects of RA treatment on cell differentiation and BDNF/TrkB signaling: To induce differentiation, 
we treated SH-SY5Y cells with 10 µM of RA for 5 days. Tracing and quantification of neurite length 
indicated that RA treatment increased neurite outgrowth as compared to non-treated cells (p=0,0019, after 
5 days of treatment; Figure 1A). In a similar manner, RA-treated SH-SY5Y cells showed increased 
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viability as compared to non-treated cells (p=0.0007; Figure 1A). Then, we wanted to investigate the 
potential implication of BDNF/TrkB signaling in RA-induced SH-SY5Y cell differentiation. We thus 
performed different kinetics of stimulation with 10 µM of RA in order to visualize the time-dependent 
implication of BDNF/TrkB signaling during SH-SY5Y cell differentiation. As shown by western blot 
analysis, the expression of full-length TrkB (≅ 145 kDa) increased gradually over the 5 days of RA 
treatment (Figure 1B). In a similar manner, the phosphorylation of TrkB at tyrosine residue 817 
progressively increased with RA treatment, indicating an overall increase of TrkB activation during RA-
induced SH-SY5Y cell differentiation (Figure 1B). Parallel RT-PCR quantifications showed that TrkB 
mRNA levels were increased by more than 200 times after a 5-day RA treatment (p=0.0087; Figure 1B), 
while those of BDNF mRNA did not significantly change (Figure 1B). As such, we also measured the 
expression of diverse genes implicated at different levels of neuronal and synaptic plasticity, and known 
to be involved in BDNF/TrkB downstream signaling. Accordingly, the transcripts of AKT1, BCL2, 
cFOS, HOMER1 and VGF were significantly upregulated (p=0.033, p=0.0008, p<0.0001, p=0.004 and 
p=0.03 respectively; Figure 2), while those of CREB, ERK1 and JNK genes did not change significantly 
after a 5-day RA treatment  (p>0.05; Figure 2). 
 
 
Effects of cyclotraxin-B on gene expression and epigenetic regulation: Because differentiated SH-
SY5Y cells were found to express high levels of TrkB and phospho-TrkB, experiments were performed in 
order to assess whether they could represent a model of choice to explore the cellular and molecular 
changes evoked by TrkB blockade. Differentiated SH-SY5Y cells were exposed for various times to the 
TrkB antagonist cyclotraxin-B (1 µM), and the resulting effects on the expression of downstream target 
genes were evaluated by real-time RT-qPCR. Quantitative determination of gene expression profiles at 
various times (see Figure 3) revealed that the AKT1, BCL2, TRKB and VGF genes were significantly 
downregulated after a 6 h exposure to cyclotraxin-B (p=0.011, p=0.0003, p=0.0062 and p=0.042 
respectively), whereas mRNA expression of the BDNF and cFOS genes remained unchanged. After a 24 
h treatment with cyclotraxin-B, only the AKT1 and BCL2 gene expression was still downregulated 
(p=0.0002 and p=0.0021 respectively; Figure 3). Finally, a tendency for a downregulation of AKT1 
expression and a significant decreased expression of BCL2 were observed after the 96 h exposure to 
cyclotraxin-B (p=0.10 and p=0.014 respectively; Figure 3). Thus, the gene expression profiles pointed 
towards a lasting downregulation of BCL2 and AKT1 during exposure to cyclotraxin-B.  
 
We then examined whether these changes observed at the gene expression level could be attributed to 
epigenetic modifications. As such, we performed chromatin immunoprecipitation after 4 successive 
stimulations of 24 hours each with 1 µM of cyclotraxin-B and measured H3K9ac, H3K27me3 and 
MeCP2 binding at the AKT1, BCL2, TRKB and VGF genes. A t-test comparison between control and 
cyclotraxin-B groups showed a specific enrichment of H3K27me3 (generally known as a repressive 
TrkB blockade and epigenetic changes 
	   113	  
mark) at the AKT1 gene promoter (p=0.036; Figure 4). Similarly, MeCP2, known as a repressor of gene 
transcription, was significantly increased at the TRKB and VGF gene promoters (p=0.0057 and p=0.030 
respectively; Figure 4). In contrast, a tendency (p=0.083; Figure 4) for decreased H3K9ac, known as a 
permissive mark, was observed at the BCL2 gene promoter. Of note, a general tendency towards a 
decreased H3K9ac and increased H3K27me3 at TrkB target genes was observed. Hence, cyclotraxin-B 
appears to mediate its effects on gene expression via modification at histone tails and MeCP2 binding. 
 
 
IV – Discussion  
 
     In the present study, we explored to which extent the inhibition of BDNF/TrkB signaling by 
cyclotraxin-B underlies epigenetic remodeling at downstream target genes. Our results showed that 
cyclotraxin-B induced a lasting downregulation of the expression of a subset of genes involved in 
neuroplasticity pathways, concomitant with post-translational modifications at histone tails as well as 
altered MeCP2 binding at those genes. 
 
A recent study demonstrated that RA treatment of SH-SY5Y cells induced their differentiation into a 
predominantly mature dopaminergic-like neuronal phenotype, characterized by increased dopamine 
synthesis and reuptake, together with a substantial suppression of other neurotransmitter phenotypes 
(Korecka et al., 2013). In the present study, we showed that RA treatment induced the expression and 
activation of TrkB receptor as previously reported (Encinas et al., 2000). Hence, the RA-treated SH-
SY5Y cells constitute a unique in vitro approach to explore BDNF/TrkB signaling in human 
dopaminergic neuron-like cells, and the high levels of TrkB phosphorylation represent a valuable model 
to study the action of TrkB inhibitors. An increase of TrkB signaling in the mesolimbic dopaminergic 
system has been reported following repetitive administration of psychostimulants, as well as after social 
defeat stress in rodents (Krishnan et al., 2007; Russo et al., 2009). In SH-SY5Y cells, we showed that 
BDNF levels were not significantly modulated by RA treatment indicating that the increased TrkB 
activation observed in differentiated SH-SY5Y cells might be triggered by BDNF-independent 
mechanisms. Such kind of phenomenon, known as transactivation, has been described for the TrkB 
receptor, and might be responsible for the maintenance of an excessive TrkB activation and a disturbed 
cellular homeostasis (Boulle et al., 2012). Interestingly, cyclotraxin-B was previously shown to inhibit 
both BDNF-dependent and -independent activation of TrkB (Cazorla et al., 2010). The administration of 
cyclotraxin-B on RA-treated cells resulted in the lasting downregulation of the AKT1 and the BCL2 
genes. Activation of the PI3K/Akt pathway through TrkB stimulation, involving AKT1 gene, is known to 
lead to structural changes in neuronal plasticity such as dendritic arborization and cellular morphology 
(Kumar et al., 2005), whereas BCL2 has been described as an important regulator of cell survival 
(Davies, 1995). Some studies found that the activation of Akt signaling in the striatal dopaminergic 
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system mediated excessive alcohol drinking behavior in rats, as well as nicotine and cocaine-induced 
plasticity (Neasta et al., 2011; Collo et al., 2012, 2013). Similarly, repetitive administration of cocaine 
was shown to induce BCL2 activation in the rat dorsal striatum (Ahn et al., 2010). 
 
On the other hand, an expanding body of evidence indicates that the maintenance of neuronal plasticity 
and integrity is controlled by epigenetic regulation involving DNA methylation and histones 
modifications (Maze et al., 2012; Sultan and Day, 2011). In particular, BDNF appears to be a primary 
target for epigenetic regulation, and persistent epigenetic modification of BDNF in the striatum has been 
observed after cocaine administration or prolonged stressors of high intensity (Boulle et al., 2012). Hence, 
the lasting upregulation of BDNF might subsequently impact on TrkB signaling and the epigenetic 
control of downstream gene expression. In the present study, we provide evidence that cyclotraxin-B, via 
the downregulation of TrkB signaling, could involve persistent changes in gene expression, mediated by 
epigenetic regulations. We found that cyclotraxin-B impacts on post-translational modifications at histone 
residues as observed by the changes in H3K9 acetylation and H3K27 tri-methylation. Similarly, 
cyclotraxin-B increased MeCP2 binding at some specific TrkB target genes, suggesting higher levels of 
methylation at the corresponding promoters. These latter observations might explain, at least in part, the 
persistent downregulation of TrkB target gene expression and indicate that epigenetic remodeling is part 
of the pharmacological action of cyclotraxin-B. 
 
Altogether, our data support the notion that TrkB signaling can underlie epigenetic remodeling at 
plasticity-related genes, and that its selective blockade by cyclotraxin-B is able to induce epigenetic 
remodeling in order to significantly impact on neuroplasticity. The usage of such compounds might be 
relevant to investigate the therapeutic value of TrkB inhibitors in models of drug addiction, where 
epigenetic alterations at BDNF/TrkB signaling seem to be critically implicated in underlying 
pathophysiological mechanisms. 
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Figures and legends. 	  	  	  
	  	  	  	  
Figure 1. TrkB receptor is essential for SH-SY5Y cells differentiation and survival.  
 
(A) SH-SY5Y cells were treated with RA (10 µM) or kept in normal culture medium for 5 days. Representative 
micrographs of 3 independent experiments are shown in the top panel (scale bar = 50 µm). Neurite extensions, 
measured using the Neuron J plug-in of Image J software, are expressed as mean length (µm) per cell (bottom panel 
left). SH-SY5Y cell viability after 5 days of RA was determined by a MTT assay (bottom panel right). (B) Western 
Blot analysis of SH-SY5Y cells treated for 1, 2, 3, 4 or 5 days (D1, D2, D3, D4 and D5) with 10 µM of RA. A 
representative picture from 3 independent experiments is shown. TRKB and BDNF mRNA expressions after 5 days 
of RA treatment are depicted in the bottom panel. Data are expressed as mean + SEM of triplicate determinations in 
3 independent experiments. **p < 0.01, ***p < 0.001 vs. CTL; Student’s t test.  
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Figure 2. Effects of RA treatment on the expression of genes involved in TrkB-mediated neuroplasticity. 
 
SH-SY5Y cells were treated with RA (10 µM) or maintained under normal control conditions for 5 days before RT-
qPCR determinations of mRNAs. The fold changes evoked by RA are expressed with respect to non-treated cells 
(CTL). Each bar is the mean + SEM of two representative experiments performed in triplicate. *p < 0.05, **p < 
0.01, ***p < 0.001 vs. CTL; Student’s t test. 
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Figure 3. Gene expression profiles after TrkB inhibition in differentiated cells. 
 
Differentiated SH-SY5Y cells were exposed to 1 µM of cyclotraxin-B (Cyclo-B) for 6, 24 or 96 hours. Exposure for 
96 hours corresponded to 4 successive administrations, every 24 hours. Cyclotraxin-B-induced effects on mRNA 
expression are expressed as fold changes in respective mRNA levels compared to the non-treated conditions (CTL). 
Each bar is the mean + SEM of two representative experiments performed in triplicate. *p < 0.05, **p < 0.01, ***p 
< 0.001 vs. CTL; Student’s t test. 
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Figure 4. Epigenetic expression profiles after TrkB inhibition in differentiated cells. 
 
Differentiated SH-SY5Y cells were exposed to 1 µM of cyclotraxin-B (Cyclo-B) for 96 hours, corresponding to 4 
successive administrations for 24 hours each. The specific enrichment of H3K9ac, H3K27me3 and MeCP2 at 
corresponding genes is expressed as percentage of non-treated conditions (CTL). Each bar is the mean + SEM of 3 
independent determinations. *p < 0.05, **p < 0.01 vs. CTL; Student’s t test. 
 
 
 
 
 
 
 
 
 
  
 
TrkB blockade and epigenetic changes 
	   121	  
Supplementary Material. 
 
 
 
 
 
 
 
Table S1. Sequences of primers used for real time quantitative RT-PCR. 
 
 
 
 
 
 
 
 
 
 
 
 
Table S2. Sequences of primers used for chromatin immunoprecipitation. 
 
The promoter regions and transcription start sites (TSS) were predicted using the “TRED Promoter Database”. 
Genomic regions of 2000 bases upstream of the first TSS of each candidate gene were used to design the different 
primer pairs. Further, CpG islands in the promoter regions were determined with Methprimer software and used as a 
putative indicator of MeCP2 binding sites. 
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Abstract 
 
 
There is a growing use of selective serotonin reuptake inhibitor (SSRIs) medications for treatment of 
depression during pregnancy and the postpartum period. However, very little research has investigated the 
long-term effects of perinatal SSRI exposure on offspring development. The aim of the present study was 
to determine the role of developmental fluoxetine exposure on affect-related behaviors and associated 
molecular mechanisms in adult male and female offspring using a rodent model of maternal adversity. 
For this purpose, gestationally stressed and non-stressed Sprague-Dawley rat dams were treated with 
either fluoxetine (5mg/kg/day) or its vehicle from postnatal day 1 (P1) to postnatal day 21 (P21). At 
adulthood, male and female offspring were assessed for anxiety- and depressive-like behaviors, and after 
sacrifice, epigenetic regulation of hippocampal brain-derived neurotrophic factor (BDNF) signaling was 
investigated. Results show that among male offspring, maternal fluoxetine exposure increased anxiety in 
naïve animals, while it decreased anxiety in prenatally stressed offspring. Moreover, among male 
offspring, exposure to prenatal stress increased depressive-like behavior, whereas among females, 
fluoxetine exposure, independent of maternal adversity, profoundly increased depressive-like behavior in 
adulthood. In addition, developmental exposure to fluoxetine decreased BDNF exon IV mRNA levels, 
which was associated with increased levels of the repressive histone 3 lysine 27 tri-methylated 
(H3K27me3) mark at the corresponding promoter in female offspring. Altogether, these data provide 
important evidence on the long-term programming effects of early-life exposure to SSRIs on the 
regulation of adult mood-related behaviors and their underlying molecular mechanisms.  
 
 
Keywords: Antidepressant, Prenatal stress, Mood, Serotonin, Epigenetics, BDNF 
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I – Introduction 
 
     Selective serotonin reuptake inhibitor (SSRIs) medications are commonly used for the treatment of 
maternal mood disorders with up to 10% of pregnant women being prescribed these medications (Cooper 
et al., 2007; Oberlander et al., 2006; Ververs et al., 2006). SSRIs cross the placental barrier and are 
present in breast milk and, therefore, can affect development (Homberg et al., 2010; Kristensen et al., 
1999; Rampono et al., 2004). Recent clinical studies reported that neonates exposed to SSRI medications 
during gestation have an increased risk for complications at birth such as low birth weight, younger 
gestational age, and reduced heart rate variability (Moses-Kolko et al., 2005; Nulman et al., 2002; 
Oberlander et al., 2009). In addition, clinical reports in infants also showed that prenatal exposure to 
SSRI-medications may alter neurodevelopment as evidenced by alterations in S100B levels (Pawluski et 
al., 2009), alter serotonergic system functioning (Laine et al., 2003), and the actions of the hypothalamic-
pituitary-adrenal (HPA) system (Oberlander et al., 2009; Oberlander et al., 2008; Pawluski et al., 2011; 
Pawluski et al., 2012b). Although there is limited clinical evidence on the long-term outcomes of 
developmental exposure to SSRI medications on mood-related outcomes in children, preclinical research 
is showing that perinatal exposure to SSRIs can impact upon measures of mood and HPA physiology in 
juvenile and adult offspring (Noorlander et al., 2008; Pawluski et al., 2012b; Rayen et al., 2011). Studies 
in rodent models have shown that there is a well-documented increase in anxiety-like behavior in adult 
male rodents perinatally exposed to fluoxetine (Ansorge et al., 2004; Noorlander et al., 2008; Karpova et 
al., 2009; Smit-Rigter et al., 2012; Lee et al., 2009). Interestingly, the reverse is true in female offspring, 
with a recent report showing that perinatal exposure to fluoxetine decreases anxiety- and depressive-like 
behaviors in adult female offspring (McAllister et al., 2012). Nevertheless, the molecular pathways 
underlying neurodevelopmental changes and long-term behavioral effects of early-life SSRIs exposure 
are still poorly understood. Serotonin plays an important role in the development of the brain modulating 
neuronal differentiation, axon guidance or dendritic pruning (Gaspar et al., 2003; Homberg et al., 2010). 
Conversely, administration of SSRIs, possibly by increasing the levels of serotonin at the synapse, is 
known to enhance brain-derived neurotrophic factor (BDNF) levels and promote neuroplasticity (Castren 
et al., 2008).  
Brain-derived neurotrophic factor (BDNF) is a small-secreted protein known to be critically involved in 
the regulation of neuronal plasticity, and alterations of BDNF signaling have been extensively implicated 
in the pathophysiology and treatment of mood disorders (Castren et al., 2010). Accordingly, a recent 
study showed that early postnatal administration of fluoxetine could induce long-lasting behavioral 
impairment, accompanied with changes in hippocampal BDNF mRNA levels in adult mice (Karpova et 
al., 2009). Similarly, epigenetic changes at the BDNF gene in adulthood have been associated with mood 
disorders (Boulle et al., 2012). Furthermore, serotonin transporter (5-HTT) knockout rats displayed 
decreased BDNF levels in the hippocampus and frontal cortex, concomitant with epigenetic dysregulation 
at the BDNF gene – i.e. increased DNA methylation at BDNF promoters IV and VI (Molteni et al., 2010). 
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Interestingly, mounting evidence suggest that early-life experience, including environmental adversity, 
reduced maternal care and exposure to toxins, can induce epigenetic reprogramming and increase the 
susceptibility for the development of mood disorders in adulthood (Onishchenko et al., 2008; Roth et al., 
2009; Weaver et al., 2004).  
 
The aim of the present study was to investigate the long-term molecular and behavioral consequences of 
developmental administration of fluoxetine, a popular SSRI regularly used during pregnancy and the 
post-partum period. Since perinatal maternal stress and depression itself can have marked, sex-dependent 
effects on the development of mood disorders and stress regulation (Morley-Fletcher et al., 2003; Maccari 
et al., 2007; Van den Hove et al., 2013), it is also important to investigate the effects of SSRIs using a 
model of maternal adversity (Ishiwata et al., 2005; Van den Hove et al., 2008; Pawluski., 2011). Hence, 
we explored the effects of maternal fluoxetine using a model of prenatal stress in rat, and focused 
particularly on measures related to affective behavior, HPA axis responsivity as well as epigenetic 
regulation of hippocampal BDNF signaling in adult male and female offspring. 
 
 
II – Material and methods 
 
Animals and procedures: All experiments were approved by the Animal Ethics Board of Maastricht 
University in accordance with Dutch governmental regulations (DEC 2008-157 and 2008-158). All 
efforts were made to minimize the pain and stress levels experienced by the animals. Thirty-eight adult 
female Sprague-Dawley rats (250–300 g; Charles River Laboratories, France) were used in the present 
study. Females were initially housed in pairs in opaque polyurethane bins (48 cm × 27 cm × 20 cm) with 
ad libitum access to rat chow (Sniff, The Netherlands) and tap water. Rats were kept under standard 
laboratory conditions in a 12 h:12 h light/dark schedule (lights on at 07:00 h). Pregnancy was determined 
by observation of vaginal plugs (embryonic day 0 – E0). Restraint stress was performed daily during the 
last week of pregnancy (E14-E21). Pregnant female rats (n=18) were individually restrained 3 times a day 
(at approximately 9.00, 13.00, and 17.00 h) for 45 minutes in transparent plastic cylinders, whilst being 
exposed to bright light (Van den Hove et al., 2005; Ward and Weisz, 1984). Control pregnant females 
(n=20) were left undisturbed in their home cages. Only litters of 10 or more pups were included in this 
study. Litters were culled to 10 pups if necessary (5 males and 5 females). Dams were randomly assigned 
to one of two treatment groups: fluoxetine (5 mg/kg/day) or vehicle, for a total of four groups of dams: 
(1) No stress + Vehicle (NS VEH), (2) No stress + Fluoxetine (NS FLX), (3) Prenatal Stress + Vehicle 
(PNS VEH), (4) Prenatal Stress + Fluoxetine (PNS FLX). A maximum of 2 male and female pups per 
litter were examined to prevent litter effects (Chapman and Stern, 1978). At postnatal day 21 (P21), pups 
were weaned and group-housed for further examination (2 male or 2 female rats/cage; n=12-16 rats per 
experimental condition per sex). Rats were kept at a reversed day-night cycle from this point onwards 
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(lights on from 17.00 - 5.00 h). Anxiety- and depression-related behavior of the rats was analyzed from 
P140 onwards (in the order as discussed below). At P196, the animals were killed by quick decapitation. 
 
Fluoxetine treatments: Fluoxetine and its active metabolite, norfluoxetine, can pass to offspring through 
lactation (Gentile et al., 2007), therefore fluoxetine treatment was administered via osmotic minipumps 
(Alzet Osmotic pumps, 2ML4) to the dams as previously described (Rayen et al., 2011). Implants were 
filled with either fluoxetine–HCl (Fagron, Belgium) dissolved in vehicle (50% propylenediol in saline; 
5mg/kg/day), or with vehicle as previously described (Pawluski et al., 2012a). Minipumps were implanted 
subcutaneously in the dorsal region of the dams while the dams were under mild isofluorene anaesthesia 
on post-partum day 1 (P1). Implants took a maximum of 20 min and therefore dams were separated from 
their litters for a maximum of 20 min. Fluoxetine exposure to offspring occurred during a stage of neural 
development in rodents analogous to that of the third trimester in humans (Romijn et al., 1991).  
 
Behavioral testing: 
 
Open field test (OFT) 
The open field test (OFT) was conducted in a square Plexiglas base (100 x 100 cm) with a black floor and 
transparent plexiglas walls (40 cm high; Van den Hove et al., 2013). The arena was subdivided into a 60 x 
60 cm central zone, 20 x 20 cm corners and 60 x 20 cm walls. Immediately after the rat had been placed 
in the centre of the open field, the movements of the animal were scored automatically under low light 
conditions using a camera connected to a computerized system (Ethovision Pro, Noldus, The 
Netherlands). Both the time spent in the different zones and total distance moved were scored. After five 
minutes, the rat was removed from the apparatus and the maze was cleaned with ethanol (70%) and water 
and dried thoroughly to prevent transmission of olfactory cues. 
 
Forced swim test (FST) 
In the forced swimming test (FST), originally designed by Porsolt and colleagues (2006), four cylindrical 
glass tanks (50 cm tall, 20 cm in diameter) were filled to a height of 30 cm with 25°C water. The 
movements of the rat were scored automatically with a computerized system (Ethovision Pro, Noldus, 
The Netherlands) during a 10 min session under low light conditions. Scored were ’immobility’, which 
reflects no movement at all and/or minor movements necessary to keep the nose above the water, and 
‘strong mobility’, reflecting ‘escape behavior’ (e.g. climbing against the walls and diving). Settings 
within Ethovision were adjusted based on manually recorded sessions and were attuned for each sex 
separately (immobility/mobility threshold: 12 and 20; mobility/strong mobility threshold: 16.5 and 23.9 
for males and females, respectively (Strackx et al., 2009; Van den Hove et al., 2013).  
 
Elevated zero maze (EZM) 
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The elevated zero maze (EZM) introduced by Shepherd and colleagues (1994) consisted of a circular 
alley (diameter of 100 cm; path width 10 cm) made from black plastic material that was transparent for 
infrared light and elevated 20 cm above the floor. The maze was divided into four parts, i.e., two opposite 
open parts and two opposite closed parts with sidewalls 30 cm in height. The open parts (open arms; OA) 
had borders with a height of 5 mm to prevent the rat from stepping down from the apparatus. For the test, 
the rat was placed into one of the open parts facing a closed part (closed arms; CA) of the apparatus. After 
five minutes the rat was removed from the apparatus and the maze was cleaned with ethanol (70%) and 
water and dried thoroughly. The movements of the rat were scored automatically under dark conditions 
with a computerized system using an infrared video camera (Ethovision Pro, Noldus, The Netherlands). 
Percentage of time spent in the open part of the maze and total distance traveled were determined as 
described previously (Van den Hove et al. 2013).  
 
Corticosterone response and radioimmuno assay: To test the HPA axis responsivity, rats were 
individually placed in a type II (mouse) cage filled with 500 ml 25°C water. Experiments were performed 
in an isolated room between 09.00 and 13.00 h. Immediately after taking the rat from its home cage, a 
first blood sample was collected via a saphenous vein puncture representing the basal corticosterone level. 
Immediately after this first sample was taken, the rat was put in the cage filled with water for 20 min after 
which a second blood sample was taken. Afterwards, the animal was returned to its home cage and left 
undisturbed for 40 min after which a final blood sample was taken. Blood samples were kept on ice and 
centrifuged at 5000 rpm for 10 min at 4 °C, after which the plasma was frozen down to -75 °C for 
subsequent determination of corticosterone levels. Samples were run in duplicate using a commercially 
available radioimmunoassay (RIA) kit for rat corticosterone from MP Biomedicals (Corticosterone I-125 
for rats and mice, MP Biomedicals), as explained previously (Van den Hove et al., 2013). The average 
intra- and inter-assay coefficients of variation for all assays were below 10%. The assay had a sensitivity 
of 7.7 ng/mL. 
 
Quantitative reverse transcriptase PCR (qRT-PCR): Total mRNA extraction was performed using 
RNeasy lipid tissue mini kit (Qiagen, Venlo, The Netherlands), after which, cDNA synthesis was 
performed using a First Strand cDNA synthesis kit (Fermantas International Inc. Canada) according to the 
manufacturer’s protocol. Amplification was performed using SYBR green I Master Mix (Roche 
Diagnostic, IN, USA). Primer sequences are indicated in Table S1. Gene expression analysis was 
performed with the LightCycler 480 Real-Time PCR System (Roche Applied Science, IN, USA) and the 
conditions for the reaction involved 35 cycles in a fixed sequence of 95°C for 30 s, 62°C for 15 s, and 
72°C for 15 s. Gene expression was normalized using HPRT and RS27A as reference genes. 
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Chromatin immunoprecipitation (ChIP): Since developmental exposure to fluoxetine markedly affected 
behavior and BDNF IV mRNA expression in females as compared to males, we decided to investigate the 
epigenetic regulation at BDNF promoters only in the female gender. Hippocampal tissues were fixed in a 
1% formaldehyde solution, after which they were lysed in ice-cold SDS lysis buffer containing protease 
inhibitors (Roche, Meylan, France). The chromatin was sheared in order to obtain DNA fragments that 
were approximately between 400 and 800 base pairs. The solution of chromatin was pre-cleared with a 
mixture of protein A-agarose (Pierce, Thermo-Fischer, Illkirch, France) and salmon sperm (Agilent 
technologies, CA, USA), and then immunoprecipitated overnight at 4°C with 2 µg of rabbit anti-H3K9ac, 
mouse anti-H3K27me3 (Millipore, Molsheim, France) or rabbit anti-MeCP2 (Sigma Aldrich, MO, USA) 
antibodies. After intensive washing, the immunoprecipitate was eluted from the beads using a 1 % SDS 
elution buffer and the protein-DNA cross-links were removed by incubating the samples overnight at 
65°C in the presence of 5 M NaCl. DNA fragments were then treated with proteinase K in order to digest 
the proteins, after which DNA was isolated using phenol/chloroform/isoamyl alcohol and subsequently 
precipitated with 100% ethanol and 20 µg of glycogen. Fragments of promoter regions of target genes 
were quantified by quantitative PCR (see Table S2 for primer sequences and design). Ct values of 
immunoprecipitated samples were normalized to Ct values obtained from Input DNA. The specificity of 
the antibodies used in the experiments was determined by immunoprecipitation of the sample with non-
specific HA-probe (Y-11) antibody (Santa Cruz Biotechnology Inc, CA, USA). 
 
Statistical analysis: Because of profound expected sex and experimental condition interactions (e.g. Van 
den Hove et al., 2013; Zuena et al., 2008), parameters studied in the offspring were analyzed for each sex 
separately using a two-way analysis of variance (ANOVA; condition x treatment). Plasma corticosterone 
levels were analyzed by a repeated measures ANOVA (experimental condition x time) and also 
independently at the different time points using ANOVA. Statistical significance was assumed to exist at 
p ≤ 0.05. All statistics were carried out using SPSS software version 17 (SPSS Inc, USA). 
 
 
III – Results 
 
Effect of prenatal stress and maternal fluoxetine on affective behaviors: 
 
Elevated Zero Maze (EZM) 
The time spent in the open arms and the distance covered in the EZM are depicted in Figure 1. In 
addition, the frequency to visit the open and closed arms is shown in Table S3. No differences were found 
in terms of the time spent in the open arms or the frequency of open arm visits in the EZM.  
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Among males, a significant condition x treatment interaction was observed regarding the distance 
traveled within the EZM [F(3,51)=4.038; p=0.05], indicating that FLX exposure decreased the distance 
traveled in naïve animals, while it increased the distance moved in animals previously exposed to PNS.  
Among females, there was significant condition x treatment interaction effect regarding the distance 
traveled within the EZM [F(1,52)=3.99, p=0.05]. 
 
Open Field Test (OFT) 
Time spent in the various zones of the open field as well as the number of visits to the center and the total 
distance covered in the OFT are shown in Figure 2 and Figure S4.  
Among males, a significant condition x treatment interaction was observed on the number of visits to the 
center of the open field [F(1,51)=5.04; p=0.029], with FLX decreasing the number of visits to the center 
in naïve animals and increasing the frequency of visits to the center in prenatally stressed offspring (NS 
FLX < PNS FLX; p=0.024). Similarly, regarding the distance traveled within the open field, a tendency 
towards a condition x treatment interaction was observed in adult males [F(1,51)=3.48; p=0.067], 
indicating that FLX exposure differentially affected distance traveled in NS versus PNS adult male 
offspring.  
Among females, PNS exposure tended to increase time spent along the walls [F(1,52)=3.78; p=0.057] of 
the open field. There were no other significant effects observed in any of the other parameters. 
 
Forced Swim Test (FST) 
Results from the FST are shown in Figure 3. Among males, a significant effect of PNS on strong mobility 
in the FST was found [F(3,51)=4.09; p=0.048], indicating that PNS increased escape-like behavior i.e. 
struggling in this behavioral test. 
Among females, a significant treatment effect was observed [F(1,52)=11.48; p=0.001], indicating 
increased immobility after FLX exposure, independent of prenatal stress experience (NS VEH < NS FLX; 
p=0.016 and PNS VEH < PNS FLX; p=0.025). 
 
 
Effects of prenatal stress and maternal fluoxetine on biological parameters: 
 
Weight and corticosterone response  
Plasma corticosterone levels prior to restraint, immediately after 20 min of restraint stress, and 40 min 
after being placed back into the home cage are depicted in Figure S2. As expected, there was a significant 
main effect of time in both males (F(2,36)=71.215, p<0.001) and females (F(2,38)=72.284, p<0.001) 
showing that 20 min after restraint stress plasma corticosterone levels were elevated. There were no other 
significant differences with treatment in males or females in corticosterone levels (0.2 < p <0.9).  
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In addition, the weight of the animals was modified neither by developmental fluoxetine exposure nor 
than maternal adversity in male and female offspring (Figure S3). 
Gene expression in the hippocampus 
Hippocampal gene expression profiles are shown in Figure 4 and Table S4. Among males, a significant 
effect of FLX treatment on BDNF IV and tropomyosin-related kinase receptor B (TrkB) mRNA levels 
was observed [F(1,51)=5.57; p=0.022 and F(1,51)=7.21; p=0.0098 respectively], indicating that FLX 
decreased both BDNF IV and TrkB mRNA levels. In addition, BDNF IV mRNA levels were decreased in 
animals exposed to PNS (PNS VEH < NS VEH; p=0.041). Finally, there was a tendency towards a stress 
x treatment interaction for BDNF IX mRNA levels [F(1,51)=4.30; p=0.043].  
Among females, there was a significant effect of PNS exposure on BDNF IV mRNA levels 
[F(1,47)=8.34; p=0.0058]. Accordingly, BDNF IV mRNA expression was increased in the hippocampus 
of female rats exposed to PNS (NS VEH < PNS VEH; p=0.018). Finally, there was a significant effect of 
FLX exposure on BDNF IV mRNA levels [F(1,47)=5.01; p=0.030], pointing towards a global decrease of 
BDNF IV mRNA levels independent of prenatal stress experience.  
 
Epigenetic regulation of the BDNF gene 
The specific enrichments of methyl CpG binding protein 2 (MeCP2), histone 3 lysine 27 tri-methylated 
(H3K27me3) and histone 3 lysine 9 acetylated (H3K9ac) at the BDNF promoter IV and the BDNF 
promoter IX in female offspring are represented in Figure 5. There was a significant stress x treatment 
interaction for H3K27me3 enrichment at the BDNF promoter IV [F(1,32)=6.35; p=0.017]. In addition, 
FLX treatment significantly increased the specific enrichment of H3K27me3 at the BDNF promoter IV 
(PNS VEH < PNS FLX; p=0.016). Of note, a trend for PNS exposure to decrease the specific enrichment 
of H3K27me3 at the BDNF promoter IV (PNS VEH < PNS FLX; p=0.056) was observed. Furthermore, a 
tendency for a treatment effect on MeCP2 specific enrichment at the BDNF promoter IV was observed 
[F(1,30)=3.00; p=0.093], indicating that FLX tended to increase MeCP2 occupancy in this promoter 
region. It is interesting to note that MeCP2 binding at the BDNF promoter IV correlated with immobility 
score in the FST (Figure S7). Finally, a tendency for a stress x treatment effect on H3K9ac specific 
enrichment was also reported [F(1,30)=3.00; p=0.073], indicating that FLX tended to increase H3K9ac at 
the BDNF promoter IX, while decreasing H3K9ac at this same promoter.  
 
 
IV – Discussion  
 
     Fluoxetine, an antidepressant belonging to the class of SSRIs, is widely used in the clinic for the 
treatment of mood disorders during pregnancy and the post-partum period (Cooper et al., 2007; 
Oberlander et al., 2006; Ververs et al., 2006). However, the long-term effects of early-life treatment with 
this medication are still poorly understood. In this context, the aim of the present study was to investigate 
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the long-term effects of developmental fluoxetine exposure using a model of maternal adversity, at the 
level of anxiety and depression-related behavior, HPA axis responsivity and epigenetic regulation of 
BDNF/TrkB signaling in adult male and female offspring. 
 
Effect of prenatal stress and maternal fluoxetine on affective behavior and HPA response: Our data 
showed that maternal adversity tended to increase depressive-like behavior in male offspring, whereas, 
among females, no effects of prenatal stress on depressive-like or anxiety-like behaviors were observed. 
Those results are in accordance with previous studies that reported similar observation in male and 
females offspring prenatally exposed to maternal stress, and further support a sex-dependent effect of 
perinatal maternal stress on mood-related behaviors (Van den Hove et al., 2013).  
Further, among male offspring, maternal fluoxetine exposure increased anxiety in naïve animals, while it 
decreased anxiety in prenatally stressed offspring. Increase in anxiety behavior following perinatal 
exposure to fluoxetine has been well documented in male rodents (Ansorge et al., 2004; Ansorge et al., 
2008; Noorlander et al., 2008; Karpova et al., 2009; Smit-Rigter et al., 2012; Lee et al., 2009). However, 
the present study was one of the first to investigate the long-term effects of fluoxetine using a model of 
maternal adversity. Accordingly, this work shows that the effects of developmental exposure to SSRI 
medications may profoundly differ when using healthy dams and offspring in comparison to using a 
model of maternal adversity. This notion may have important implications when examining e.g. the long-
term behavioral effects (and its neurobiological underpinnings) of early life SSRI exposure. 
On the other hand, among females, fluoxetine exposure profoundly increased depressive-like behavior in 
adulthood, independent of maternal adversity. This finding is of particular interest because it 
demonstrates that the effects of developmental SSRI exposure are strongly sex- and age-dependent, as we 
have previously shown, using the exact “fluoxetine-maternal adversity model” that developmental 
fluoxetine exposure was able to reverse the effects of prenatal maternal stress on depressive-like behavior 
in adolescent male and female offspring (Rayen et al., 2011), i.e. pointing towards overall beneficial 
effects of perinatal SSRI exposure. Here, we provide clean-cut evidence that early-life exposure to SSRIs 
negatively impacts upon mood-related behaviors in adult female offspring. 
Nevertheless, previous findings using the exact prenatal stress procedures found an alteration in HPA axis 
responsivity, showing that male offspring prenatally exposed to maternal restrain stress displayed a 
significant alteration in basal and stress-induced corticosterone secretion (Van den Hove et al., 2013).  
The discordance between this study and previous reports may be attributed to the implantation mini-
pump. Such type of surgery might represent additional stress for the mothers and result in differential 
outcome in the neuroendocrine measures.  
 
Effect of prenatal stress and maternal fluoxetine on BDNF/TrkB signaling: To further understand the 
molecular pathways underlying behavioral dysfunction in male and female offspring prenatally exposed 
to fluoxetine, we examined the hippocampal expression of BDNF/TrkB downstream target genes. BDNF 
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IV mRNA levels were decreased in males prenatally exposed to stress, whereas the opposite was 
observed in females. The literature on prenatal stress and BDNF expression is not very consistent, and the 
timing, duration and intensity of stress as well as the species or strain of animals used seems to 
meticulously interfere with this biological parameter (Roceri et al., 2002; Karpova et al., 2009; Neeley et 
al., 2011). The present findings indicate that distinct mechanisms are implicated in the adaptation and 
response to stress in male versus female offspring, leading to differential BDNF expression. Moreover, 
maternal fluoxetine decreased BDNF IV mRNA levels only in naïve male offspring. Similarly, the 
mRNA levels of TrkB, the high-affinity receptor for BDNF, were decreased in naïve male offspring 
exposed to maternal fluoxetine. These findings, together with the observation that maternal fluoxetine 
increased anxiety-like behavior in naïve male offspring, support the notion that BDNF/TrkB signaling 
plays an important role in anxiety regulation (Chen et al 2006; Martinowich et al., 2007).  
Moreover, maternal fluoxetine decreased BDNF IV mRNA levels independently of exposure to prenatal 
stress in female offspring, an observation that correlated with the increased despair-like behavior found in 
the FST. A decrease of BDNF in the hippocampus has been reported in post-mortem brain analysis of 
suicide victims (Dwivedi et al., 2003; Pandey et al., 2008), and rodent models of stress and depression 
also showed similar decrease of BDNF expression, including reduced levels of BDNF exon IV and exon 
IX (Tsankova et al., 2006; Onishchenko et al., 2008; Fuchikami et al., 2009). BDNF expression is tightly 
regulated at the level of transcription with differential exon usage, suggesting a crucial role for the various 
transcripts in different functions and related processes (Pruunsild et al., 2007; Baj et al., 2011). More 
specifically, the BDNF IV transcript was shown to be involved in the regulation of the stress response, 
and in the mechanism of action of antidepressants (Boulle et al., 2012). Interestingly, fluoxetine treatment 
in adulthood has been shown to increase BDNF levels (including BDNF IV mRNA levels) in cortico-
limbic structures to induce antidepressant and anxiolytic effects in rodents (Martinowich et al., 2007). 
Data from the current study suggest that the molecular mechanisms involve in early-life versus adulthood 
intervention with fluoxetine are distinct. This can partly be explained by the fact that during postnatal 
development, certain populations of neurons express a transient serotonergic phenotype that no longer 
exists at adulthood, and the modulation of this partial serotonin system might interfere with the fine-
tuning process of neuronal networks (Cases et al., 1998; Gaspar et al., 2003). Moreover, fluoxetine was 
shown to interact with several targets including serotonin receptors (2A, 2C and 2B) and ion channels 
(Mostert et al., 2008), next to the serotonin transporter. Hence, the differential patterns of expression of 
these systems in early-life might be determinant in the long-term biological action of fluoxetine. 
 
 
Epigenetic regulation of BDNF/TrkB siganling in female offspring: Since maternal fluoxetine mostly 
affected long-lasting behavioral and molecular measures in female offspring, we conducted additional 
investigations in this sex to test whether the observed alterations could be attributed to epigenetic 
programming. Developmental experiences have been shown to modulate post-translational histone 
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modifications and DNA methylation, thereby altering the epigenetic program and leading to long-lasting 
neurochemical changes causally related to adult psychopathology (Onishchenko et al., 2008; Weaver et 
al., 2004). In addition, increasing evidences suggest that epigenetic regulations are involved in the 
molecular mechanisms of action of antidepressant drugs, including SSRIs (Vialou et al., 2013). In the 
present study, maternal fluoxetine tended to increase MeCP2 binding at BDNF promoter IV in female 
offspring, independent of prenatal stress exposure. MeCP2 has been shown to selectively bind to BDNF 
promoter IV to repress its transcription in post-mitotic neurons (Chen et al., 2003; Martinowich et al., 
2003). In addition, this epigenetic regulator is essential in neurodevelopment (Gonzales et al., 2010), and 
increased MeCP2 binding and upregulation in the brain promoted anxiety in mice (Samaco et al., 2012). 
Furthermore, developmental fluoxetine increased H3K27me3 at the BDNF promoter IV in female 
offspring prenatally exposed to maternal adversity. H3K27me3 is a repressive histone mark. Hence, this 
observation is in accordance with the decreased expression of BDNF IV mRNA in the hippocampus of 
female offspring. This finding is of particular interest because it indicates that the long-term 
neurochemical effects of developmental fluoxetine might reside in long-lasting epigenetic repression of 
gene transcription. Of note, this effect was observed only in female offspring prenatally exposed to stress, 
indicating that maternal adversity increased the vulnerability for fluoxetine-induced epigenetic 
reprogramming in the hippocampus. 
 
Conclusion and perspectives: The number of children exposed to SSRI medications during development 
in constantly increasing (Oberlander et al., 2006; Cooper et al., 2007), and the long-term effects of such 
exposure are still to be determined. In this context, we showed that the developmental exposure to 
fluoxetine, a popular SSRI for post-partum depression, had negative impact on mood-related behaviors, 
which appeared to be strongly age- and sex- dependent. In addition, the effect on developmental 
fluoxetine may profoundly differ when using healthy dams and offspring in comparison to using a model 
of maternal adversity in rodents. Further, the present study brings novel insights into the long-term 
molecular regulations underlying developmental exposure to fluoxetine. To our knowledge, this study is 
the first one to demonstrate that maternal fluoxetine exposure could be associated with persistent 
epigenetic remodeling at BDNF/TrkB signaling in adulthood. Hence, our data support the idea that 
exposure to SSRI medications during development might have negative consequences on 
neurodevelopment and mood-related behavior in adulthood, which may be attributed, at least in part, to 
enduring epigenetic reprogramming in signaling pathways implicated in neuronal plasticity. 
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Figures and legends. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Effect of prenatal stress and maternal fluoxetine in the elevated zero maze (EZM) 
 
Males (A) and females (B) offspring were exposed to an EZM, and the time spent in open arms (OA) and the total distance 
travelled are represented. In both male and female offspring, there was a significant stress x treatment interaction in the distance 
moved in the EZM, suggesting a differential effect of fluoxetine in naïve versus prenatally stressed animals. Data are expressed 
as mean + SEM of n=12-16 rats per group. *p < 0.05; Two-way ANOVA. NS = no stress, PNS = prenatal stress, VEH = vehicle, 
FLX = fluoxetine. 
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Figure 2. Effect of prenatal stress and maternal fluoxetine in the open field test (OFT)  
 
Males (A) and females (B) offspring were exposed to an OFT, and the time spent in the center, the frequency to the center and 
the total distance travelled are represented. Maternal fluoxetine treatment (FLX) had opposite effects on the frequency to the 
center in naïve animals (NS) as compared to prenatally stressed animals (PNS) in male offspring. Of note, a trend towards a 
similar effect was observed in the distance moved in males. No differences in any parameter were observed in females. Data are 
expressed as mean + SEM of n=12-16 rats per group. *p < 0.05; Two-way ANOVA, Fisher LSD post hoc test. NS = no stress, 
PNS = prenatal stress, VEH = vehicle, FLX = fluoxetine. 
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Figure 3. Effect of prenatal stress and maternal fluoxetine in the forced swim test (FST) 
 
Males (A) and females (B) offspring were exposed to a FST, and the time spent in immobility, mobility and strong mobility is 
represented. There was a significant stress x treatment interaction in the mobility time in males. A trend toward a similar effect in 
the immobility time was also observed. In addition, male rats exposed to prenatal stress (PNS) showed a decrease time of strong 
mobility as compared to non-stress animals (NS). In females, maternal fluoxetine treatment (FLX) significantly increased the 
time spent in immobility in naïve (NS) and prenatally stressed (PNS) animals. No differences were observed in the mobility and 
strong mobility time in female offspring. Data are expressed as mean + SEM of n=12-16 rats per group. *p < 0.05; **p < 0.01;  
Two-way ANOVA, Fisher LSD post hoc test. NS = no stress, PNS = prenatal stress, VEH = vehicle, FLX = fluoxetine. 
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Figure 4. Effect of prenatal stress and maternal fluoxetine on BDNF/TrkB signaling in the hippocampus  
 
mRNA levels of BDNF and TrkB in the hippocampus of males (A) and females (B) offspring were measured by quantitative 
real-time RT-PCR, and are expressed as fold changes as compared to naïve animals (NS SAL). There was a significant effect of 
maternal fluoxetine treatment (FLX) on BDNF IV and TrkB mRNA levels in males. In addition, male rats exposed to prenatal 
stress (PNS) showed decreased BDNF IV mRNA expression as compared to non-stressed animals. In females, there was a 
significant effect of maternal fluoxetine on BDNF IV mRNA levels. In contrast to what observed in males, prenatal stress 
increased BDNF IV mRNA levels in female offspring. No differences were observed in BDNF IX and TrkB mRNA levels in 
females. Data are expressed as mean + SEM of n=12-16 rats per group. *p < 0.05; **p < 0.01; Two-way ANOVA, Fisher LSD 
post hoc test. NS = no stress, PNS = prenatal stress, VEH = vehicle, FLX = fluoxetine. 
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Figure 5. Effect of prenatal stress and maternal fluoxetine on epigenetic regulation of BDNF gene in female offspring  
 
The specific enrichment of MeCP2, H3K27me3 and H3K9ac at the BDNF promoter IV (A) and the BDNF promoter IX (B) was 
measured by chromatin immunoprecipitation (ChIP) followed by quantitative real-time PCR, and is expressed as percentage of 
control animals (NS SAL). A trend towards an increase of MeCP2 binding at the BDNF promoter IV was observed after maternal 
fluoxetine treatment (FLX). In addition, maternal fluoxetine treatment significantly increased the enrichment of H3K27me3 at 
the BDNF promoter IV in female rats exposed to prenatal stress (PNS). Further, a tendency for a stress x treatment interaction for 
H3K9ac enrichment at the BDNF promoter IX was observed, but did not reach statistical significance. Data are expressed as 
mean + SEM of n=7-9 rats per group. **p < 0.01; Two-way ANOVA, Fisher LSD post hoc test. NS = no stress, PNS = prenatal 
stress, VEH = vehicle, FLX = fluoxetine. 
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Supplementary data. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S1. Schematic representation of experimental timeline 
 
Restraint stress was performed daily during the last week of gestation (G14-G21). Fluoxetine or with vehicle was administered 
via osmotic minipumps (Alzet Osmotic pumps, 2ML4) to the dams during the postpartum period (P1-P21). At postnatal day 21 
(P21), pups were weaned and group-housed for further examination (2 male or 2 female rats/cage; n=12-16 rats per experimental 
condition per sex). Anxiety- and depression-related behavior of the rats was analyzed from P140 onwards (in the order as 
discussed below). At P196, the animals were killed by quick decapitation. 
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Table S1. Summary table of behavioral analysis in male offspring  
 
Data are represent mean ± SEM of n=12-16 rats per group. *p < 0.05; Two-way ANOVA, Fisher LSD post hoc test. NS = no 
stress, PNS = prenatal stress, VEH = vehicle, FLX = fluoxetine. 
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Table S2. Summary table of behavioral analysis in female offspring 
 
Data are represent mean ± SEM of n=12-16 rats per group. *p < 0.05; **p < 0.01; Two-way ANOVA, Fisher LSD post hoc test. 
NS = no stress, PNS = prenatal stress, VEH = vehicle, FLX = fluoxetine. 
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Figure S2. Effect of prenatal stress and maternal fluoxetine on corticosterone response  
 
The plasma corticosterone levels were measured by radioimmuno assay in basal condition, stress condition and after recovery 
from stress. Corticosterone levels were increased after 20 min of stress exposure in both males and females, and returned to 
baseline after 40 min after the stress exposure. Maternal fluoxetine treatment and prenatal stress did not affect corticosterone 
response in basal, stress or recovery condition. Data are expressed as mean ± SEM of n=12-16 rats per group. CV = control 
vehicle, CF = control fluoxetine, PSV = prenatal stress vehicle, PSF = prenatal stress fluoxetine 
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Figure S3. Effect of prenatal stress and maternal fluoxetine on body weight 
 
The weight of rats was measure on week 17, week 21, week 23 and week 28 after birth. No differences between groups were 
found at any time point. Data are expressed as mean ± SEM of n=12-16 rats per group. Two-way ANOVA. NS = no stress, PNS 
= prenatal stress, SAL = saline, FLX = fluoxetine. 
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Table S3. Primer sequences used in q RT-PCR experiments  
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Table S4. Primer sequences used in ChIP experiments  
 
The primers for the BDNF IV promoter were obtained from previous studies (Gomez-Pinilla et al., 2011). The promoter region 
of BDNF IX and its transcription start sites (TSS) were predicted using the “TRED Promoter Database”. Genomic regions of 
2000 bases upstream of the first TSS of each candidate gene were used to design the different primer pairs. Further, CpG islands 
in the promoter regions were determined with Methprimer software and used as a putative indicator of MeCP2 binding sites. 
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Table S5. Effect of prenatal stress and maternal fluoxetine on hippocampal gene expression in male offspring 
 
 mRNA levels of BDNF/TrkB downstream target genes were measured in the hippocampus of males offspring by quantitative 
real-time RT-PCR, and are expressed as fold changes as compared to naïve animals (NS SAL). Data are represent mean ± SEM 
of n=12-16 rats per group. *p < 0.05; Two-way ANOVA, Fisher LSD post hoc test. NS = no stress, PNS = prenatal stress, VEH 
= vehicle, FLX = fluoxetine. 
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Table S6. Effect of prenatal stress and maternal fluoxetine on hippocampal gene expression in female offspring 
 
 mRNA levels of BDNF/TrkB downstream target genes were measured in the hippocampus of females offspring by quantitative 
real-time RT-PCR, and are expressed as fold changes as compared to naïve animals (NS SAL). Data are represent mean ± SEM 
of n=12-16 rats per group. *p < 0.05; Two-way ANOVA, Fisher LSD post hoc test. NS = no stress, PNS = prenatal stress, VEH 
= vehicle, FLX = fluoxetine. 
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Abstract 
 
 
 
Growing evidences indicate that impairment of the hypothalamo-pituitary-adrenal (HPA) axis, a key 
regulator of the stress response, might be responsible for the hippocampal atrophy and dysfunction often 
observed in mood disorders. Antidepressants, possibly through the activation of BDNF signaling, may be 
able to enhance neuroplasticity and restore a normal hippocampal function. In this context, glucocorticoid 
receptor-impaired (GRi) mice – a transgenic mouse model for mood disorders – were used to investigate 
the role of BDNF/TrkB signaling in the behavioral and neurochemical effects of the new generation 
antidepressant agomelatine. GRi mice and their wild-type littermates were treated for 21 days with either 
agomelatine (50mg/kg/day; i.p) or the TrkB inhibitor Ana12 (0.5mg/kg/day, i.p) alone, or in combination. 
GRi mice exhibited a marked alteration in depressive and anxiety-like behaviors as well as fear response, 
together with a decreased cell proliferation and altered neuroplastic and epigenetic regulation in the 
hippocampus. Chronic treatment with agomelatine resulted in antidepressant and anxiolytic effects in GRi 
mice, and reversed the deficit in hippocampal cell proliferation and alteration of plasticity-related gene 
expression. The dual administration with Ana12 could block the anxiolytic effect of agomelatine as well 
as its ability to restore a normal expression of Bcl2 and cFos mRNA. Altogether, our findings indicate 
that agomelatine represents an efficient alternative to reverse the neuroplastic and behavioral alterations 
caused by HPA axis impairment. In addition, our findings provide further insights into the role of 
BDNF/TrkB signaling in the molecular and behavioral actions of antidepressants, as well as in the 
pathophysiology of mood disorders.  
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I – Introduction 
 
 
The impairment of the hypothalamo-pituitary-adrenal (HPA) axis, a major component of the 
neuroendocrine system regulating the stress response, has been implicated in the pathophysiology of 
mood disorders (Pariante et al., 2008; Vreeburg et al., 2009). Among several growth factors, brain-
derived neurotrophic factor (BDNF) has been postulated as a key mediator of stress-induced synaptic 
dysfunction and neuronal atrophy often observed in the prefrontal cortex and hippocampus of mood 
disorder patients (Duman et al., 2012; Berton et al., 2006). The decrease of BDNF and its tropomyosin-
related kinase receptor (TrkB) were both observed in the hippocampus of suicide completers and 
depressed patients (Autry et al., 2012; Dwivedi et al., 2003), and the functional val66met polymorphism 
in the gene encoding BDNF has been associated with a wide variety of psychiatric phenotypes (Hong et 
al., 2009). In addition, animal studies showed that prolonged exposure to stress could be associated with 
decreased BDNF signaling, as well as impaired neurogenesis in the hippocampus (Mirescu et al., 2006; 
Taliaz et al., 2011; Tsankova et al., 2006). Accordingly, various classes of antidepressants were shown to 
activate BDNF-mediated signaling and reverse neuronal atrophy and cell loss induced by chronic stress in 
rodents (Castren et al., 2010; Schmidt et al., 2007), and infusion of BDNF directly into the hippocampus 
resulted in antidepressant effect in naïve mice (Shirayama et al., 2002; Ye et al., 2011). BDNF 
heterozygous knockout mice (BDNF+/_), displaying a reduction by half of BDNF levels, failed to show 
any depressive-like behavior in basal condition (Korte et al., 1995; MacQueen et al., 2001), whereas 
knockdown of BDNF in specific brain sites could impair neurogenesis and precipitate depressive-like 
behavior (Taliaz et al., 2010). In addition, genetic mice models lacking BDNF showed an increased 
vulnerability to stress as compared to their wild-type littermates (Yu et al., 2012), as well as an inability 
to respond to antidepressant treatment (Adachi et al., 2008; Yu et al., 2012), indicating a critical role for 
BDNF in the behavioral and neurochemical mediation of antidepressant response. Increasing evidences 
also suggest that the elevation of BDNF levels observed after antidepressant treatment might be attributed 
to epigenetic regulation (Boulle et al., 2012). Interestingly, diverse classes of antidepressants were 
evidenced to target the epigenetic machinery, which appeared to be necessary in mediating their 
therapeutic effects (Vialou et al., 2013). For instance, chronic treatment with imipramine was sufficient to 
increase histone acetylation specifically at the BDNF gene, which causally correlate with the reversal of 
behavioral impairments induced by social defeat stress in mice (Tsankova et al., 2006). Additionally, in 
this same model, the downregulation of histone deacetylase 5 (HDAC5) was necessary to correct for 
histone H3K9 hypoacetylation in the hippocampus and mediate the antidepressant action of imipramine 
(Tsankova et al., 2006). Moreover, DNA methyltransferase (DNMT) inhibitors and HDAC inhibitors 
produced antidepressant-like effects when administered in naïve mice (Sales et al., 2011; Covington et al., 
2011), and the local administration of HDAC inhibitors in the nucleus accumbens exhibited similar gene 
expression profiles than the selective serotonin recapture inhibitor (SSRI) antidepressant fluoxetine 
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(Covington et al., 2009). Among antidepressants, agomelatine has emerged as an innovative and atypical 
treatment, mediating its effects via the activation of melatonin receptor 1 (MT1) and 2 (MT2), and the 
inhibition of the serotonin 2C receptor (5-HT2C). Agomelatine was shown to normalize altered BDNF 
regulation and impaired neurogenesis in rodent models of depression (Paizanis et al., 2010). Hence in the 
present study, we wanted to determine whether TrkB signaling was required for the neurobiological and 
behavioral actions of agomelatine. We used a recently developed TrkB inhibitor, Ana-12, which has been 
described as a potent and selective TrkB inhibitor that could lead to a decreased TrkB activity in mouse 
brain after peripheral administration (Cazorla et al., 2011). In our experiments, we performed dual 
administration of agomelatine, together with Ana-12, in a transgenic mouse model of affective disorders 
known as the glucocorticoid-receptor impaired (GR-i) mice. We previously showed that GR-i mice 
displayed a deficit in the hypothalamo-pituitary-adrenal (HPA) axis feedback under stressful conditions 
as well as neuroplastic impairment and despair-like behavior (Froger et al., 2004; Paizanis et al., 2010). 
Hence, in this transgenic mouse model we wanted to test the ability of agomelatine to rescue the 
behavioral and neurochemical alterations, and explore the involvement of TrkB in the mechanism of 
action of this new generation antidepressant. 
 
 
II – Material and methods 
 
Animals: Transgenic mice (strain B6C3F1; line 1.3) bearing a transgene for the glucocorticoid receptor 
(GR-i) and their paired wild-type (WT) were used in the experiments. Mice issued from the same 
gestation were housed in the same cage, under standard conditions (22± 21 C, 60% humidity, 12-h light–
dark cycle with lights on at 7.00 am, food and water ad libitum). The mice were bred at INSERM 
UMR894 / UPMC animal facility. Experiments were performed using 12-week-old mice (25–30 gm body 
weight). Procedures involving animals and their care were conducted in conformity with the institutional 
guidelines that are in compliance with national and international laws and policies (Council directive 87-
848, October 19, 1987, Ministere de l’Agriculture et de la Foret, Service Veterinaire de la Sante et de la 
Protection Animale; permissions 75-116 to M.H. and 006269 to L.L.). 
 
Drug treatments: Administration of drugs was performed everyday at 6.00 pm (i.e. 1 hour before the 
onset of dark period), for a total period of 21 days. The doses used in the experiments have been chosen 
on the basis of previous studies performed in validated mice models of depression and anxiety (Cazorla et 
al., 2011; Paizanis et al., 2010). First, Ana-12 (0.5 mg/kg, Maybridge, Illkirch, France) or its vehicle 
(NaCl 0,9%, tween80 1% and dimethylsuphoxyde 1%) was administered via intraperitoneal injections. 
After a 30-minute delay, agomelatine (50 mg/kg, Servier, Suresnes, France) or its vehicle 
hydroxyethylcellulose (HEC 1%, Servier, Suresnes, France) were administered via the same injection 
mode. The animals were sacrificed 18 hours after the last injection. 
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Behavioral testing: 
 
Tail suspension test (TST) 
The apparatus consists of three suspension units divided by walls (ID-Tech-Bioseb, Chaville, France). 
The mice were suspended by the tail with an adhesive tape, and the duration of immobility was measured 
automatically by the software over a 6-minute period.  
 
Splash test 
The splash test, previously described by Surget et al., 2008, consists into spraying a 10% sucrose solution 
on the back of mice in their home cage. Because of its viscosity, the sucrose solution dirties the coat and 
induces grooming behavior. The total time of grooming over a 5-minute period was recorded in our 
experiments. 
 
Open field test 
The apparatus consisted of four open boxes of 40 x 40 cm separated by white wood walls and equipped 
with an infrared floor for the measurement of motor activity. The arena was subdivided into a central and 
a peripheral zone. Mice were placed in the open field boxes for 20 min under normal light conditions, and 
the motor activity of the animals were automatically scored with a camera connected to a computerized 
system (Viewpoint, Lyon, France). The time spent in the different zones and the distance moved were 
scored. 
 
Forced swim test (FST) 
In the FST, originally designed by Porsolt and colleagues (1977), mice were placed into plastic buckets 
(19 cm diameter, 23 cm deep, filled with 23°C–25°C water) under low light conditions and videotaped for 
6 min (Viewpoint, Lyon, France). The different outcome measures were “immobility” reflecting no 
movement at all and/or minor movements necessary to keep the nose above the water; “mobility” 
reflecting medium activity such as swimming; and “bursts” reflecting strong mobility and struggling 
behaviors. 
 
Fear conditioning 
The fear conditioning paradigm consisted into 3 days of behavioral testing, and was conducted in an 
operant chamber (26 cm long × 18 cm wide × 22 cm high) possessing aluminum sidewalls and Plexiglas 
rear and front walls, and a stainless steel grid floor. On the first day, all mice were allowed to acclimate to 
the training chamber for 3 min, and then a tone (CS; conditioned stimulus) of 2500 Hz frequency and 85 
dB intensity was presented for 30 s and terminated in the last 2 s with a mild foot shock (0.75 mA) (US; 
unconditioned stimulus). After a period of two minutes (ITI; inter-trial interval), another CS-US pairing 
was presented. For the contextual fear conditioning test, rats were returned to the same chamber used for 
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the conditioning trial 24 h after conditioning and allowed to explore for 20 min without presentation of 
the auditory CS or foot shock. Twenty-four hours after the contextual fear conditioning test, the mice 
were tested for cued fear memory by returning them to the same chamber, which was modified by adding 
various hatch designs to the walls as well as a vanilla scent. Stimulus presentation and data acquisition 
were controlled by a computerized system interface. Freezing behavior, defined as complete absence of 
voluntary movements except for respiratory movements, was measured every 1 s. 
 
Social interaction 
Mice were placed in an open boxes of 40 x 40 cm2 separated by white wood walls for 20 minutes the day 
preceding the experiment in order to habituate the animal to the novel arena, and to maximize the 
duration of social interactions. The following day, mice of same genotype and unfamiliar to each other 
were placed in the same arena for 10 minutes, and videotaped using a fixed camera. Total time spent in 
active social interactions (including sniffing, chasing and grooming) was scored by an observer unaware 
of groups. 
 
Quantitative reverse transcriptase PCR (qRT-PCR): Total mRNA extraction was performed using 
NucleoSpin RNA II kit (Macherey-Nagel, Hoerdt, France), after which, the cDNA synthesis was 
performed using a High Capacity cDNA Reverse Transcription kit (Applied Biosystems, Courtaboeuf, 
France) according to the manufacturer’s protocol. The amplification was made with Absolute SYBR 
Green ROX Mix (Thermo Scientific, Illkirch, France) using the 7300 Real Time PCR System (Applied 
Biosystems, Courtaboeuf, France) and the sequences of primers used are indicated in Supplementary 
Table 1. Gene expressions were normalized using Hprt as a reference gene and the conditions for the 
reaction included 35 cycles in a fixed sequence of 95°C for 20 s, 62°C for 30 s, and 72°C for 30 s. The 
2ΔΔCT (Delta-Delta Comparative Threshold) method was used to normalize the fold change in gene 
expressions. 
 
Immunohistochemistry: Coronal sections of 25 µm between bregma levels -1.340 and -2.300 were 
collected at the cryostat (Leica CM 3050, Leica Microsystems, Wetzlar, Germany), after which sections 
were directly mounted on double dipped gelatin coated glass slides and stored at -80°C until use. The 
sections were then fixed with 4% paraformaldehyde at 4°C for 10 min. After permeabilizing the 
membranes with TBS-triton 0.05 %, the sections were incubated overnight at 4°C with the Ki-67 
antibody (1:1000, Vector Laboratories, Burlingame, Calif., USA). The sections were then incubated for 2 
hour at room temperature in presence of appropriated biotinylated secondary antibodies, and the reaction 
was amplified using the ABC staining system (Vector Laboratories, Burlingame, Calif., USA) for one 
additional hour. Finally, the sections were treated with 3,3’-diaminobenzidine for 4 minutes. After 
dehydrating the sections and mounting with cover slip, the positive cells were counted under the 
microscope (Nikon Eclipse E400, Nikon Instruments Inc., Shanghai, China).  
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Statistical analysis: Data are represented as mean ± SEM and were analyzed using Student’s t test for 
comparison between two groups (Prism 5.0, GraphPad software, USA). When more than two groups of 
data, a one-way analysis of variance (ANOVA) was used followed by Fisher’s LSD post hoc test in order 
to compare all the groups between them. In addition, a two-way ANOVA (agomelatine treatment x 
Ana12 treatment) was sometimes used to investigate the effect of the drug treatments in the GRi 
phenotype. The level of significance was set as P <0.05. 
 
 
III – Results  
 
Effects of impaired GR function on behavior: The battery of test routinely used to characterize 
depressive-like, anxiety-like and fear-related behaviors in rodents showed that GRi mice exhibited robust 
alterations in mood and emotions as compared to their wild-type littermates. As shown by figure S1, GRi 
mice showed an increased immobility in the TST  (+ 27 %, Figure S1) and decreased grooming behavior 
in the splash test (– 28 %, Figure S1). As previously reported by Barden and colleagues, GRi mice 
showed increased escape-like behavior in the FST (Barden et al., 2005). GRi mice had an increase of 
swimming behavior (+ 59 %, Figure S1), and a decrease immobility time (– 20 %, Figure S1) as 
compared to wild type mice. GRi mice also showed increased anxiety behavior and exaggerated fear 
responses. GRi mice had a decreased motor activity (– 23 % in small movement duration) and exploration 
(– 31 % in distance moved) in the open field test (Figure S2). In addition, these transgenic mice displayed 
a high score of inactivity in the open field arena (+ 15 %, Figure S2), which might involve freezing 
behaviors (Figure S2). Accordingly, GRi mice displayed an increased freezing behavior when subjected 
to the fear conditioning paradigm (Figure S3). GRi mice showed higher rates of freezing in the fear 
acquisition test, the contextual fear conditioning test and the cued fear memory test. In addition, GRi mice 
showed elevated freezing behavior at baseline in the cued fear memory test, possibly indicating a 
generalization of fear (data not shown). Hence, the phenotype characterization of GRi mice pointed 
towards a marked dysregulation in mood and emotion responses, making this transgenic mouse a suitable 
model to explore different aspects of antidepressant action.  
 
Effects of impaired GR function on hippocampal cell proliferation and gene expression: To further 
elucidate the cellular and molecular mechanisms underlying the reduced glucocorticoid receptor function, 
the expression of Ki67 (a marker of cell proliferation), as well as the expression of various genes 
implicated in neuronal plasticity and in transcription and epigenetic regulations, were measured. 
Immunohistochemical analysis revealed that cell proliferation in the subventricular zone (SVZ) of the 
dentate gyrus was decreased in GRi mice (– 34 %, Figure 4). Similar results using BrdU and DCX 
stainings in this region were reported in GRi mice (Paizanis et al., 2011). qRT-PCR analysis revealed a 
complex regulation of genes involved in neuronal plasticity. There was a decreased expression of the 
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Bdnf4 transcript (– 24 %, Figure 5). Similarly, GRi mice exhibited a decreased expression of the B-cell 
lymphoma 2 (Bcl2) gene (– 26 %, Figure 5), a critical mediator of cell survival, as well as decreased 
expression of the FBJ osteosarcoma oncogene (cFos) gene (– 50 %, Figure 6), known as a marker of 
neuronal activity. In contrast, the expression of glial cell line-derived neurotrophic factor (Gdnf) and 
nerve growth factor inducible (Vgf), two genes involved in neurotrophic signaling, were increased in GRi 
mice (+ 58 % and + 37 % respectively, Figure 5). The expression of the corticotropin releasing factor 
(Crf) gene was also increased in GRi mice. The GR usually exert a negative feedback on Crf expression, 
so it is not surprising to observe such variation. Similarly, the gene expression of various transcription 
factors, including the cAMP responsive element binding protein (Creb) gene and the early growth 
response 1 (Egr1) gene was increased (+ 31 % and + 22 % respectively, Figure 5 and 6). Finally, 
expression of the epigenetic regulators was investigated. The expression of the DNA methyltransferase 1 
(Dnmt1) gene and the DNA methyltransferase 3a (Dnmt3a) gene, both involved in active DNA 
methylation, was decreased in GRi mice (- 43 % and – 46 % respectively, Figure 6). In addition, the 
expression of the histone-lysine N-methyltransferase HRX 3 (Mll3) gene and the histone-lysine N-
methyltransferase HRX 4 (Mll4) gene, involved in histone methylation activity and transcription co-
activation, was decreased in GRi mice (- 35 % and – 28 % respectively, Figure 6), but did not reach 
statistical significance.  
 
Effects of agomelatine and TrkB antagonist on grooming and despair-like behavior: In a second step of 
the work, the ability of agomelatine to reverse the behavioral alterations was investigated. We combined 
the administration of agomelatine with a newly developed TrkB antagonist, Ana12, in order to investigate 
the involvement of TrkB in the mechanism of action of agomelatine. Agomelatine could significantly 
increase the time spent in grooming behavior in GRi mice (Figure 1). However, this effect could not be 
blocked when co-administered with Ana12 (Figure 1). In the TST, chronic administration of agomelatine 
to GRi mice could restore the immobility time to the level observed in wild type (GRi HEC SAL vs. GRi 
AGO SAL: – 42 %, Figure 1). Chronic treatment with the TrkB inhibitor Ana12 could reverse the 
increased immobility observed in GRi mice receiving only the vehicle (GRi HEC SAL v.s. GRi HEC 
ANA: – 44 %, Figure 1). This effect has already been described after acute exposure of 4h with Ana12 in 
naïve mice (Cazorla et al., 2011). However, the co-administration of agomelatine and Ana12 did not show 
such kind of antidepressant effects. In the FST, GRi mice treated for 3 weeks with the vehicle of 
agomelatine and Ana12 (GRi HEC SAL) showed increased immobility as compared to WT mice treated 
with the 2 vehicles (WT HEC SAL), which appeared to be in opposition to what have been reported in 
basal conditions. This contrasting observation might be attributed to the effects of manipulation and stress 
of chronic injections on innate flight response and reactivity. However, chronic treatment with 
agomelatine significantly decreased the immobility time in the FST in the GRi phenotype (Two-way 
ANOVA, Figure 1), an effect usually observed after acute treatment with selective serotonin reuptake 
inhibitor (SSRI) antidepressants in this behavioral test. Similarly, agomelatine could increase the mobility 
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of GRi mice, as shown by higher swimming and burst duration (Figure 1). Of note, the antidepressant-like 
effect of agomelatine could not be abolished by Ana12 treatment (Figure 1). 
 
Effects of agomelatine and TrkB antagonist on fear and anxiety: Chronic treatment with agomelatine 
significantly reversed the anxious phenotype of GRi mice in the open field test (Figure 2). Accordingly, 
agomelatine increased the distance covered and the small movement activity, and decreased the inactivity 
duration. In contrast, Ana12 had an anxiogenic effect in the open field test by decreasing the distance 
covered and duration in small movement activity, and increasing the inactivity duration. Interestingly, the 
effect of agomelatine on the distance covered and activity duration could be blocked when this 
antidepressant was administered together with Ana12. No effect was observed for the inactivity duration. 
Further, the effects of agomelatine and Ana12 on fear response were investigated. GRi mice displayed 
robust freezing behavior in response to fearful stimuli, as well as impairment to erase fear memories 
(Figure S3 and Figure 3). However, neither agomelatine nor Ana12 could prevent the exaggerated fear 
response in the fear conditioning test. 
 
Effects of agomelatine and TrkB antagonist on hippocampal gene expression and cell proliferation: As 
previously reported, GRi mice have an impaired hippocampal neurogenesis including a decrease 
proliferation in the SGZ of the dentate gyrus (Paizanis et al., 2011). In this same study, it was evidenced 
by BrdU labeling that chronic treatment of 21 days with agomelatine (50 mg/kg/day) could significantly 
restore a normal cell proliferation in the SGZ. Here, a similar effect of agomelatine on cell proliferation in 
the SGZ was evidenced by Ki67 immunolabelling (Figure 4). Agomelatine increase the number of 
proliferative cells by approximately 74 % in GRi mice. In addition, clear-cut evidences demonstrate that 
this effect could be abolished when agomelatine was administered together with the TrkB antagonist 
Ana12 (– 44 % between GRi AGO SAL and GRi AGO ANA, Figure 4). Further, the levels of Bcl2, 
Bdnf4 and cFos mRNAs, which was decreased in GRi mice, could be significantly upregulated after 
chronic treatment with agomelatine (+ 66 %, + 50 % and + 61 % respectively, Figure 5 and 6). In 
contrast, chronic administration of agomelatine significantly decreased the levels of Vgf mRNAs (- 37 %, 
Figure 5). Furthermore, chronic treatment with Ana12 significantly decreased the expression of Gdnf and 
cFos in GRi mice (two-way ANOVA, Figure 5 and 6), whereas an upregulation of Bdnf4, Crf and Egr1 
mRNA levels was observed (GRi HEC SAL vs. GRi HEC ANA: + 116 %, + 31 % and + 30 % 
respectively, Figure 5 and 6). However, no modulations of Creb, Dnmt1, Dnmt3a, Mll3 and Mll4 mRNA 
levels were observed after either agomeltine or Ana12 treatments. Finally, there was a significant 
difference between GRi mice treated with agomelatine alone (GRi AGO SAL) and GRi mice treated with 
agomelatine + Ana12 (GRi AGO ANA) regarding the expression of Bcl2 and cFos genes (GRi AGO SAL 
vs. GRi AGO ANA: - 39 % and - 49 % respectively, Figure 5 and 6), suggesting that Ana12 could block 
the ability of agomelatine to restore a normal expression at those specific genes. 
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IV – Discussion 
 
     Mounting evidences suggest that HPA axis impairment may play an important part in the 
pathophysiology of major depression, and that the neuronal loss and synaptic dysfunction induced by 
prolonged stress exposure might involve alterations in neurotrophic signaling (Pariante et al., 2008; 
Vreeburg et al., 2009). Furthermore, many studies have reported a critical involvement of BDNF/TrkB 
signaling in the mechanism of action of conventional antidepressants (Castren et al., 2010). In this 
context, the aim of the present study was to investigate the implication of TrkB signaling in the 
behavioral and neuroplastic effect of the new generation antidepressant agomelatine in the GRi transgenic 
mouse, a rodent model of glucocorticoid-induced mood disorders. 
 
Effect of impaired GR function on neuroplasticity and behavior: As previously reported, GRi mice 
displayed a reduced expression of GR mRNA in the brain and a disrupted HPA axis (Pepin et al., 1992; 
Froger et al., 2004). In addition, the present study showed an elevation of Crf mRNA in the hippocampus 
of GRi mice. Under normal conditions, the HPA axis exerts a negative feedback on Crf expression via 
GRs. Hence, it is not surprising that a reduced function of GR resulted in increasing Crf mRNA levels in 
the brain. Further, an impairment of hippocampal cell proliferation and decreased Bdnf mRNA levels 
were observed in previous investigations (Paizanis et al., 2011). Here, we confirmed the deficit in 
hippocampal cell proliferation, and bring more insight into the exon-specific regulation of the Bdnf gene 
and in GRi mice. The expression of Bdnf4 transcript was decreased in the hippocampus of GRi mice. 
BDNF expression is tightly regulated at the level of transcription with differential exon usage, suggesting 
a crucial role for the various transcripts in different functions and related processes (Pruunsild et al., 
2007; Baj et al., 2011). The Bdnf4 transcript has been particularly reported in rodent models of stress, and 
in the mechanism of action of antidepressants (Tsankova et al., 2006; Dwivedi et al., 2006; Boulle et al., 
2012). Next to that, the mRNA levels of Bcl2 and cFos were decreased in GRi mice. Bcl2 plays a critical 
role in cell survival, and cFos is a marker of neuronal activation (Bullitt et al., 1990; Davies et al., 1995; 
Zhang et al., 2002). Hence, the decrease of these two factors, together with Bdnf4, is in accordance with 
the impaired hippocampal neurogenesis in GRi mice. In contrast, the mRNA levels of Gdnf, Vgf, Creb 
and Egr1 were increased in the hippocampus of GRi mice. These genes are also implicated, at different 
levels, in the mediation of neuronal plasticity (Benito et al., 2010; Bozdagi et al., 2008; Li et al., 2005; 
Sariola et al., 2003). Accordingly, it is possible that compensatory mechanisms involving other types of 
neuroplastic adaptations might be activated in response to the deficit in neurogenesis. Finally, the 
investigation of epigenetic markers revealed a strong alteration in the machinery controlling histone post-
translational modifications and DNA methylation. Such kind of epigenetic regulations in the central 
nervous system has been described as a key-role mechanism in the maintenance of neuronal plasticity 
(Maze et al., 2012; Sultan and Day, 2011). In particular, stress and environmental adversity has been 
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shown to impact on chromatin and histone regulations to generate an epigenetic reprogramming, possibly 
increasing the susceptibility for mood disorders (Tsankova et al., 2007; Boulle et al., 2012). 
 
At the behavioral level, we found that GRi mice exhibited an anxious phenotype as well as a marked 
impairment in fear-related behaviors. GRi mice also showed a decrease in grooming behavior, an 
indicator of a self-neglecting and motivational deficit that has been linked to altered ACTH function 
(Argiolas et al., 2000). As reported by previous findings, GRi mice displayed an increase immobility time 
in the TST and increased activity in the FST in basal conditions (Barden et al., 2005; Paizanis et al., 
2011). These results could be confirmed in the present study. However, the observed phenotype in the 
FST tended to disappear after 21 days of chronic drug injections. This effect can be attributed to the 
manipulation of the animals that might interfere with the innate mechanisms involved in the stress 
response. Altogether, the behavioral analysis indicated a marked alteration in mood-related behaviors in 
the transgenic GRi mice. Accordingly, the impairment of neurogenesis, together with the alterations in 
gene expression and epigenetic regulations, might be causally related to the alterations observed at the 
behavioral level.  
 
TrkB signaling in the mechanism of action of agomelatine: Chronic treatment with agomelatine could 
produce an antidepressant-like effect in GRi mice, as observed by the decrease of despair-like behavior in 
the TST and FST, and increase of self-grooming behavior in the splash test. Interestingly, the effect of 
agomelatine in the splash test and the FST was not dependent on TrkB signaling. On the other hand, the 
effects of agomelatine in the TST were blocked by Ana12, suggesting a critical role of TrkB signaling in 
the neurochemical pathways underlying this behavioral performance. Similarly, the inhibition of TrkB 
could abolish the anxiolytic effect of agomelatine in the open field test. This observation is especially 
interesting since other studies, using genetic BDNF knockdown approaches in mice, also showed an 
inability for diverse classes of antidepressants to exert their effects in the above-mentioned behavioral 
tasks (Adachi et al., 2008; Yu et al., 2012). In addition, post-mortem studies showed that the expression 
of BDNF was significantly higher in patients treated with antidepressants (Chen et al., 2001), and some 
subpopulation of individuals carrying the functional val66met polymorphism in the gene encoding for 
BDNF showed an impaired antidepressant response (Niitsu et al., 2013). Further, agomelatine could 
restore the deficit in hippocampal cell proliferation observed in GRi mice. This effect was entirely 
dependent on TrkB, since the co-administration of agomelatine with Ana12 completely abolished the 
increased hippocampal cell proliferation observed with agomelatine treatment alone. This finding is of 
particular relevance because BDNF/TrkB signaling has been frequently associated with neurogenesis, and 
alteration of such physiological mechanisms might be causally linked to mood disorders (Snyder et al., 
2011). Accordingly, the decrease of Bcl2, Bdnf4 and cFos in GRi mice could be restored by chronic 
agomelatine treatment, which appeared to be dependent on TrkB signaling. This latter finding confirmed 
the importance of BDNF/TrkB signaling and downstream neuroplastic changes in the mediation of 
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antidepressant actions. Interestingly, agomelatine could normalize the expression of other genes such as 
Egr1 and Vgf further supporting that this antidepressant is efficient to restore a normal balance in gene 
expression profiles in pathological models. However, chronic treatment with agomelatine could not 
restore normal epigenetic patterns in the hippocampus of GRi mice. These latter findings do not support 
the notion that the reversal of epigenetic alterations by antidepressant drugs is required for their 
therapeutic response.  
 
Effect of TrkB antagonist on mood-related behaviors: Moreover, the present findings also bring some 
novel insights into the behavioral and neuroplastic properties of TrkB inhibitors. As already shown by 
Cazorla and colleagues in a recent study, the newly developed TrkB inhibitor Ana12 displayed 
antidepressant properties in the TST when injected acutely (Cazorla et al., 2011). Using this same dose of 
0.5 mg/kg, we found a comparable effect after chronic injections of 21 days. These findings are rather 
provocative because a growing body of literature indicated similar results after administration of BDNF 
directly in the hippocampus, or peripheral administration of TrkB agonists (Liu et al., 2010; Shirayama et 
al., 2002). However, clean-cut evidences in both rodents and human studies demonstrated that stress 
and/or major depression could be associated with increased BDNF levels in the nucleus accumbens 
(Krishnan et al., 2007). Hence, the pathophysiology of depression appears to be complex, and might 
involve a region-specific regulation of BDNF/TrkB signaling. Further, chronic administration of Ana12 
resulted in an anxiogenic effects in GRi mice, and might causally correlate with the reduced expression of 
cFos and Gdnf observed in the hippocampus. In line with the present results, previous studies showed the 
val66met polymorphism in the gene encoding BDNF has been linked to anxiety disorders (Chen et al 
2006), and reduced levels of BDNF in the hippocampus have been associated with an increased anxiety in 
rodents (Martinowich et al., 2007). 
 
Conclusion and perspectives: In conclusion, our data provide a deeper understanding about the 
involvement of TrkB signaling in the mechanism of action of agomelatine, and in the treatment of mood 
disorders. In accordance with other studies that proposed a critical role for BDNF in the therapeutic action 
of classical antidepressants (Castren et al., 2010), our findings provide further evidences that novel 
antidepressant displaying an atypical mechanism of action could also target BDNF/TrkB signaling to 
exert its behavioral and neuroplastic effects in a transgenic mouse model of mood disorders. Our data 
support the idea that therapeutic actions of antidepressants involve various neurocircuits, and that some of 
these neurochemical pathways may require BDNF/TrkB and downstream neuroplastic signaling to 
regulate mood. 
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Figures and legends. 
 
 
 
 
 
 
 
 
 
Figure 1. Effects of chronic agomelatine treatment in combination with a TrkB inhibitor on depressive-like 
behavior  
 
(A) The time spent in grooming behavior over a total period of 5 minutes was measured in mice. The two-way 
ANOVA between agomelatine and Ana12 factors in the GRi genotype indicated a significant effect of agomelatine 
[F(1,21)=5.71; p<0.01], but no effect of Ana12 [F(1,21)=0.002; p>0.05] on the time spent in grooming behavior. (B) 
The immobility time in the tail suspension test paradigm was measured after chronic mild stress. The one-way 
ANOVA indicated a significant interaction F(4,28)=3.17; p<0.05]. A LSD post hoc test was used to determine the 
significant difference between groups (*p < 0.05). (C) Mice were subjected to a forced swim test, and the time spent 
in immobility, swimming and high mobility (burst), over a 6-minute period, is represented. The two-way ANOVA 
between agomelatine and Ana12 factors in the GRi genotype indicated a significant effect of agomelatine on 
immobility [F(1,22)=17.65; p<0.001], swimming [F(1,22)=17.94; p<0.001] and high mobility [F(1,22)=6.39; 
p<0.05]. No significant effects were observed in the LSD post hoc test. Data are expressed as mean + S.E.M of n=5-
8 mice per group. *p < 0.05; ***p < 0.001. 
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Figure 2. Effects of chronic agomelatine treatment in combination with a TrkB inhibitor on anxiety behavior 
 
Mice were subjected to an open field test, and the distance covered, the time spent in small movement activity and 
the time spent in inactivity were measured over 20 minutes. A one-way ANOVA indicated a significant interaction 
in the distance covered [F(4,32)=10.72; p<0.001], the time spent in small movement activity [F(4,32)=9.20; 
p<0.001] and the time spent in inactivity [F(4,32)=6.91; p<0.01]. A LSD post hoc test was used to determine the 
significant difference between groups (*p < 0.05; **p < 0.01). Data are expressed as mean + S.E.M of n=5-8 mice 
per group. 
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Figure 3. Effects of chronic agomelatine treatment in combination with a TrkB inhibitor on fear behavior 
 
 (A) A schematic representation of the fear conditioning procedure is represented. For more details see the material 
and methods section. (B) The freezing behavior during the fear acquisition (Day 1; left panel), the contextual fear 
conditioning (Day 2; center panel) and the cued fear memory (Day 3; right panel) test was measured during the tone 
periods, and the average freezing is represented. A one-way ANOVA indicated a significant interaction in the fear 
acquisition test [F(4,32)=6.76; p<0.001], the contextual fear conditioning test [F(4,32)=9.23; p<0.001] and the cued 
fear memory test [F(4,32)=13.75; p<0.001]. The LSD post hoc test revealed a significant difference in freezing 
between WT mice treated with vehicles (WT HEC SAL) and GRi mice treated with all the different combinations of 
treatments (GRi HEC SAL, GRi HEC ANA, GRi AGO SAL and GRi AGO ANA). Data are expressed as mean + 
S.E.M of n=5-9 mice per group. *p < 0.05; **p < 0.01; ***p < 0.001. 
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Figure 4. Effects of chronic agomelatine treatment on hippocampal cell proliferation 
 
(A) An example of proliferative Ki67 immunoreactive cells in the dentate gyrus (DG) of the hippocampus is 
illustrated. (B) Mice were treated with agomelatine with or without TrkB inhibitor, and the number of proliferative 
Ki67 immunoreactive cells per section in the SGZ of the DG was investigated. A one-way ANOVA indicated a 
significant interaction [F(4,29)=3.07; p<0.05], and the significant differences between groups were determined with 
a LSD post hoc test (*p < 0.05; **p < 0.01; ***p < 0.001). Data are expressed as mean + S.E.M of n=5-9 mice per 
group. 
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Figure 5. Effects of chronic agomelatine treatment in combination with a TrkB inhibitor on plasticity-related 
gene expression in the hippocampus 
 
mRNA levels of plasticity-related genes in the hippocampus of mice were measured by quantitative real-time RT-
PCR, and are expressed as fold changes as compared to the WT mice treated with the two vehicles (WT HEC SAL). 
A one-way ANOVA indicated a significant interaction for Bcl2 [F(4,65)=4.16; p<0.01], Bdnf4 [F(1,29)=7.12; 
p<0.01], Creb [F(4,34)=3.86; p<0.05], Crf [F(4,34)=7.61; p<0.001], Gdnf [F(4,66)=7.44; p<0.001] and Vgf 
[F(4,66)=7.56; p<0.001]. In addition, the significant differences between each groups revealed by the LSD post hoc 
test are represented (*p < 0.05; **p < 0.01; ***p < 0.001). Of note, the two-way ANOVA between Agomelatine and 
Ana12 factors in the GRi genotype indicated a significant effect of Ana12 on Gdnf [F(1,45)=12.64; p<0.001]. Data 
are expressed as mean + S.E.M of n=5-9 mice per group. 
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Figure 6. Effects of chronic agomelatine treatment in combination with a TrkB inhibitor on the expression of 
transcription factors in the hippocampus 
 
 mRNA levels of genes encoding for transcription factors were measured in the hippocampus of mice by 
quantitative real-time RT-PCR, and are expressed as fold changes as compared to the WT mice treated with the two 
vehicles (WT HEC SAL). A one-way ANOVA indicated a significant interaction for cFos [F(4,30)=16.20; 
p<0.001], Dnmt1 [F(4,29)=12.88; p<0.001], Dnmt3a [F(4,29)=8.26; p<0.001], Egr1 [F(4,34)=6.81; p<0.001], Mll3 
[F(4,29)=2.39; p=0.076] and Mll4 [F(1,29)=1.42; p>0.05]. In addition, the significant differences between each 
groups revealed by the LSD post hoc test are represented (*p < 0.05; **p < 0.01; ***p < 0.001). Of note, the two-
way ANOVA between agomelatine and Ana12 factors in the GRi genotype indicated a significant effect of Ana12 
on cFos [F(1,21)=15.02; p<0.001], and a significant effect of agomelatine on Egr1 [F(1,22)=12.70; p<0.01]. Data 
are expressed as mean + S.E.M of n=5-9 mice per group. 
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Figure S1. Characterization of mood-related behaviors in GRi mice 
 
 Mice were subjected to a battery of test routinely use to measure depressive-like behavior and response to 
antidepressant drugs. The difference between wild type (WT) and glucocorticoid receptor-impaired (GRi) mice in 
basal conditions was monitored. (A) The immobility time in the tail suspension test paradigm was measured, and a 
Student’s t-test revealed a significant increase of immobility in GRi mice. (B) The time spent in grooming behavior 
over a total period of 5 minutes was measured in mice, and a Student’s t-test revealed a significant decrease of the 
time spent in grooming behavior in GRi mice. (C) The time spent in active social interaction was measure over 10 
minutes, and no significant difference was found in the Student’s t-test analysis. (D) Mice were subjected to a forced 
swim test, and the time spent in immobility, swimming and high mobility (burst), over a 6-minute period, is 
represented. The Student’s t-test revealed a significant increase in mobility, together with a decrease of immobility, 
in GRi mice as compared to their wild type littermates. Data are expressed as mean ± S.E.M of n=8-12 mice per 
group. *p < 0.05; **p < 0.01; ***p < 0.001.  
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Figure S2. Characterization of anxiety-like behavior using the open field test in GRi mice 
 
Mice were subjected to an open field test for 20 minutes. The difference between wild type (WT) and glucocorticoid 
receptor-impaired (GRi) mice in basal conditions was investigated. There was no difference in the tie spent in the 
periphery between WT and GRi mice. However, a trend was observed for the time spent in the center, as well as the 
number of entries in the central compartment, but did not reach statistical significance. Further, there was a 
significant difference in the motor behavior and exploration of GRi mice. The Student’s t-test revealed that GRi 
mice spent more time in inactivity, and less time in small movement activity. Similarly, the distance covered by GRi 
mice was significantly decreased, especially during the first 6 minutes of the test, where a lower exploration was 
observed in GRi mice. Data are expressed as mean ± S.E.M of n=8-12 mice per group. *p < 0.05; **p < 0.01; ***p 
< 0.001. 
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Figure S3. Characterization of fear response using the fear conditioning paradigm in GRi mice 
 
Mice were tested in the fear conditioning paradigm, and the average freezing during the fear acquisition (A), the 
contextual fear conditioning (B) and the cued fear memory (C) is represented. A two-way ANOVA followed by a 
Bonferroni post hoc test revealed that GRi mice displayed significantly more freezing behaviors than WT. Data are 
expressed as mean ± S.E.M of n=5-9 mice per group. *p < 0.05; **p < 0.01; ***p < 0.001. 
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Gene Definition Primer sense Primer antisense 
Bcl2 B-cell CLL/lymphoma 2 ATGACTGAGTACCTGAACCG ATGCTGGGGCCATATAGTTC 
Bdnf4 Brain derived neurotrophic factor exon 4 AATCTCCCAGCCTCTGCCTA CGAGTCTTTGGTGGCCGATA 
cFos FBJ murine osteosarcoma viral oncogene homolog AGGGAACGGAATAAGATGGC TGCAACGCAGACTTCTCATC 
Creb cAMP responsive element binding protein 1 GTTGTTATGGCGTCCTCCC TACGACATTCTCTTGCTGCC 
Crf Corticotropin releasing factor CCTTGAATTTCTTGCAGCCG GGACTTCTGTTGAGATTCCCC 
Dnmt1 DNA methyltransferase (cytosine-5) 1 AGCCGCTCAAAGCAAAAGTG TGGGGTTCATCCACAGCATC 
Dnmt3b DNA methyltransferase (cytosine-5) 3b GATGAGGAGAGCCGAGAACG CAGAGCCCACCCTCAAAGAG 
Egr1 Early growth response 1 TCAATCCTCAAGGGGAGCC ACTCGTCTCCACCATCGC 
Gdnf Glial derived neurotrophic factor TGGGTTTGGGCTATGAAACC AACATGCCTGGCCTACTTTG 
Hprt Hypoxanthine-guanine phosphoribosyltransferase GATGATGAACCAGGTTATGAC GTCCTTTTCACCAGCAAGCTTG 
Mll3 Histone-lysine N-methyltransferase HRX 3 TCCCGATAGTTTCGTCCCCT AGAATGGGGATGATGGGGGA 
Mll4 Histone-lysine N-methyltransferase HRX 4 CTCGCCACTGAGGATACGTC CCCTGTAGACCCTGTAGGCT 
Myst2 MYST histone acetyltransferase 2 GGTACTGCTCCGATACCTGC TCTGAAGGGCTTGCAGAGTG 
Ncoa6 Nuclear receptor coactivator 6 TCTACCCAGCATAGCCCCTT AGTTTCTTCGGCTCGTCAGG 
Vgf VGF nerve growth factor inducible TTGACACCCTTATCCAAGGC ACCTGAGCTAATCCTTGCTG 
 
 
 
 
 
 
 
Table S1. Primer sequences used in q RT-PCR experiments  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter VII 
	  178	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Agomelatine, stress and hyperactivity 
	   179	  
 
CHAPTER VIII 
 
 
 
 
 
 
Agomelatine normalizes hippocampal and behavioral dysfunction in a mouse 
model of environmental stress 
 
 
 
 
FABIEN BOULLE1,2, RENAUD MASSART1,3, LARA ZAIDAN2, SAMY MARDAY2, CECILIA GABRIEL4, ELISABETH 
MOCAER4, MICHEL HAMON1, LAURENCE LANFUMEY1 
 
 
 
 
1Centre de Psychiatrie et Neuroscience (INSERM U894), Universite Pierre et Marie Curie, Paris, France 
 
2Department of Psychiatry and Neuropsychology, European Graduate School for Neuroscience (EURON), 
Maastricht University, Maastricht, The Netherlands 
 
3Department of Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada 
 
 
4Institut de Recherche International Servier, Suresnes, France 
 
 
 
 
In preparation 
 
 
 
 
 
Chapter VIII 
	  180	  
Abstract 
 
     Stress-induced alterations in neuronal plasticity and associated hippocampal dysfunctions have been 
reported as a major culprit in the course and development of mood disorders. Here, we investigated the 
activation of intracellular signaling cascades, and the expression of epigenetic markers and plasticity-
related genes in the hippocampus of a mouse model of hyperactive and mixed affective disorders. Further, 
we analyzed the ability of agomelatine, a mixed MT1/MT2 melatonin receptor agonist/5-HT2c receptor 
antagonist, to prevent stress-induced neurobiological and behavioral alterations. Adult male C57BL/6J 
mice were exposed to daily unpredictable socio-environmental stressors of mild intensity for a total 
period of 3 weeks. Behavioral investigations showed that stressed mice exhibited robust increase in 
emotional arousal, vigilance and motor activity, together with reduced anxiety as well as motivation and 
reward deficits. Neurobiological investigations showed an increased activation of Akt and Creb signaling 
pathways in the hippocampus of stressed mice. The decreased hippocampal levels of the repressive 
epigenetic marks HDAC2 and H3K9me2, as well as the increased levels of the permissive mark 
H3K9/14ac suggested that chronic mild stress could be associated with increased gene transcription, and 
clear-cut evidence for such changes was found for neuroplasticity-related genes, including Arc, Bcl2, 
Bdnf, Gdnf, Igf1 and Neurod1. Altogether, the present data suggest that chronic ultra-mild stress can 
model the hyperactivity or psychomotor agitation, as well as mixed affective behaviors often observed in 
the manic state of bipolar disorders. Interestingly, agomelatine could normalize both behavioral and 
neurobiological alterations induced by stress, providing further molecular and behavioral evidence in the 
action of this new generation antidepressant. 
 
 
 
 
Key words: Plasticity, hyperactivity, hippocampus, stress, mood, epigenetic 
 
 
 
 
 
 
 
 
 
 
 
Agomelatine, stress and hyperactivity 
	   181	  
I – Introduction  
 
     Stress is a predisposing factor for the course and development of a broad range of behavioral and 
pathophysiological disturbances, among which mood disorders have been abundantly reported (Gunnar 
and Quevedo, 2007). More specifically, the hippocampus - a key region in emotional and cognitive 
process - is known to be highly sensitive to glucocorticoid providing to this limbic structure an important 
role in the integration of stress response (McEwen et al., 1992; Sala et al., 2004). However, the exact 
mechanism by which stress, via glucocorticoid, modulates functional and structural plasticity in the brain 
remains largely unknown, and the timing and intensity of the stressors seem to be critical in the 
determination of the neuroendocrine and behavioral outcomes (McEwen et al., 2007). It is well accepted 
that severe and long-lasting traumatic stress might lead to neuronal loss and synaptic dysfunction in the 
hippocampus, generally associated with low mood, anxiety and impaired cognition, which constitute core 
symptoms of major depression (Apfel et al., 2011; Snyder et al., 2011, Stockmeier et al., 2004). 
Nevertheless, stressful life events, especially when disrupting circadian rhythms, can also be a precipitant 
of manic episodes of bipolar disorders including elevated mood, hyperactivity, impulsivity and increased 
vigilance (Malkoff-Schwartz et al., 1998; Proudfoot et al., 2011). 
 
At the molecular level, the sustained elevation of glucocorticoids observed in stressful situations might 
interfere with various intracellular signaling and transcriptional processes. In particular, chromatin 
remodeling via histones modifications occurs in response to diverse environmental variations and 
represents a key regulator of nuclear integration to promote structural and functional adaptations 
underlying neuronal plasticity (Maze et al., 2013). Hence, during the past decade, epigenetic mechanisms 
have emerged as a key process by which environmental variations could leave persistent imprints on gene 
expression thereby increasing the risk for mood disorders (Boulle et al., 2012). In addition, 
antidepressants and mood stabilizers have been shown to mediate their therapeutic effects at least in part 
through epigenetic remodeling (Boulle et al., 2012; Vialou et al., 2012). 
 
More recently, Agomelatine, a mixed melatonin receptor 1 (MT1) and 2 (MT2) agonist and serotonin 5-
HT2C receptor antagonist, has been described as an emerging and efficient treatment for major depressive 
episodes (De Bodinat et al., 2010). Agomelatine is though to exert its effects via a re-synchronization of 
circadian rhythms (De Bodinat et al., 2010). Moreover, disruption of circadian periodicity has been 
proposed as a major player in the onset of bipolar disorders, and successful antidepressant treatment is 
associated with normalization of disturbed biological rhythms (Harvey AG, 2008; Lanfumey et al., 2013). 
Hence, the modulation of melatonin receptors may provide a specific an innovative way to treat bipolar 
disorders. 
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Hence, in our experiments, we used a prolonged repetition of low-intensity stressors in adult mice, 
including social isolation, perturbations of circadian rhythms and daily life habits, in order to induce 
affective disorders. We previously reported that this chronic mild stress procedure was associated with 
reduced glucocorticoid receptor expression in the hippocampus and impulsive choice in the decision 
making task (Froger et al., 2004). In the present study, we aimed at further characterizing the manic-like 
phenotype of the mice, as well as exploring the intracellular signaling, epigenetic regulations and gene 
transcription profiles following stress exposure. In addition, we wanted to test the ability of the new-
generation antidepressant agomelatine to reverse the eventual cellular and molecular alterations and to 
restore a normal phenotype in stressed mice. 
 
 
II – Material and methods 
 
Animals: C57BL/6J male mice (Charles River Laboratories, l’Arbresle, France) were used in the 
experiments. Upon arrival in the laboratory, the mice were housed in groups of four per cage under 
standard conditions (22± 21 C, 60% humidity, 12-h light–dark cycle with lights on at 07h00, food and 
water ad libitum) for 1 week before the beginning of experimental procedures. Experiments were 
performed using 10- to 12-week-old mice (25–30 g body weight). Procedures involving animals and their 
care were conducted in conformity with the institutional guidelines that are in compliance with national 
and international laws and policies (Council directive 87-848, October 19, 1987, Ministere de 
l’Agriculture et de la Foret, Service Veterinaire de la Sante et de la Protection Animale; permissions 75-
116 to M.H. and 006269 to L.L.). 
 
Stress and treatments: The chronic ultra mild stress procedure used in this study has been presented 
elsewhere (Froger et al., 2004), and is a modified version of the chronic mild stress protocol described by 
Willner in rats (Willner, 1992). Briefly, mice were subjected to daily socio-environmental stressors of low 
intensity, in an unpredictable manner (See supplementary table S1) during a 25-day period. 
Administration of compounds was initiated at the beginning of stress procedures, everyday at 6:00 pm 
(i.e. 1 hour before the onset of dark period), for a total period of 25 days. The doses used in the 
experiments have been chosen on the basis of previous studies performed in validated mice models of 
depression and anxiety (Paizanis et al., 2010). Agomelatine (50 mg/kg, Servier) or its vehicle 
(Hydroxyethylcellulose; HEC 1%, Servier) was administrated via intraperitoneal injections.  
 
Behavioral tests: The animals were tested for behavioral analysis after the fourth week of stress. The tests 
were performed at least 18 hours after the last stressor, so as to avoid an eventual effect of acute stress. 
The animals were kept in the testing room for more than 2 hours prior to the test so as to enable the mice 
to habituate to the new environment.  
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The behavioral tests were adapted from existing protocols. Classical test for measuring depressed like 
behavior (TST, FST, splash test, saccharin intake) locomotor activity (OF, actimetry) and anxiety (EPM, 
OF) described in supplementary material, were performed between day 21 and day 25.  
Finally, the animals were sacrificed 18 hours after the last day of both stress and drug injection, and the 
brains were kept at -80°C until use. 
 
Quantitative reverse transcriptase PCR (qRT-PCR): Total mRNA extraction was performed using 
NucleoSpin RNA II kit (Macherey-Nagel, Hoerdt, France), after which the cDNA synthesis was 
performed using a High Capacity cDNA Reverse Transcription kit (Applied Biosystems, Courtaboeuf, 
France) according to the manufacturer’s protocol. One part of the amplification was made with Absolute 
SYBR Green ROX Mix (Thermo Scientific, Illkirch, France) using the 7300 Real Time PCR System 
(Applied Biosystems, Courtaboeuf, France), and the other part of gene expression was measured using 
TaqMan (Applied Biosystems, Courtaboeuf, France) gene expression assays. The sequences of primers 
used are indicated in Table S2 and Table S3. The 2ΔΔCT (Delta-Delta Comparative Threshold) method was 
used to normalize the fold change in gene expressions for both qPCR technologies.  
 
Western blots: The hippocampus were lysed in ice-cold lysis buffer (1% Triton X-100, 150 mM NaCl, 1 
mM EDTA, 10 mM Tris, pH 8.0, 10%, 10 mM NaF, 1 mM sodium orthovanadate and protease inhibitor 
cocktail) and protein extracts was loaded on a SDS-PAGE gel for electrophoresis migration and then 
transferred to a PVDF membrane for 7 min using the iBlot gel transfer system (Life technologies, St 
Aubin, France). Non-specific binding was blocked by incubating the membranes in a blocking buffer 
(PBS-Tween 0.01% supplemented with 5% of BSA) for 1 h at room temperature. The membranes were 
incubated with the primary antibody (see Table S4) overnight at 4°C in the same blocking buffer. Then, 
after extensive washing, the membranes were incubated with the appropriate fluorescent secondary 
antibodies (Alexa Fluor 488 goat anti-rabbit or Alexa Fluor 488 donkey anti-mouse; Molecular Probes, 
OR, USA) for 1 h at room temperature. Finally, the membranes were washed, dried and scanned using the 
Odyssey infrared imaging system (Westburg, Leusden, The Netherlands). 
 
Immunohistochemistry: Coronal sections of 20 µm were collected using a cryostat, after which sections 
were directly mounted on Superfrost Plus slides (Thermo Scientific, Illkirch, France) and stored at -80°C 
until use. The sections were then fixed with 4% paraformaldehyde at 4°C for 10 min. After blocking non-
specific binding with 0.4% of BSA and 5% of appropriate serum, and permeabilizing the membranes with 
0.05% of tween 20, the sections were incubated overnight at 4°C with the primary antibodies (see Table 
S4). The sections were then incubated for 1 hour at room temperature in presence of appropriated 
biotinylated secondary antobodies, and the reaction was amplified using the ABC staining system 
(Vectastain ABC Elite Kit, Vector Laboratories, Les Ullis, France) for one additional hour. Finally, the 
sections were treated with 3,3’-diaminobenzidine (Sigma FASTTM, D4293, Sigma-Aldrich, Saint 
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Quentin-Fallavier, France). After dehydrating the sections and mounting with cover slip, pictures were 
taken under optic microscope (Leica, zoom 2,5) and optical density was measured and then normalized by 
the background using ImageJ software.  
 
Statistical analysis: Data are represented as mean ± SEM and were analyzed using Student’s t test for 
comparison between two groups (Prism 5.0, GraphPad software, USA). When more than two groups of 
data were compared, two-way ANOVA (Stress x Treatment) were used followed by Bonferroni post hoc 
test, or when necessary a planned pairwise comparison using Dunn’s t-test. The level of significance was 
set as P <0.05. 
 
 
III – Results  
 
Agomelatine reverses stress-induced alterations in behavior: A battery of well-established behavioral 
tests usually employed to measure mood, emotions and motor performances in rodents were performed at 
the end of the stress period. Stressed animals displayed a pronounced hyperactivity, as shown by the 
increase exploration in the open field (OF) arena (Figure 1A, + 30 ± 6.4 %), especially during the first 
minutes of the test (Figure 1A, upper panel). This increase in motor activity was confirmed by measuring 
spontaneous locomotion in actimetry boxes. The ambulation, corresponding either to the total number of 
square crossed (Figure S7) or the number of crossing in the center of the actimetry box (Figure 1B), was 
increased in stressed mice (+ 82 ± 11.5 %). The numbers of rearings, corresponding to a vertical activity 
where the mouse leaves the floor with the fore feet, was also increased after exposure to stress (+ 95 ± 
12.5 %, Figure 1B). Similarly, the distance covered in the elevated plus maze (EPM) test was increased in 
mice subjected to chronic mild stress (+ 20 ± 7.6 %, Figure S6). However, the performance of motor 
activity in the rotarod test was altered in stressed mice. Mice exposed to stress displayed a decrease in the 
latency to fall (– 39 ± 9.5 %, Figure S6) indicating impairment of balance and movement coordination.  
Interestingly, the alterations in the distance covered in the OF, as well as the numbers of crossings and 
rearings in actimetry boxes could be significantly prevented by chronic administration of agomelatine 
(Figure 1A and 1B). Further, we assess the motivation and reward alterations, and measured the 
consumption of saccharin solution and the time spent in self-grooming. Data on Figure 2 indicate that 
chronic mild stress significantly decreased saccharin intake and grooming behavior (– 35 ± 6.5 % and – 
43 ± 7.6 % respectively, Figure 2A and 2B). Agomelatine could normalize the alteration in both saccharin 
consumption and grooming behavior (Figure 2A and 2B). We also performed some tests to measure the 
defense mechanisms and anxiety levels such as the tail suspension test (TST), the forced swim test (FST), 
the OF test and the EPM test (Figure 2, Figure S5, Figure S6 and Figure S7). Chronic mild stress 
significantly reduced the immobility time in the tail suspension test (– 52 ± 11.7 %, Figure 2D), which 
could be prevented by agomelatine treatment. There was no difference in the immobility time in the FST 
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(Figure S5). However, a small increase in the number of burst (especially during the first 2 minutes, see 
Figure S5) and mobility was observed in the FST after stress exposure (+ 16 ± 7.2 % and + 9 ± 4.8 % 
respectively, Figure 2E and 2F). The mobility time was significantly different between stressed mice 
treated with vehicle or agomelatine, indicating a preventive effect of agomelatine on escape-like 
behaviors in this paradigm (Figure 2F). In the OF, we observed a reduced anxiety as shown by the 
increased numbers of entries in the center (+ 46 ± 12.4 %, Figure 2C), which could be corrected by 
agomelatine. Of note, the chronic mild stress procedure did not modify the water consumption and weight 
of the animals (Figure S4). Altogether, the behavioral analysis indicate that chronic ultra mild stress 
caused a marked hyperactivity, together with increase of defense mechanisms and decrease of motivation 
and reward. Those behavioral alterations could be prevented when mice were treated with agomelatine 
(50 mg/kg/day) during the whole stress procedure. 
 
Agomelatine reverses stress-induced alterations in intracellular signaling cascades: To further 
elucidate the cellular mechanisms underlying chronic ultra mild stress, the activation of hippocampal 
intracellular signaling pathways involved in survival, proliferation and differentiation was measured. As 
shown by western blots analyses (Figure 3), chronic ultra mild stress significantly impacted on 
hippocampal intracellular signaling cascades. The phosphorylation of the protein-kinase B (Akt), the 
extracellular signal-regulated kinase (Erk), the p-38 mitogen-activated protein kinase (p38), the cAMP 
response element-binding protein (Creb), and the activating transcription factor 1 (Atf1) were increased 
after chronic ultra mild stress (+ 17 ± 6.2 %,  + 42 ± 10.5 %, + 22 ± 8 %, + 55 ± 14.8 % and + 71 ± 14.6 
% respectively, Figure 3), whereas no significant modulations were observed at TrkB phosphorylation. 
The increase of phospho-Akt, phospho-Erk, phospho-Creb and phospho-p38 induced by stress could be 
normalized by chronic agomelatine treatment (Figure 3). The western blot investigations suggest that 
specific effectors of the MAPK and PI3K pathways, involving Akt, Erk, p38, Creb and Atf1, were 
increased after chronic ultra mild stress, and that the administration of agomelatine could significantly 
prevent most of those alterations. 
 
Agomelatine reverses stress-induced abnormal epigenetic regulation and gene expression: To further 
elucidate the molecular and transcriptional mechanisms underlying chronic ultra mild stress, the 
expression of various genes implicated in the regulation of transcription such as epigenetic regulators or 
transcription factors, as well as genes involved in neuronal plasticity was measured (Table S5, S6 and 
S7). First, qPCR screening (Table S5) revealed that chronic stress induced the hippocampal expression of 
many plasticity-related genes including the brain derived neurotrophic factor (Bdnf) gene (+ 28 ± 7 %), 
the neurogenic differentiation 1 (Neurod1) gene (+ 69 ± 10 %), the insulin growth factor 1 (Igf1) gene (+ 
41 ± 7 %), the activity-regulated cytoskeleton-associated protein (Arc) gene (+ 56 ± 10 %), the expression 
the glial cell-derived neurotrophic factor (Gdnf) gene  (+ 58 ± 15 %) and the b-cell lymphoma 2 (Bcl2) 
gene (+ 46 ± 9 %). In addition, the expression of the nuclear receptor subfamily 1, group D, member 2 
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(Nr1d2), known as a transcription activator was increased (+ 40 ± 5 %, Table S6), and the expression of 
the nuclear receptor co-repressor 1 (Ncor1), known as a transcription repressor, was decreased (- 37 ± 6 
%, Table S6). A screening for modulations of epigenetic marks involved in synaptic plasticity including 
histone deacetylase, DNA methyltransferase, methyl binding domain protein and histone acetyltransferase 
was also investigated (Table S7). Among all the epigenetic regulators, a significant reduction of the 
epigenetic repressor Hdac2 (– 22 ± 4 %, Table S7) - a key role player in hippocampal plasticity - was 
observed. Hence, we expressed further interest in the expression of epigenetic markers, and measured the 
expression of HDACs and post-translational modifications at histone tails (Figure S1, S2 and S3). As 
shown by immunostaining analyses, chronic mild stress decreased the HDAC2 protein levels in the CA1 
and CA3 subfields of the hippocampus (– 18 ± 1.2 % and – 14 ± 4.3 % respectively, Figure S1A), 
whereas the expression of HDAC1 was not modulated. The expression of histone 3 lysine 9 di-methylated 
(H3K9me2) was specifically decreased in the CA3 region (– 23 ± 4.3 %, Figure S2A), whereas the 
expression of histone 3 lysine 9 and 14 acetylated (H3K9/14ac) was increased in the CA1 and CA3 
subfields (+ 63 ± 12.5 % and + 32 ± 12.5 % respectively, Figure S2B). The expression of histone 4 
acetylated (H4ac) and histone 3 lysine 4 tri-methylated (H3K4me3) were not modulated by the stress 
(Figure S2C and S2D). Given the pronounced alterations of gene expression and epigenetic regulations, 
the ability of agomelatine to correct for these abnormal epigenetic modifications in the hippocampus was 
investigated. The figure 4 shows that chronic treatment with agomelatine could significantly prevent the 
stress-mediated decrease of HDAC2 and H3K9me2, as well as the increase of H3K9/14ac in the CA3 
region of the hippocampus. The action of agomelatine was rather specific to the CA3 subfield, since no 
significant effects were observed in the CA1 and DG subfields (Figure S3). In a similar manner, some of 
the alteration in plasticity-related gene expression observed after chronic ultra mild stress exposure could 
be normalized by chronic agomelatine treatment (Figure 5). Agomelatine significantly restored the 
abnormal expression of the Bdnf gene, the Neurod1 gene, the Igf1 gene, the Arc gene, whereas the 
expression the Gdnf gene and the Bcl2 gene could not be normalized. All in all, these data indicate that 
chronic stress triggered a marked reorganization at histone post-translational modifications, pointing 
towards an open state of chromatin. Interestingly, this permissive state of chromatin observed after chonic 
ultra mild stress was associated with increased transcription of genes involved in neuroplasticity, and 
preventive administration of agomelatine could abolish these latter alterations. 
 
 
IV – Discussion  
 
     Mounting evidences suggest that stressful life events might play a part in the development and course 
of mood disorders, and that successful antidepressant treatments might involve a normalization of stress-
related alterations in cortico-limbic structures (Calabrese et al., 2009; Touma C, 2011). In this context, the 
aim of the present study was to investigate the effect of prolonged socio-environmental stressors of low 
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intensity on mood-related behaviors and hippocampal function in mice, and explore the biological 
mechanisms and therapeutic potentialities of the new generation agomelatine in this stress model. 
 
Effect of stress on neuroplasticity and behavior: In the present study, we found that a chronic, 
unpredictable and ultra mild stress could induce a decrease in saccharin consumption and grooming 
behavior, reflecting motivation and reward deficits, two core symptoms generally related to depression 
like behavior and observed after chronic stress exposure (Willner P, 2005). We also found a robust 
decrease of immobility in the TST, an increased mobility and number of burst in the FST. These 
behavioral measures can be seen as the expression of defense mechanisms in reaction to innate fear 
stimuli. Hence, in our experiments, the chronic mild stress exposure facilitated flight response as shown 
by tonic/energetic agitation and escape-like behaviors, which might be interpreted as an excessive 
emotional arousal and high vigilance state. In addition, stressed mice displayed a reduced anxiety in the 
open field test. Further, we observed an increased locomotor and motor activity, reflecting a hyperactive 
state of mice after stress exposure. Some studies have reported such locomotor activity following chronic 
mild stress exposure in rodents and could be interpreted as a psychomotor agitation often seen in mood 
disorders (Gronli et al., 2005; Pardon et al., 2000; Negroni et al., 2004). Since many studies demonstrated 
that physical activity and exercise could significantly enhance hippocampal neurogenesis and plasticity 
(Van Praag et al., 1999; Fabel et al., 2008), the increased locomotor activity observed after chronic stress 
might explain, at least in part, the increased in hippocampal plasticity in our mice model. In addition, 
stressed mice displayed a pronounced impairment in motor coordination and balance, which can be 
related to the fact that mice subjected to stress had difficulty to learn the task and to keep focus on 
movement coordination. At the neurobiological level, chronic mild stress was shown to enhance 
hippocampal intracellular signaling pathways such as mitogen-activated protein kinases (MAPK) known 
to be involved in neuronal survival, differentiation and proliferation (Thomas et al., 2004). In addition, we 
found robust changes in epigenetic regulation and gene transcription. The increased in chromatin 
permissive state and plasticity-related gene expression might correspond to the nuclear integration of the 
observed increased in intracellular signaling cascades. Among all the epigenetic modifications, a 
significant decrease of the repressive mark HDAC2 was reported. The low levels of HDAC2 in the 
hippocampus were shown to strongly correlate with enhanced synaptic plasticity (Guan et al., 2009). In 
addition, stress and environmental adversity has been shown to impact on chromatin and histone 
regulations to generate an epigenetic reprogramming, possibly increasing the susceptibility for mood 
disorders (Roth et al., 2009; Tsankova et al., 2006; Weaver et al., 2004). Further, many genes including 
trophic factors (Bdnf, Gdnf, Igf1), pro-survival factor (Bcl2), differentiation factor (Neurod1) and 
cell/dendritic growth factor (Arc), known to be critical in neuronal plasticity, were increased after chronic 
mild stress. Hence, the neurobiological investigations points towards drastic molecular and cellular 
changes underlying increased hippocampal plasticity. These results are rather provocative since it is well 
established that chronic stress paradigms in rodents are generally associated with impaired synaptic 
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integrity, reduced dendritic arborization and decreased neurogenesis in the hippocampus, as well as 
depressive- and anxiety-like behaviors (Alonso et al., 2004; Goshen et al., 2008; Mineur et al., 2007). 
However, few studies reported that chronic stress could also enhance neurogenesis as well as dendritic 
spines and excrescence in CA3 neurons of the hippocampus (Parihar et al., 2011; Sunanda et al., 1995). In 
our protocol of chronic mild stress - in contrast to other protocols using longer or stronger stressors - we 
used a repetition of low-intensity socio-environmental stressors for a total period of 3 weeks suggesting 
that the timing, duration and intensity of the stressors might be critical in the determination of the 
neuroendocrine and behavioral outcomes. Further, we previously reported a reduced hippocampal 
expression of GR mRNA in stressed mice (Froger et al., 2004). Other reports showed that downregulation 
of GR in the hippocampus in rodents, either by genetic knockdown or by pharmacological blockade after 
exposure to chronic stress, could be associated with an increased synaptic plasticity (Avital et al., 2006; 
Fitzsimons et al., 2013; Krugers et al., 2006).  
 
 Effect of agomelatine treatment on stress-related alterations: Agomelatine is an atypical antidepressant 
that acts on the melatoninergic and the serotoninergic systems. Like many commonly used 
antidepressants, agomelatine was shown to positively modulate neurogenesis, hippocampal plasticity and 
neurotrophic signaling in rodent models of depression (Banasr et al., 2006; Soumier et al., 2009). In our 
experiments we did not observed any effects of chronic agomelatine treatment on hippocampal plasticity 
in non-stressed mice. Interestingly, agomelatine could specifically normalize the hippocampal alterations 
induced by chronic mild stress, indicating that this drug has a disease-dependent action on neuronal 
activity. MT2 receptors, one of the key players in agomelatine action, are abundantly expressed in various 
cell population of the hippocampus (Musshoff et al., 2002). Melatonin receptors are coupled to Gαi 
proteins resulting into an inhibition of cyclic AMP signaling (De Bodinat el al., 2010). Some studies 
showed that melatonin, most likely through the interaction via MT2 receptors, reduced neuronal firing 
and excitability, and inhibited long-term potentiation in mouse hippocampal slides (Hogan et al., 2001; 
Wang et al., 2005). This latter effect might explain the normalization of the increased intracellular 
signaling and associated epigenetic and neuroplastic changes observed after chronic mild stress. A 
previous study also showed that agomelatine could specifically normalize the increased hippocampal c-
Fos levels, an indicator of increased neuronal activity, induced by prenatal stress in rat (Mairesse et al., 
2013). At the behavioral level, chronic mild stress caused reward, motivation and attention deficit. These 
symptoms are known to be highly dependent on the mesolimbic dopaminergic system. The normalization 
of these behavioral alterations by agomelatine can be attributed to the inhibition of 5-HT2C receptor, 
known to enhance dopamine released in several brain structures including the frontal cortex, striatum and 
nucleus accumbens (De Deurwaerdere et al., 2004; Di Matteo et al., 1999). In addition, our model of 
stress induced an overall increased in motor activity, which could be corrected by agomelatine. Previous 
studies also reported similar effects of agomelatine on hyperactivity in mice models of mood disorders 
(Mairesse et al., 2013; Norman et al., 2011), and systemic administration melatonin was also shown to 
Agomelatine, stress and hyperactivity 
	   189	  
reduce spontaneous locomotor activity in rats exposed to stress (Chuang et al., 1994). Finally, the 
emotional reactivity or vigilance is also known to be sensitive to melatonin receptor agonists, shifting the 
arousal state from hyperactive to sleep (Pandi-Perumal et al., 2007). 
 
Conclusions and perspectives: In summary, the neurobiological and behavioral investigations provided 
clean-cut evidences that prolonged exposure to socio-environmental stressors of low intensity in C57Bl/6 
mice could induce drastic molecular and cellular changes leading to an increased hippocampal plasticity, 
together with marked hyperactivity, hyperarousal, reward and motivation deficits, distractibility and 
increased risk taking. Agomelatine could prevent both neurochemical and behavioral alterations triggered 
by stress, providing novel insights into the molecular, cellular and behavioral mechanisms of action of 
this atypical antidepressant in a rodent model of mood-related disorders. In addition, the altered 
epigenetic regulations in the hippocampus support the notion that chromatin remodeling via histone 
modifications can increase susceptibility for mood disorders, and that the reversal of such changes by 
antidepressants are required for their therapeutic action. 
 
Finally, the abovementioned behavioral responses described in our stress model can be assimilated to 
common symptoms usually observed in mixed manic state of bipolar disorders (see Table S8). Although, 
no compelling evidences for hippocampal hyperactivity were shown in humans, validated models of 
manic-like behaviors showed similar neurochemical changes in the hippocampus, including upregulation 
of BDNF protein and increased PI3-K and MAPK signaling (Kirshenbaum et al., 2011; Prickaerts et al., 
2006). In addition, both human and animal studies established a pivotal role for circadian rhythms and 
seasonal changes in the pathophysiology and treatment of bipolar disorders (Arey et al., 2013; Harvey 
A.G, 2008; Kirshenbaum et al., 2011). Hence, this model might be of particular interest to further 
investigate the causal relationship between stress, circadian rhythms and hippocampal dysfunction in the 
development and course of manic and bipolar disorders.  
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Figures and legends 
 
 
 
 
 
 
 
Figure 1. Effects of chronic agomelatine treatment on stress-induced locomotor dysfunction. (A) Mice were subjected to an 
open field test, and the distance covered in the arena was measured over the time (top panel). On the bottom panel, the total 
distance over a 20-minute period is represented. The two-way analysis of variance (ANOVA) indicated significant effect of 
Stress [F(1,28)=5.78; p<0.05], but no effect of Treatment [F(1,28)=2.95; p>0.05]. However, the was a significant interaction 
between the Stress and the Treatment factors [F(1,28)=6.89; p<0.05], and the Bonferroni post hoc test revealed a significant 
increase of the distance covered in stressed mice (p<0.01), which could be prevented by agomelatine (p<0.01). (B) Mice were 
placed in actimetry boxes and the numbers of crossings in the center of the apparatus, as well as the numbers of rearings were 
measured with an infrared dispositive over one hour (top panel). On the bottom panel, the total numbers of crossing and total 
numbers of rearings over a one-hour period are indicated. The two-way ANOVA indicated significant effect of Stress on crossing 
activity [F(1,28)=15.21; p<0.01], and rearing activity [F(1,28)=9.12; p<0.001]. A significant interaction between the Stress and 
the Treatment factors on crossing [F(1,28)=7.30; p<0.05] and rearing behaviors [F(1,28)=12.43; p<0.01] was observed. 
Bonferroni post hoc test revealed a significant increase of the crossings and rearings in stressed mice (p<0.001), which could be 
prevented by agomelatine (p<0.01 and p<0.001 respectively). Data are expressed as mean ± S.E.M of n=8 mice per group. **p < 
0.01  CMS HEC vs CMS AGO; ***p < 0.001 CMS HEC vs CMS AGO. 
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Figure 2. Effects of chronic agomelatine treatment on stress-induced affective behaviors. (A) The time spent in grooming 
behavior over a total period of 5 minutes was measured in mice. The two-way ANOVA indicated significant effect of Stress 
[F(1,70)=13.9; p<0.01] as well as Treatment [F(1,70)=7.62; p<0.05] on grooming behavior. Bonferroni post hoc test revealed a 
significant decreased in the self-grooming of stressed mice (p<0.01), which could be prevented by agomelatine (p<0.01). (B) The 
saccharin consumption was measured for an overnight period. There was a significant interaction between the Stress and the 
Treatment factors [F(1,39)=8.29; p<0.01], and Bonferroni post hoc test revealed a significant decreased in the saccharin intake of 
stressed mice (p<0.05), which could be prevented by agomelatine (p<0.001). (C) Mice were subjected to an open field test, and 
the number of visit to the center of the arena was measured over a 20-minute period. There was a significant interaction between 
the Stress and the Treatment [F(1,26)=5.94; p<0.05], and Bonferroni post hoc test revealed a significant decreased in the number 
of entries in the center of the arena in stressed mice (p<0.05). (D) The immobility time in the tail suspension test paradigm was 
measured after chronic mild stress. The two-way ANOVA indicated significant effect of Stress [F(1,30)=7.69; p<0.01] as well as 
Treatment [F(1,30)=16.59; p<0.001] on immobility time. There was a significant interaction between the Stress and the 
Treatment [F(1,30)=4.55; p<0.05], and Bonferroni post hoc test revealed a significant decreased in the immobility time of 
stressed mice (p<0.01), which could be prevented by agomelatine (p<0.001). (E) Mice were subjected to the forced swim test, 
and the time spent in swimming activity (mobility) and the struggling activity (number of bursts), over a 6-minute period, are 
represented. There was a significant interaction between the Stress and the Treatment factors [F(1,26)=4.25; p<0.05] for the 
mobility time, and the Bonferroni post hoc test revealed a significant decreased in the mobility time of stressed mice treated with 
vehicle as compared to stressed mice treated with agomelatine (p<0.05). A tendency towards an interaction for the number of 
burst [F(1,26)=3.12; p=0.089] was observed, and a planned pairwise comparison using Dunn’s t-test indicated a significant 
decreased in the number of bursts of stressed mice treated with vehicle as compared to stressed mice treated with agomelatine 
(p<0.05). Data are expressed as mean ± S.E.M of n=7-12 mice. *p < 0.05;  **p < 0.01; ***p < 0.001.  
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Figure 3. Effects of chronic agomelatine treatment on intracellular signaling in the hippocampus of stressed mice. Western 
blot analysis of phospho-Akt, phospho-Creb, phospho-Erk, phospho-TrkB, phospho-Atf1 and phospho-p38 were performed in 
the hippocampus of mice, and quantifications of optical density were monitored with ImageJ. A two-way ANOVA revealed a 
significant interaction between Stress and Treatment factors for p-Creb [F(1,28)=10.63; p<0.01], p-Atf1 [F(1,11)=5.19; p<0.05] 
and p-p38 [F(1,12)=16.22; p<0.001]. There was a significant effect of Treatment on p-Akt [F(1,26)=13.72; p<0.001], p-Creb 
[F(1,28)=6.49; p<0.05], p-Erk [F(1,14)=23.82; p<0.001] and p-p38 [F(1,12)=18.35; p<0.01], and effect of Stress on p-p38 
[F(1,12)=11.77; p<0.01]. Of note, a trend for a Stress effect was observed for p-Akt [F(1,26)=4.09; p=0.053], p-Erk 
[F(1,14)=4.55; p=0.051] and p-Atf1 [F(1,11)=3.55; p=0.086]. Bonferroni post hoc analyses revealed a significant increased 
between non-stressed mice treated (NS HEC) with vehicle and stressed mice treated with vehicle (CMS HEC) for p-Creb 
(p<0.05), p-Atf1 (p<0.05) and p-p38 (p<0.001). Agomelatine treatment (50 mg/kg/day) could prevent the phosphorylation of 
Creb (p<0.001) and p38 (p<0001) induced by stress (CMS HEC v.s. CMS AGO). In addition, agomelatine could decrease p-Akt 
(p<0.05) and p-Erk (p<0.05) in stressed mice (CMS HEC v.s. CMS AGO). Data are represented as percentage of non-stressed 
mice treated with vehicle (NS HEC), and each bar represent the mean + S.E.M of (n=4-8 mice). *p < 0.05, **p < 0.01, ***p < 
0.001. 
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Figure 4. Effects of chronic agomelatine treatment on epigenetic remodeling in the hippocampus of stressed mice 
Representative photomicrographs of HDAC2 (A), H3K9me (B) and H3K9ac (C) immunolabelings in the CA3 subfield of the 
hippocampus (top panel) are shown, as well as the quantification of optical density (bottom panel). (A) The two-way ANOVA 
analysis indicated a significant effect of Stress [F(1,16)=5.76; p<0.05], but no effect of Treatment [F(1,16)=2.02; p>0.05] for the 
repressive mark HDAC2. There was a significant interaction between the Stress and the Treatment [F(1,16)=5.17; p<0.05], and 
the Bonferroni post hoc test revealed a significant decreased HDAC2 in the CA3 subfield (p<0.01), which could be prevented by 
agomelatine (p<0.05). (B) The two-way ANOVA analysis indicated a significant effect of Treatment [F(1,17)=4.75; p<0.05], but 
no effect of Stress [F(1,17)=3.46; p>0.05] for the repressive mark H3K9me. There was a significant interaction between the 
Stress and the Treatment [F(1,17)=6.83; p<0.05], and the Bonferroni post hoc test revealed a significant decreased H3K9me in 
the CA3 subfield (p<0.05), which could be prevented by agomelatine (p<0.01). (C) The two-way ANOVA analysis indicated a 
significant effect of Stress [F(1,16)=5.25; p<0.05] and a tendency for an effect of Treatment [F(1,16)=3.71; p=0.072] for the 
repressive mark H3K9ac. There was a significant interaction between the Stress and the Treatment [F(1,16)=9.86; p<0.01], and 
the Bonferroni post hoc test revealed a significant decreased H3K9ac in the CA3 subfield (p<0.01), which could be prevented by 
agomelatine (p<0.01). Quantifications of immunolabelings are expressed as arbitrary units and each bar represent the mean + 
S.E.M of n=5 (NS HEC), n=6 (NS AGO), n=4 (CMS HEC) and n=6 (CMS AGO) mice. *p < 0.05; **p < 0.01. 
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Figure 5. Effects of chronic agomelatine treatment on plasticity-related gene expression in the hippocampus of stressed 
mice. mRNA levels of plasticity-related genes in the hippocampus of mice were measured by quantitative real-time RT-PCR, and 
are expressed as fold changes as compared to the non-stressed mice treated with hydroxyethylcellulose (NS HEC). The two-way 
ANOVA indicated a significant interaction between Stress and Treatment factors for Arc [F(1,29)=7.05; p<0.05], Igf1  
[F(1,34)=6.15; p<0.05] and Neurod1 [F(1,32)=4.80; p<0.05]. In addition, there was also an effect of Stress on Bcl2 
[F(1,26)=12.47; p<0.01], Gdnf [F(1,25)=56.71; p<0.001], Igf1 [F(1,34)=13.30; p<0.001] and Neurod1 [F(1,32)=14.41; p<0.001], 
and a Treatment effect on Arc [F(1,29)=4.50; p<0.05], Bdnf [F(1,31)=17.16; p<0.001], Gdnf [F(1,25)=5.57; p<0.05] and Neurod1 
[F(1,32)=21.05; p<0.001]. The Bonferroni post hoc tests indicated a significant increase of Arc (p<0.05), Bcl2 (p<0.05), Bdnf  
(p<0.05), Gdnf (p<0.001), Igf1 (p<0.001) and Neurod1 (p<0.001), between non-stressed mice treated with vehicle (NS HEC) and 
stressed mice treated with vehicle (CMS HEC). Similarly, there was a significant difference between stressed mice treated with 
vehicle (CMS HEC) versus stressed mice treated with agomelatine (CMS AGO) for Arc (p<0.01), Bdnf (p<0.001), Igf1 (p<0.05) 
and Neurod1 (p<0.001). Each bar represent the mean + S.E.M of n=7-12 mice. *p < 0.05; **p < 0.01; ***p < 0.001.   
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Supplementary methods. 
 
Saccharin consumption test 
At the beginning of the test, plastic pipettes filled with tap water were proposed to the mice so as to 
measure the daily consumption of water using such kind of apparatus. Then, after habituation, two 
pipettes filled either with water or a 10% saccharin solution were assigned to every cage and the mice 
were able to freely choose between the two solutions. The pipettes were presented to the animals for an 
overnight period of 18 hours, after which they were removed from the cages. 
 
Tail suspension test 
The apparatus consists of three suspension units divided by walls (ID-Tech-Bioseb, Chaville, France).	  
The mice were suspended by the tail, using an adhesive tape, and	   the duration of immobility was 
measured automatically by the software over a 6-minute period.  
 
Splash test 
The splash test, previously described by Surget et al., 2008, consists into spraying a 10% sucrose solution 
on the back of mice in their home cage. Because of its viscosity, the sucrose solution dirties the coat and 
induces grooming behavior. The total time of grooming over a 5-minute period was recorded in our 
experiments. 
 
Open field test 
The apparatus consisted of four open boxes of 40 x 40 cm separated by white wood walls and equipped 
with an infrared floor for the measurement of motor activity. The arena was subdivided into a central and 
a peripheral zone. Mice were placed in the open field boxes for 20 min under normal light conditions, and 
the motor activity of the animals were automatically scored with a camera connected to a computerized 
system (Viewpoint, Lyon, France). The time spent in the different zones and the distance moved were 
scored. 
 
Forced swim test 
In the forced swimming test (FST), originally designed by Porsolt and colleagues (1977), mice were 
placed into plastic buckets (19 cm diameter, 23 cm deep, filled with 23°C–25°C water) under low light 
conditions and videotaped for 6 min (Viewpoint, Lyon, France). The different outcome measures were 
“immobility” reflecting no movement at all and/or minor movements necessary to keep the nose above 
the water; “mobility” reflecting medium activity such as swimming; and “bursts” reflecting strong 
mobility and struggling behaviors. 
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Rotarod test 
Motor coordination and balance were assessed with the rotarod test using an accelerating rotarod 
(Accelerating Rotarod, UGO Basile, Comerio, Italy). Mice were placed on rotating drums (3 cm 
diameter), and the time that each animal maintained its balance on the rod was measured. The speed of 
the rotarod accelerated from 4–40 rpm over a 5-min period. 
 
Spontaneous locomotor activity 
Locomotor activity was measured using a computer-based photobeam apparatus. Actimeter box (area: 
300 × 150  mm2; height 180  mm; with plexiglass wall and grid floor) detected mouse movements by 
means of two infrared light beams. Mice were placed in the testing apparatus for 1 hour. The ambulations 
corresponding to the number of squares crossed in periphery and centre during the observation period, 
and the rearings corresponding to the number of times the mouse stands on its hind feet (and leaves the 
floor with the fore feet) were measured. 	  	  
Elevated plus maze 
The elevated plus maze (EPM), as described previously by Narboux-Neme and colleagues (2011), 
consisted of a plus-shaped apparatus with two open and two closed arms. The apparatus was made from 
dark plastic material that was transparent for infrared light, and the walls of the closed compartment were 
covered with opaque scotch tape. For the test, the mouse was placed into one of the closed arm facing a 
closed part of the apparatus, and the movements of the animal were scored automatically under dark 
conditions with a computerized system using an infrared video camera (Viewpoint, Lyon, France). 
Percentage of time spent in the open and closed parts of the maze, numbers of entries to the open and 
closed arms, and total distance traveled were investigated. 	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  Morning Afternoon Night 
Monday   30° cage-tilt (1h) Difficult access to food 
Tuesday Confinement (1h) Paired housing (2h) Overnight illumination 
Wednesday 30° cage-tilt (1h) Confinement (2h) 30° cage-tilt (1h) 
Thursday Paired housing (2h) Confinement (1h) Soiled cage 
Friday Confinement (1h) 30° cage-tilt (2h) Reverse light/dark cycle 
Week-end Reverse light/dark cycle 
 
 	  
Table S1. Procedures used for the chronic mild stress paradigm. The stressors consisted into repeated periods of 
30° cage tilt, confinement to small cages (11 x 8 x 8 cm), two 2 hour periods of paired housing, one overnight period 
of difficult access to food (without modifying the daily food ration), one period of continuous overnight 
illumination, and one overnight period in a soiled cage (50 ml of water/l of sawdust bedding). Animals were also 
placed on a reversed light/dark cycle from Friday evening to Monday morning. These stressors were scheduled over 
a 1-week period and repeated throughout a total period of 3 weeks.  
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Symbol Sense Anti-sense 
   
Arc TCATTCAGTATGTGGTGGGC GTCCTGCACTTCCATACCC 
Akt1 TATTGGCTACAAGGAACGGC ATAAAGGTGTTGGGCCTTGG 
Bdnf9 AAAACCATAAGGACGCGGAC TAGACATGTTTGCGGCATCC 
Creb1 GTTGTTATGGCGTCCTCCC TACGACATTCTCTTGCTGCC 
Crf CCTTGAATTTCTTGCAGCCG GGACTTCTGTTGAGATTCCCC 
Mapk3 TACGATCCGACAGATGAGCC GAAGATCAACTCCTTCAGCCG 
Gdnf TGGGTTTGGGCTATGAAACC AACATGCCTGGCCTACTTTG 
Glur1 TGTGACACCATGAAAGTGGG AAAACCGCTAGGTTTACGGG 
Igf1 GACTGGAGATGTACTGTGCC GTACTTCCTTCTGAGTCTTGGG 
NeuroD1 TGAAGCCATGAATGCAGAGG TTTCTTTTTGGGACCCCGTC 
Vgf TTGACACCCTTATCCAAGGC ACCTGAGCTAATCCTTGCTG 
cfos AGGGAACGGAATAAGATGGC TGCAACGCAGACTTCTCATC 
Egr1 TCAATCCTCAAGGGGAGCC ACTCGTCTCCACCATCGC 
Bcl2 ATGACTGAGTACCTGAACCG ATGCTGGGGCCATATAGTTC 
 
 
Table S2. Primers used for SybrGreen protocols. One part of the amplification was made with Absolute SYBR 
Green ROX Mix (Thermo Scientific, Illkirch, France) using the 7300 Real Time PCR System (Applied Biosystems, 
Courtaboeuf, France) and the sequences of primer sets are indicated. Gene expressions were normalized using Hprt 
as a reference gene and the conditions for the reaction included 35 cycles in a fixed sequence of 95°C for 20 s, 62°C 
for 30 s, and 72°C for 30 s. 	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Symbol	   Reference	  	   	  Bmal1	   Mm00500226_m1	  Cbp	   Mm01342452_m1	  Id2	   Mm01293217_g1	  Nr1d2	   Mm00441730_m1	  Ncor1	   Mm00448681_m1	  Rpol1-­‐2	   Mm00485813_m1	  Dnmt1	   Mm01151065_g1	  Hdac1	   Mm02745760_g1	  Hdac2	   Mm00515108_m1	  Hdac3	   Mm00515916_m1	  Hdac4	   Mm01299565_m1	  Hdac5	   Mm00515941_g1	  Hdac9	   Mm00458454_m1	  Mbd1	   Mm01262472_g1	  Mecp2	   Mm01193537_g1	  Myst2	   Mm01304323_m1	  Gapdh	   Mm99999915_g1	  	  	  
Table S3. Primers used for Taqman protocols. The second part of gene expression was measured using TaqMan 
(Applied Biosystems, Courtaboeuf, France) gene expression assays, and the sequences of primer sets are indicated. 
Gene expressions were normalized using Gapdh as a reference gene and the conditions for the reaction were set as 
follow: 50 °C, 2 min; 95 °C, 10 min, and followed by 40 cycles at 95 °C, 15 s; 60 °C, 1 min. 	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Symbol Name Supplier 
   
p-Akt Phospho-Akt (Ser473) (587F11) 4051 Cell signaling 
p-Creb Phospho-CREB (Ser133) (87G3) 9198 Cell signaling 
p-Erk Monoclonal Anti-MAP Kinase, Activated (Diphosphorylated ERK1&2) M9692 Sigma aldrich 
p-p38 Phospho-p38 MAPK (Thr180/Tyr182) (D3F9) 4511 Cell signaling 
p-TrkB Trk B Phospho (pY817) (NTRK2) 2149-1 Epitomics 
H3K9me2 Anti-Histone H3 (di methyl K9 [mAbcam 1220] ab1220 Abcam 
H3K4me3 Anti-trimethyl-Histone H3 (Lys4) Antibody, clone MC315 Millipore 
H4ac Anti-acetyl-Histone H4 Antibody 06-866 Millipore 
H3K9/14ac H3K9/14ac polyclonal antibody pAb-005-044 Diagenode 
HDAC1 Anti-HDAC1 antibody - ChIP Grade ab7028 Abcam 
HDAC2 Anti-HDAC2 antibody - ChIP Grade ab7029 Abcam 
 
 
 
Table S4. List of antibodies used in the experiments. The names (including the reference) and suppliers for the 
antibodies used for western blots and immunohistochemistry are indicated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter VIII 
	  204	  
 
 
 
 
 
Symbol Definition NS CMS % over NS P value 
      
Arc Activity-regulated cytoskeleton-associated protein 1.03 ± 0.08 1.59 ± 0.10 56% * 
Akt1 Thymoma viral proto-oncogene 1 1.01 ± 0.04 1.07 ± 0.04 6% ns 
Bcl2 B cell lymphoma 2 1.01 ± 0.09 1.47 ± 0.09 46% ** 
Bdnf9 Brain-derived neurotrophic factor exon 9 1.00 ± 0.08 1.28 ± 0.07 28% * 
Creb1 cAMP responsive element binding protein 1 1.01 ± 0.08 1.17 ± 0.07 16% ns 
Crf Corticotropin releasing factor 1.02 ± 0.07 1.13 ± 0.07 11% ns 
Mapk3 Mitogen-activated protein kinase 3 1.01 ± 0.08 0.87 ± 0.05 -14% ns 
Gdnf Glial-derived neurotrophic factor 1.01 ± 0.07 1.59 ± 0.15 58% *** 
Glur1 Glutamate receptor, ionotropic, AMPA1 1.01 ± 0.10 0.96 ± 0.08 -5% ns 
Gpr88 G-protein coupled receptor 88 0.99 ± 0.17 1.17 ± 0.17 18% ns 
Igf1 Insulin growth factor 1 1.01 ± 0.05 1.42 ± 0.07 41% *** 
NeuroD1 Neurogenic differentiation 1 1.02 ± 0.07 1.71 ± 0.10 69% ** 
Vgf Nerve growth factor inducible 1.04 ± 0.10 0.78 ± 0.13 -26% ns 
 
 
Table S5. Effect of chronic mild stress on hippocampal plasticity-related gene expression profiles. Diverse 
genes involved in neuroplasticity have been measured in the hippocampus of mice subjected or not to the chronic 
mild stress procedure. mRNA levels were quantified by quantitative real-time RT-PCR, and data were normalized to 
the house keeping gene Actb. Data are expressed as mean ± S.E.M of arbitrary units representing the fold changes as 
compared to the non-stress (NS) condition. ns: non significant *p < 0.05 vs. NS; **p < 0.01 vs. NS; ***p < 0.001 
vs. NS. Student’s t test.  
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Symbol Definition NS CMS % over NS P value 
  
Bmal1 Aryl hydrocarbon receptor nuclear translocator-like 1.00 ± 0.04 0.91 ± 0.04 -9% ns 
cfos FBJ osteosarcoma oncogene 1.05 ± 0.18 0.63 ± 0.11 -42% * 
Cbp Creb binding protein 1.00 ± 0.02 1.01 ± 0.04 1% ns 
Egr1 Early growth response 1 1.00 ± 0.08 1.06 ± 0.14 6% ns 
Id2 Inhibitor of DNA binding 2 1.00 ± 0.05 0.89 ± 0.05 -11% ns 
Nr1d2 Nuclear receptor subfamily 1, group D, member 2 1.00 ± 0.01 1.40 ± 0.05 40% *** 
Ncor1 Nuclear receptor co-repressor 1 1.00 ± 0.05 0.63 ± 0.06 -37% ** 
Rpol1-2 RNA polymerase 1 1.00 ± 0.03 0.96 ± 0.12 -4% ns 
 
 
Table S6. Effect of chronic mild stress on hippocampal transcription regulators. Diverse genes involved in the 
control of transcription have been measured in the hippocampus of mice subjected or not to the chronic mild stress 
procedure. mRNA levels were quantified by quantitative real-time RT-PCR, and data were normalized to the house 
keeping gene Actb. Data are expressed as mean ± S.E.M of arbitrary units representing the fold changes as 
compared to the non stress (NS) condition. ns: non significant *p < 0.05 vs. NS; **p < 0.01 vs. NS; ***p < 0.001 vs. 
NS. Student’s t test. 
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Symbol Definition NS CMS % over NS P value 
  
Dnmt1 DNA methyltransferase 1 1.00 ± 0.02 0.99 ± 0.05 -1% ns 
Hdac1 Histone deacetylase 1 1.00 ± 0.02 1.01 ± 0.07 1% ns 
Hdac2 Histone deacetylase 2 1.00 ± 0.03 0.78 ± 0.04 -22% ** 
Hdac3 Histone deacetylase 3 1.00 ± 0.03 1.01 ± 0.03 1% ns 
Hdac4 Histone deacetylase 4 1.00 ± 0.02 1.06 ± 0.10 6% ns 
Hdac5 Histone deacetylase 5 1.01 ± 0.04 1.03 ± 0.06 2% ns 
Hdac9 Histone deacetylase 9 1.00 ± 0.02 1.04 ± 0.06 4% ns 
Mbd1 Methyl binding domain 1 1.01 ± 0.06 1.00 ± 0.04 -1% ns 
Mecp2 Methyl CpG binding protein 2 1.00 ± 0.03 0.95 ± 0.02 -5% ns 
Myst2 MYST histone acetyltransferase 2 1.00 ± 0.03 0.99 ± 0.02 -1% ns 
 
 
Table S7. Effect of chronic mild stress on hippocampal expression of epigenetic regulators. Diverse genes 
involved in epigenetic repression or activation have been measured in the hippocampus of mice subjected or not to 
the chronic mild stress procedure. mRNA levels were quantified by quantitative real-time RT-PCR, and data were 
normalized to the house keeping gene Actb. Data are expressed as mean ± S.E.M of arbitrary units representing the 
fold changes as compared to the non stress (NS) condition. ns: non significant *p < 0.05 vs. NS; **p < 0.01 vs. NS; 
***p < 0.001 vs. NS. Student’s t test. 
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Figure S1. Effect of chronic mild stress on HDAC1 and HDAC2 expression in the hippocampus. The levels of 
HDAC2 (A) and HDAC 1 (B) in the hippocampus were measured by immunostaining, and the quantifications of 
optical density of the different hippocampal subfields are represented. Data are expressed as percentage of the non-
stress (NS) condition and each bar represent the mean + S.E.M of n=5 (NS) and n=6 (CMS) mice. *p < 0.05 vs. NS. 
Student’s t test. 
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Figure S2. Effect of chronic mild stress on histone post-translational modifications in the hippocampus. The 
levels of H3K9me2 (A), H3K9/14ac (B), H4ac (C) and H3K4me3 (D) were measured by immunolabeling in the 
hippocampus, and the quantifications of optical density of the different hippocampal subfields are represented. (B) 
Data are expressed as percentage of the non-stress (NS) condition and each bar represent the mean + S.E.M of n=5 
(NS) and n=6 (CMS) mice. *p < 0.05 vs. NS; **p < 0.01 vs. NS; ***p < 0.001 vs. NS. Student’s t test. 
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Figure S3. Effect of agomelatine on stress-induced epigenetic changes in the hippocampus. The levels of 
HDAC2 (A), H3K9me2 (B) and H3K9/14ac (C) were measured by immunolabeling in the hippocampus, and the 
quantifications of optical density of the CA1 (top panel) and the DG (bottom panel) are represented. The two-way 
ANOVA analysis indicated a significant effect of Stress on HDAC2 [F(1,16)=7.03; p<0.05], H3K9/14ac 
[F(1,16)=8.89; p<0.01], but not on H3K9me2  in the CA1 region. Further, the two-way ANOVA analysis indicated 
no significant effect of Stress on HDAC, H3K9me2 and H3K9/14ac in the DG. Quantifications of immunolabelings 
are expressed as arbitrary units and each bar represent the mean + S.E.M of n=5 (NS HEC), n=6 (NS AGO), n=4 
(CMS HEC) and n=6 (CMS AGO) mice. *p < 0.05  CMS HEC vs CMS AGO; **p < 0.01 CMS HEC vs CMS 
AGO.  
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Figure S4. Water consumptions and weights. (A) The weight of mice was measure before and after the chronic 
mild stress procedure. (B) The consummation of water over the night is represented. Each bar represents the mean + 
S.E.M of n=7-8 animals per group. There were no significant modulations of the weights and water consumptions 
by stress or agomelatine treatment. 
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Figure S5. Effects of stress and agomelatine treatment in the FST.  Mice were subjected to the forced swim test, 
and the time spent in immobility (right panel) and in burst activity (center panel) over a 6-minute period is 
represented. The numbers of bursts during the first 2 minutes is also represented (left panel). There was no 
significant modulation of the immobility and burst time by stress or agomelatine treatment. A two-way ANOVA 
indicated a significant effect of Stress factor on the numbers of bursts during the first 2 minutes [F(1,28)=6.84; 
p<0.05]. Data are expressed as mean + S.E.M of n=7-8 mice per group. *p < 0.05. 
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Figure S6. Effects of stress and agomelatine treatment in the EPM.  Mice were subjected to the elevated plus 
maze test for 10 minutes. The two-way ANOVA indicated no significant difference of Stress or Treatment factors 
on the time spent in open arms or closed arms. However, there was a significant effect of Stress on the distance 
covered [F(1,27)=7.85; p<0.01] and the frequency to closed arms [F(1,27)=8.03; p<0.01]. In addition, the two-way 
ANOVA indicated a significant effect of Treatment on the frequency to open arms [F(1,27)=4.68; p<0.05]. Data are 
expressed as mean + S.E.M of n=7-8 mice per group. **p < 0.01. 
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Figure S7. Effects of stress and agomelatine treatment in the OF.  Mice were subjected to the open field test, and 
the time spent in the periphery (right panel) and the time spent in the center (left panel) of the arena over a 20-
minute period are represented. Data are expressed as mean + S.E.M of n=7-8 mice per group. There was no 
significant modulation of the time spent in the center or periphery by stress or agomelatine treatment. 
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Figure S8. Effects of stress and agomelatine treatment on locomotor activity and movement coordination.  (A) 
Mice were placed in actimetry boxes and the total locomotor activity during a 1-hour period was measured. Chronic 
mild stress significantly increased the locomotor activity (p=…). (B) Mice were placed in a accelerating rotarod 
apparatus, and the latency to fall was measured. Chronic mild stress significantly altered the movement balance and 
coordination, which might be du to an increased distractibility (p=…). Data are expressed as mean + S.E.M of n=7-8 
mice per group. 
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Symptoms of mixed manic state Chronic mild stress in C57Bl6 mice 
  
Disrupted circadian rhythms Inversion of light/dark cycles in stress procedures 
Increased risk taking Reduced anxiety in the OF 
Psychomotor agitation / hyperactivity Increased locomotion and rearing 
Emotional arousal and vigilance Increased reactivity in the FST and TST 
Impulsivity Facilitation of choice in the decision making task 
Self neglect Decreased self grooming  
Distractibility / decreased concentration 
Inability to keep focussed in the rotarod test  
Impaired motor learning 
Reward deficit Decrease saccharin intake / anhedonia 
High levels of energy Increased tonic agitation or bursts in the FST 
 
 	  
Table S8. Comparison between clinical symptom of mania and behavioral response in mice exposed to 
chronic mild stress. 
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     Mood disorders are among the major health problems worldwide due to the high prevalence and 
recurrence in the general population, and the significant burden for individual life quality and the 
repercussion on healthcare systems and society (WHO, 2001). Up to date, the etiology and biological 
mechanisms underlying mood disorders are still poorly understood. Mounting evidences suggest that a 
complex interaction between genes and the environment account for the development and course of major 
depression, i.e. one of the most prevalent affective disorders (Keers et al., 2012). Accordingly, complex 
epigenetic regulations - consisting of key mechanisms by which environmental factors induce enduring 
changes in gene expression without altering the DNA code - have been suspected to plays a pivotal role in 
the pathophysiology of depression (Tsankova et al., 2007). More specifically, epigenetic repression of the 
gene encoding for brain-derived neurotrophic factor (BDNF) - a small-secreted growth factor implicated 
in brain development and neuronal plasticity - may have a preponderant role in the onset of depression 
and other mood disorders (Boulle et al., 2012). In this context, the work presented in this thesis aimed at 
exploring the role of BDNF signaling and its downstream epigenetic regulation in the pathophysiology 
and treatment of mood disorders.  
 
 
 
I – BDNF/TrkB signaling in the pathophysiology of mood disorders 
 
Exon-specific regulation of the BDNF gene: BDNF has a complex gene structure, consisting of several 
untranslated 5’ exons with independent promoters that can be connected to a 3’ coding exon to form a 
bipartite or tripartite transcript yielding different splice variants of BDNF mRNA (Pruunsild et al., 2007). 
In Chapter 6, we investigated the expression of BDNF exon IV and exon IX in the hippocampus of rats 
exposed to fluoxetine during development in a model of maternal adversity. Male offspring exposed to 
prenatal stress showed a decrease in BDNF IV mRNA levels, while no changes were observed at BDNF 
IX mRNA expression. Among prenatally stressed female offspring, an increase in BDNF IV mRNA 
levels was observed, while expression of BDNF IX mRNA was unchanged. Maternal fluoxetine exposure 
on the other hand decreased BDNF IV mRNA levels in the hippocampus of female offspring, while no 
changes were observed at the BDNF IX exon, i.e. the coding exon. These observations are rather 
provocative since the BDNF IV transcript corresponds to an alternative splice variant that is not 
representative of the total BDNF protein level. Similarly, in Chapter 7, we showed that BDNF IV mRNA 
levels were decreased in the hippocampus of GR-i mice, further supporting the exon-specific involvement 
of BDNF in the stress response regulation and in mediating depressive-like behaviour. Accordingly, it has 
been suggested that the use of distinct BDNF mRNA splice variants differing either by the 5’ or 3’ 
extremity allows for temporal and spatial regulation of BDNF expression, which appears to be critical in 
the modulation of synaptic plasticity and spine development in dendrites (Baj et al., 2011). BDNF exon 
IV contains specific binding sites for the glucocorticoid receptor, making it a target of choice for stress-
related events (Suri et al., 2013). In addition, BDNF exon IV contains specific binding sites for the cyclic 
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AMP response element binding protein (CREB) and methyl CpG binding protein 2 (MeCP2), making it a 
preferential epigenetic target (Dias et al., 2003; Martinowich et al., 2003). Accordingly, this exon has 
been shown to display a ubiquitous repartition in the brain and seems to play a key role in many processes 
related to mood, emotion, reward, learning and memory (see Chapter 2). Evidently, the exact role of the 
various BDNF transcripts and the complex regulation of BDNF mRNA and protein processing await 
further research. 
 
Regulation of BDNF/TrkB signaling by stress and glucocorticoids: Stress has been proposed as a major 
risk factor in the development of affective disorders and the persistent elevation of glucocorticoids 
induced by chronic stress can significantly alter BDNF production and impact on structural and functional 
plasticity in the hippocampus (Berton et al., 2006; Suri et al., 2013). As such, in Chapters 6, 7 and 8, we 
investigated the hippocampal regulation of the BDNF gene in two different rodent models of stress, as 
well as in a transgenic mouse model displaying impaired glucocorticoid receptor (GR) signaling. 
Interestingly, the expression of BDNF exon IV mRNA was decreased in the hippocampus of GR-
impaired (GR-i) mice. Previous experiments performed by our research group showed that GR-i mice 
displayed a deficit in the negative feedback regulation of the hypothalamo-pituitary-adrenal (HPA) axis 
under stressful conditions as well as in depressive-like behavior (Froger et al., 2004; Paizanis et al., 
2010). Hence, the decrease in BDNF and downstream neuroplastic effectors in the hippocampus of this 
transgenic mouse model supports the notion that HPA axis impairment may play a part in the 
pathophysiology of major depression, and that the neuronal loss and synaptic dysfunction induced by 
prolonged stress exposure might involve alterations in neurotrophic signaling. In line with this hypothesis, 
we found that exposure to early-life (i.e. prenatal restraint) stress in Sprague-Dawley rats reduced the 
expression of BDNF mRNA in the hippocampus of adult male offspring, and was associated with 
increased depressive-like behavior (Chapter 6). However, the opposite effect on BDNF IV mRNA levels 
was observed in the hippocampus of female offspring prenatally exposed to maternal stress. This latter 
observation indicates a sex-specific regulation of the response and adaptation to stress, potentially leading 
to differential expression of the BDNF gene. In humans, a clear sex difference exists in the incidence and 
onset of stress-related diseases (Wang et al., 2007). In contrast, rodent models of psychiatric disorders, 
because of the estrus cycle and concomitant fluctuation in sex hormones in females, are based principally 
on male animals. However, recent studies have showed that sex hormones, especially estrogen, could 
induce the expression of BDNF (Scharfman et al., 2006; Solum et al., 2002). Clearly, the link between 
glucocorticoids, sex hormones and neurotrophic signaling should be addressed more thoroughly. 
 
Further, exposure to repeated socio-environmental stressors of low intensity in adult C57Bl6J mice 
resulted in an increased BDNF IX mRNA expression and related plasticity pathways, in the hippocampus. 
Using this procedure, our research group previously reported a decrease hippocampal expression of GR 
mRNA in stressed mice (Froger et al., 2004). Endogenous decrease or pharmacological inactivation of 
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GR was shown to correlate with enhanced synaptic plasticity (Avital et al., 2006; Krugers et al., 2006). In 
addition, the mineralocorticoid receptors (MR), which bind glucocorticoids with high affinity, are most 
densely localized in hippocampal neurons (De Kloet ER, 2000). MRs are activated at low doses of 
glucocorticoids and have been associated with enhanced cognitive function and hippocampal plasticity 
(Avital et al., 2006; Sousa et al., 2008). Hence, the levels of glucocorticoids, as well as the balance 
between MRs and GRs, might play a critical role in the molecular, neuroendocrine and behavioral 
determination of the stress response. Of note, at the transcriptional level, GRs can affect BDNF 
transcription either by binding to GR binding elements (GREs) present in the promoter areas and 
therefore inhibit transcription (Zanchi et al., 2010), or by interfering with the transcription factors that 
normally activate BDNF transcription (Kassel et al., 2007).  
 
Altogether, the data presented in Chapters 6, 7 and 8 indicates that a clear link exists between stress, 
glucocorticoids and BDNF signaling, and suggest that the nature of the stressor (e.g. timing, duration, 
intensity), as well as genetic factors (e.g. GR polymorphism), are critically important in the determination 
of neuroplastic outcomes. This observation might explain, at least in part, the well-reported heterogeneity 
in stress responsivity and related pathologies.  
 
Matching BDNF expression and neurocircuits to behavior: Among several growth factors, BDNF has 
been postulated as a key mediator of the synaptic dysfunction and neuronal atrophy often observed in the 
prefrontal cortex and hippocampus of mood disorder patients (Duman et al., 2012). A decrease of BDNF 
and its tropomyosin-related kinase receptor (TrkB) were observed in the hippocampus of suicide 
completers and depressed patients (Autry et al., 2012; Dwivedi et al., 2003). In Chapters 6 and 7, we 
showed that the decrease of BDNF mRNA levels was associated with increased depressive-like behavior. 
According, male offspring that were subjected to prenatal stress exhibited decreased expression of the 
BDNF exon IV, concomitant with decreased swimming behavior in the forced swim test (FST). Similarly, 
female offspring that were exposed to maternal fluoxetine showed decreased expression of the BDNF 
exon IV and increased immobility in the FST. In GR-i mice, the decreased expression of the BDNF exon 
IV was associated with increased immobility in the tail suspension test (TST), decreased self-grooming, 
and increased fear and anxiety. Altogether, these findings suggest that BDNF/TrkB signaling and its 
associated plasticity are important in the regulation of mood. 
 
Generally, impaired BDNF levels and plasticity (i.e. neurogenesis) in the hippocampus of rodents have 
been associated with increased depressive-like behavior (Castren et al., 2010; Jha et al., 2011; Mirescu et 
al., 2006). However, depression is a very complex disease and is difficult to model in rodents. Since 
animals might not be able to express the complete symptomatology of the disease, a rational approach 
should consist into matching symptom-related endophenotypes to hypothetically malfunctioning brain 
circuits. The hippocampus is a major component of the limbic system	  known to be highly vulnerable to 
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stress and environmental variations, and is critically implicated in learning, memory and mood (see 
Chapter 3). However, in our experiments, stress or genetic variation may affect BDNF levels in various 
regions, and the observed changes in the hippocampus may not be solely attributed to the broad range of 
behavioral responses. Interestingly, approaches using region-specific knockdown or local infusion 
showed that BDNF-mediated plasticity in the hippocampus could be mostly associated with cognitive 
performance, fear memories and anxiety (Heldt et al., 2007; Quesseveur et al., 2013; Taliaz et al., 2010). 
Hence, it is possible that the observed decreased BDNF levels in the hippocampus are implicated 
predominantly in anxiety and in the cognitive symptoms of depression. In the hippocampus, BDNF/TrkB 
are abundantly expressed on neurons receiving serotonergic and glutamatergic afferences (Lessmann V, 
1998; Martinowich et al., 2008). Accordingly, the neuroplastic effects of BDNF on i.e. dendritic 
arborization, axonal growth, neuronal survival and neurotransmitter release might critically affect the 
development and functioning of specific neurotransmitter systems, which would explain at least in part 
some of the behavioral performances observed in our models. 
 
In contrast, the findings presented in Chapters 7 bring some novel insights into the region-specific 
regulation of BDNF/TrkB signaling in the pathophysiology of depression. We confirmed that the chronic 
blockade of BDNF/TrkB signaling by peripheral administration of Ana12, a recently developed TrkB 
inhibitor, could result in antidepressant-like effects in GR-i mice. These findings are rather provocative 
because a growing body of literature indicated similar effects after administration of BDNF directly in the 
hippocampus, or peripheral administration of TrkB agonists (Liu et al., 2010; Shirayama et al., 2002). 
However, as recently described by Cazorla and colleagues, Ana12 diffused preferentially in the striatum 
to inhibit TrkB (Cazorla et al., 2011). Interestingly, clean-cut evidence from both rodent and human 
studies demonstrated that stress and/or major depression is associated with increased BDNF levels in the 
mesolimbic dopaminergic system i.e. the nucleus accumbens (Krishnan et al., 2007). The ventral striatum, 
including the nucleus accumbens, plays a major part in reward, pleasure, interest, impulsivity and 
fatigue/energy. Accordingly, BDNF-mediated plasticity in the nucleus accumbens might be implicated in 
the hedonic symptoms of depression (Martinowich et al., 2008; Krishnan et al., 2007).  
 
Finally, in Chapter 8, we found that chronic exposure to low-intensity stress could be associated with 
hyperactivity. In this study, BDNF IX mRNA levels as well as neuroplasticity were increased in the 
hippocampus of mildly stressed mice. The relationship between hyperactivity and the hippocampus is not 
fully understood yet, but some evidence indicates that physical activity and exercise could significantly 
enhance hippocampal neurogenesis and plasticity (Van Praag et al., 1999; Fabel et al., 2008). In addition, 
a recent study provided evidence on the involvement of BDNF/TrkB signaling in enkephalinergic 
striatopallidal neurons in the control of locomotor behavior (Besusso et al., 2013). 
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Altogether, our data point to a complex region-specific regulation of BDNF/TrkB signaling in the 
pathophysiology of depression. BDNF/TrkB signaling is critically important in regulating plasticity in 
cortico-limbic structures. Hence, dysregulation of this neuroplastic signaling may impact on neuronal 
connectivity and neurotransmission in diverse brain regions, leading to a broad range of behavioral 
disturbances.  
 
 
II – BDNF/TrkB signaling in the mechanism of action of antidepressants 
 
Putative mechanism of the adverse effects of fluoxetine during early development: Fluoxetine, an 
antidepressant belonging to the class of SSRIs, is widely used in the clinic for the treatment of mood 
disorders during pregnancy and the post-partum period (Cooper et al., 2007). There is growing evidence 
that the use of this antidepressant during development has negative consequence on brain development 
and adult psychopathology (Pawluski et al., 2009; Laine et al., 2003; Oberlander et al., 2009). In 
adulthood, it is well established that fluoxetine increases BDNF levels (including BDNF IV mRNA 
levels) in cortico-limbic structures to induce antidepressive and anxiolytic effects in rodents (Martinowich 
et al., 2007). However, in Chapter 6, we found that early-life exposure to fluoxetine led to decreased 
levels of BDNF IV mRNA in male and female offspring in adulthood. These observations are rather 
interesting, and suggest that the molecular mechanisms involved in early-life versus e.g. adulthood 
intervention with fluoxetine are distinct. Serotonin plays an important role in the development of the brain 
modulating neuronal differentiation, axon guidance or dendritic pruning (Gaspar et al., 2003; Homberg et 
al., 2010). The serotonergic system is complex, and involves at least fifteen identified receptors 
associated with different intracellular transduction cascades (Gaspar et al., 2003). Hence, the pattern of 
expression of serotonin receptor subtypes might be critical during development, and in the determination 
of fluoxetine effects. In addition, during postnatal development, certain populations of neurons express a 
transient serotonergic phenotype that no longer exists in adulthood, and the modulation of this partial 
serotonergic system might interfere with the fine-tuning process of neuronal networks (Cases et al., 1998; 
Gaspar et al., 2003). Moreover, fluoxetine was shown to interact with several targets including serotonin 
receptors (2A, 2C and 2B) and ion channels (Mostert et al., 2008), in addition to the serotonin transporter 
(5-HTT). The differential patterns of expression of these systems in early-life might also be determinant 
in the long-term biological action of developmental fluoxetine exposure. 
Hence, future research should investigate the precise mechanisms of action of fluoxetine treatment during 
development in order to conclude whether the observed changes at BDNF signaling in adulthood are 
mediated via a direct effect of serotonin and its downstream signaling in developing neurons, via 
additional target systems of fluoxetine or via other compensatory mechanisms occurring later in life.  
 
Mechanism of action of agomelatine in the treatment of in mood disorders: As mentioned above, 
conventional antidepressants, via the modulation of monoaminergic signaling, are known to enhance 
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BDNF expression and neuroplasticity in cortico-limbic structures to exert their therapeutic effects 
(Castren et al., 2010). However, little is known about the neuroplastic mechanisms of action of the new 
generation antidepressant agomelatine. This atypical antidepressant acts as a mixed melatonin receptor 1 
and 2 agonist and serotonin receptor 2C antagonist (De Bodinat et al., 2010). In Chapters 7 and 8, we 
particularly focused on the molecular and neurotrophic actions of agomelatine in two mouse models of 
affective disorders. In GR-i mice, the decreased BDNF IV mRNA levels and deficit in cell proliferation 
in the hippocampus could be reversed by chronic agomelatine treatment. In addition, the marked decrease 
of Bcl2 and cFos mRNA levels in GR-i mice could be restored by chronic agomelatine treatment. All this 
neurochemical changes correlated with the reversal of depressive- and anxiety- like behavior in GR-i 
mice. These findings support the notion that antidepressant medications, including agomelatine, require 
BDNF/TrkB signaling to rescue the impairment of hippocampal plasticity and exert their therapeutic 
effects. However, in our model of chronic mild stress, where BDNF IX mRNA levels and neuroplasticity 
were increased, we found that chronic administration of agomelatine could restore a normal hippocampal 
function by decreasing the levels of BDNF and associated signaling pathways. Of note, agomelatine did 
not produce such effects in naïve animals. This finding is of particular interest and indicates that 
agomelatine, rather than directly targeting the BDNF/TrkB system, acts as a normalizing drug, thereby 
restoring/rebalancing gene expression specifically in pathological conditions. Accordingly, agomelatine is 
though to exert its effects via a re-synchronization of circadian rhythms (De Bodinat et al., 2010). 
Disruption of circadian periodicity, as well as seasonal changes, have been proposed as a major player in 
the onset of various mood disturbances (i.e. bipolar disorders, mania), and successful antidepressant 
treatments have been associated with normalization of disturbed biological rhythms (Harvey AG, 2008; 
Lanfumey et al., 2013). Moreover, in our model of chronic mild stress, which appears to mimic common 
symptoms usually observed in the mixed manic state of bipolar disorder, and shows neurobiological 
changes observed in mouse models of mania (including increased hippocampal BDNF levels), 
agomelatine was efficient in rescuing both the neurochemical and behavioral alterations. Hence, we 
carefully suggest that the modulation of melatonin receptors, possibly with additional blockade of 
serotonin 2c receptors, may provide a specific and innovative way to treat bipolar disorders. 
 
 
III – Epigenetic regulation of BDNF/TrkB signaling in mood disorders 
 
BDNF/TrkB signaling and chromatin remodeling in neuronal plasticity: The interaction of BDNF with 
its receptor TrkB plays a preponderant role in the induction and maintenance of neuronal plasticity (Chao 
MV, 2003). The action of BDNF on neuronal architecture and networks is tightly regulated by epigenetic 
re-arrangements at the chromatin level (Karpova N, 2013). Accordingly, BDNF has a complex gene 
structure that has been reported to be highly sensitive to environmental variations and concomitant 
epigenetic modifications (Tsankova et al., 2007) underlying changes in expression of downstream target 
genes. In Chapter 5, we explored the role of epigenetic regulation downstream of BDNF/TrkB signaling 
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using a pharmacological approach. We showed that chronic blockade of the BDNF receptor TrkB 
downregulates plasticity-related gene expression concomitant with epigenetic changes (e.g. post-
translational modifications at histone tails and MeCP2 binding) in cultured neuronal cells. These findings 
strongly suggest that TrkB signaling can underlie epigenetic remodeling at plasticity-related genes, and 
that its selective blockade is able to induce histone modifications in order to significantly alter neuronal 
plasticity. One might also suspect that the downregulation of BDNF/TrkB signaling observed in cortico-
limbic structures after severe or chronic stress might critically impact on the epigenetic program of 
neuronal cells, leading to reduced plasticity and thereby increasing the vulnerability towards mood 
disorders. 
 
Early-life events, brain development and epigenetic imprints: The modulation of gene expression by 
epigenetic mechanisms is essential during development, where a “cellular memory” is created enabling an 
appropriate pattern of gene expression and a specific cellular phenotype (Probst et al., 2009). Hence, 
early-life events, behavioral experience or genetic variations can influence epigenetic remodeling, and 
modulate neuronal architecture and networks during development (Roth et al., 2011). In Chapter 6, we 
showed that early-life exposure to maternal fluoxetine is associated with persistent epigenetic changes, 
e.g. H3K27 tri-methylation at the BDNF promoter IV, concomitant with decreased expression at the 
corresponding BDNF mRNA, in the hippocampus of adult female offspring prenatally exposed to stress. 
Of note, this effect was observed only in female offspring prenatally exposed to stress, indicating that 
maternal adversity increased the vulnerability for fluoxetine-induced epigenetic reprogramming in the 
hippocampus in a sex-dependent manner. In Chapter 7, we explored epigenetic processes in the 
hippocampus of the GR-i transgenic mice, in which a transgene affecting the GR expression is present 
throughout the lifespan. We found a marked alteration in the machinery controlling histone post-
translational modifications and DNA methylation, including e.g. decreased expression of the DNA 
methyltransferase 1 (DNMT1) gene, the DNA methyltransferase 3a (DNMT3a) gene, the histone-lysine 
N-methyltransferase HRX 3 (MLL3) gene and the histone-lysine N-methyltransferase HRX 4 (MLL4) 
gene. In addition, GR-i mice showed deficits in neurogenesis and decreased BDNF-related signaling in 
the hippocampus in adulthood. Glucocorticoid-related signaling is critical during brain development, by 
remodeling axon and dendrite networks as well as modulating neuronal maturation and survival (Lupien 
et al., 2009). Hence, it is tempting to speculate that changes in the machinery controlling epigenetic 
regulation during development are responsible for an epigenetic reprogramming associated with the 
observed permanent deficit in functioning of the adult hippocampus. Altogether, the data presented in 
Chapter 6 and 7 provide further evidence that early-life events, including exposure to drugs or stressful 
situation, are critical for brain development, and can have negative consequences involving persistent 
epigenetic imprints up to adulthood, that most likely increase the susceptibility for mood disorders.  
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Stress and epigenetic regulation in adulthood: Chromatin remodeling via histone modifications occurs 
in response to diverse environmental exposures, among which, stress insults have been most extensively 
described (Mifsud et al., 2011). At the molecular level, the sustained elevation of glucocorticoids 
observed in stressful situations might interfere with various intracellular signaling and transcriptional 
processes, and prolonged exposure to stress in adulthood have been shown to interact with the epigenome 
(Maze et al., 2013). In Chapter 8, we report that chronic exposure to a low-intensity socio-environmental 
stress could impact on chromatin regulation. We found that stress was associated with robust changes in 
epigenetic regulation and plasticity-related gene transcription. Chronic stress was associated with 
decreased HDAC2 and H3K27me3 levels in the hippocampus, while H3K9/14ac was increased in this 
same region. HDAC2 is a critical enzyme implicated in histone regulation, and low levels of this protein 
in the hippocampus have previously been shown to strongly correlate with enhanced synaptic plasticity 
(Guan et al., 2009). Further, in our model, there was also a robust increase in plasticity-related 
intracellular signaling pathways such as the mitogen-activated protein kinase (MAPK) cascade, after 
chronic exposure to stress. Hence, it remains speculative to conclude whether the changes in histone 
modifications correspond to the nuclear integration of the activated intracellular signaling cascades in 
response to stress, or whether stress directly affects histone-modifying enzymes, thereby inducing 
aberrant neuroplastic signaling. However, modifications at histone tails are considered as dynamic 
regulatory processes involved in gene transcription. Importantly, the alteration in the machinery 
controlling chromatin regulation and histone modifications, involving e.g. histone acetylating and 
methylating enzymes, might maintain stable patterns of gene expression and a persistent aberrant 
phenotype. 
 
In conclusion, it remains difficult to determine whether stress-induced histone modifications in adulthood 
represent a cause or a consequence of the disease progression, but it appears to be well established that 
such kind of chromatin regulations forms a core are part of the neurobiological alterations observed in 
adult animal models of stress and related mood disorders. In this context, genetic association studies 
investigating the role of functional single nucleotide polymorphisms (SNPs) of genes involved in 
epigenetic regulations in mood disorder patients should be addressed.  
 
 
IV – Perspectives for the development of novel antidepressant drugs 
 
Targeting BDNF/TrkB signaling to modulate epigenetic-mediated neuroplasticity: As described above, 
BDNF/TrkB signaling plays a critical role in neuronal plasticity, and appears to be required for the 
therapeutic action of antidepressants (Castren et al., 2010). However, the use of BDNF as a therapeutic 
treatment encounters many limitations, BDNF has a poor blood brain barrier penetration, low oral 
bioavailability and short half-life in plasma (Poduslo et al., 1996). In addition, the interaction of BDNF 
with pro-apoptotic p75 receptor might result in undesirable effects (Zhang et al., 2008). As such, the 
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development of specific small-molecule TrkB ligands has recently emerged, and so far, only a limited 
amount of candidates have been identified and characterized (see Chapter 3). Peripheral administration 
of small synthetic TrkB agonists could induce neurogenesis and antidepressant-like properties in rodents 
(Liu et al., 2010). Nevertheless, we found that Ana12, a small non-peptidic, TrkB inhibitor could induce 
antidepressant effect in GR-i mice. These data are in accordance with a hypothetic region-specific 
regulation of BDNF in the pathophysiology of depression, and provide novel insights into the therapeutic 
role of TrkB inhibitors in mood disorders. However, the use of TrkB antagonists as a therapeutic 
treatment for mood disorders should be regarded with caution, since we also observed signs of increased 
anxiety after chronic treatment with Ana12 (Chapter 7).  
 
Nevertheless, modulating the expression of specific BDNF exons in a targeted fashion may represent a 
promising strategy to restore enduring changes in gene expression induced by e.g. repeated environmental 
insults. In view of the region-specific distribution of BDNF transcripts in the brain and their functionally 
distinct roles, developing compounds that modulate the transcription of specific BDNF exons will provide 
considerable advantages and possibly avoid undesirable side effects. In this context, it was recently 
shown that a neutralizing inhibitor of miR-206, a small non-coding RNA regulating the expression of 
BDNF, could target specific BDNF transcripts to prevent detrimental effects of amyloid beta in a mouse 
model of Alzheimer disease (Lee et al., 2012). This finding should spur researchers to further investigate 
the possible role of such experimental strategies e.g. RNA interference therapy in the treatment of mood-
related disorders.  
 
Since aberrant BDNF signaling might play a critical role in the pathophysiology and/or treatment of mood 
disorders, directly targeting epigenetic modifications at the BDNF gene promoters represents another 
promising strategy to enduringly reverse abnormal BDNF expression and engender long-lasting clinical 
benefits. Interestingly, in Chapters 5 we show that cyclotraxin-B, a specific TrkB inhibitor, induces a 
lasting downregulation of the expression of a subset of genes involved in neuroplasticity pathways, 
concomitant with post-translational modifications at histone tails as well as altered MeCP2 binding at 
those genes. Hence, our findings provide further insight into the neuroplastic and epigenetic effects of 
TrkB modulators, and point out that the ability of TrkB antagonists to reverse abnormal BDNF-mediated 
epigenetic remodeling in the dopaminergic system could bear therapeutic value. 
 
Bcl2 as a promising therapeutic target for mood disorders: In the research work presented in this thesis, 
we studied BDNF/TrkB signaling and its downstream signaling pathways in various models, and using 
different approaches. It is interesting to note that, among all the TrkB target genes examined, the b-cell 
lymphoma 2 (Bcl2) gene was most consistently affected in our models. Accordingly, in Chapter 7, we 
found that GR impairment was associated with a robust decrease of Bcl2 mRNA levels in the 
hippocampus, and that this deficit was restored by chronic antidepressant treatment. Further, we found 
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that the Bcl2 gene expression was decreased by pharmacological intervention aiming at blocking the 
TrkB receptor (Chapter 5 and 7). In addition, the chronic downregulation of BDNF/TrkB signaling was 
associated with lasting epigenetic remodeling at the Bcl2 gene promoter (Chapter 5). Bcl2 has been 
described as an important regulator of cell survival (Davies, 1995), and antidepressants and mood 
stabilizers have been shown to enhance the expression of Bcl2 in rodents (Hunsberger et al., 2009; Kosten 
et al., 2007). Hence, compounds that specifically increase Bcl2 levels in cortico-limbic areas might be a 
therapeutic strategy for the treatment of mood disorders. 
 
Chromatin-modifying drugs in the treatment of mood disorders: As mentioned in the previous sections, 
our findings on epigenetic dysregulations in the hippocampus support the notion that chromatin 
remodeling via histone modifications can increase the susceptibility for mood disorders. In Chapter 7 
and 8, we provide further insight into the epigenetic potential of antidepressants. We showed that the 
altered HDAC2 levels, as well as post-translational modifications at histone tails (e.g. H3K27me3 and 
H3K9/14ac) in adult mice subjected to prolonged exposure to stress can be restored by chronic treatment 
with agomelatine. The reversal of chromatin-related alterations correlated with behavioral remission 
indicating that epigenetic processes are required for the therapeutic action of antidepressants. In contrast, 
chronic agomelatine treatment could not restore the alterations of epigenetic regulation (e.g. DNMT1, 
DNMT3a, MLL3 and MLL4) in GR-i mice. Although these results are conflicting, other studies have 
reported that antidepressants require epigenetic regulation to mediate their neurochemical and behavioral 
effects. The positive effect of chromatin modifying drugs in animal models of mood disorders further 
support this hypothesis. In particular, HDAC inhibitors and DNMT inhibitors represent potentially 
powerful agents for the treatment of psychiatric disorders through regulation of plasticity-related gene 
expression (Sales et al., 2011; Covington et al., 2009). On the other hand, these molecular agents are 
expected to exert their effects on a substantial proportion of the genome, thereby most likely inducing 
numerous negative side effects. More specifically, inhibitors of DNA methylation have been suggested to 
promote cancer metastasis, systemic lupus erythematosus or other autoimmune diseases. Nevertheless, 
several epigenetic drugs targeting DNA methylation and histone deacetylation enzymes have recently 
been approved for clinical application in oncology, while some are still being tested in clinical trials 
(Arrowsmith et al., 2012). Hence, in a first step of research, future clinical studies should investigate 
whether such drugs exhibit better remission rates on depressed mood in cancer patients suffering from co-
morbid depression. This would provide a first line of clinical evidence for potential therapeutic effects of 
epigenetic drugs in the treatment of mood disorders. 
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IV – Concluding remarks 
 
In the present thesis, we have investigated the involvement of BDNF/TrkB signaling and its downstream 
epigenetic regulation in the pathophsyiology and treatment of mood disorders using different rodent 
models and approaches. Our findings indicate that epigenetic regulation at BDNF/TrkB signaling is 
critically important in the establishment and maintenance of neuronal plasticity. Moreover, adverse 
environmental exposures, especially when occurring during development, are able to induce stable and 
enduring epigenetic reprogramming involving aberrant BDNF/TrkB signaling and impaired 
neuroplasticity, thereby increasing the vulnerability to stress and related mood disorders. Interestingly, 
antidepressants require TrkB to exert some of their neurochemical and behavioral effects. Hence, 
targeting the BDNF receptor TrkB in order to restore plasticity-related gene expression and associated 
neuronal functioning appears to be a promising strategy for the treatment of mood disorders.  
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SUMMARY 
 
 
 
 
     Mood disorders are among the major health problems worldwide due to the high prevalence and 
recurrence in the general population, and the significant burden for individual life quality and the 
repercussion on healthcare systems and society. Up to date, the etiology and biological mechanisms 
underlying mood disorders are still poorly understood. Mounting evidences suggest that a complex 
interaction between genes and environment might account in the development and course of major 
depression i.e. one of the most prevalent affective disorders. Accordingly, complex epigenetic regulations 
- consisting of key mechanisms by which environmental factors induce enduring changes in gene 
expression without altering the DNA code - have been suspected to plays a pivotal role in the 
pathophysiology of depression. More specifically, epigenetic repression of the gene encoding for brain-
derived neurotrophic factor (BDNF) - a small-secreted growth factor implicated in brain development and 
neuronal plasticity - may have a preponderant role in the onset of depression and other mood disorders.  
 
     In this context, the research presented in this thesis aimed at exploring the role of BDNF signaling and 
its downstream epigenetic regulations in the pathophysiology and treatment of mood disorders.  
 
     Our findings indicate that epigenetic regulation at BDNF/TrkB signaling is critically important in the 
establishment and maintenance of neuronal plasticity. Moreover, environmental variations, especially 
when occurring in development, are able to induce stable and enduring epigenetic reprogramming 
involving aberrant BDNF/TrkB signaling and impaired neuroplasticity, thereby increasing vulnerability to 
stress and mood disorders. Interestingly, antidepressants require TrkB to exert some of their 
neurochemical and behavioral effects. Hence, targeting the BDNF receptor TrkB to restore a normal 
epigenetic regulation and neuronal functioning appears to be a promising strategy for the treatment of 
mood disorders.  
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RESUME 
 
 
 	  	  	  	  	  	  	  	  Les troubles de l’humeur font partie des problèmes de santé majeurs dans le monde, du fait de leur 
forte incidence et récurrence dans la population générale, de la nuisance pour la qualité de vie des patients 
ainsi que la répercussion majeure sur les systèmes de santé. A ce jour, l’étiologie ainsi que les 
mécanismes biologiques sous-jacents les troubles de l’humeur sous encore très mal connus. Un nombre 
grandissant de preuves suggère qu’une interaction complexe entre les gènes et l’environnement serait a 
l’origine de la mise en place et évolution des épisodes dépressifs majeurs – un des troubles de l’humeur 
les plus répandus. Par conséquent, des régulations épigénétiques complexes, qui consistent en des 
mécanismes clefs par lesquels l’environnement induit des changements persistant sur l’expression des 
gènes (sans modifier le code génétique), joueraient un rôle prépondérant dans la pathophysiologie de la 
dépression. De manière plus spécifique, la répression épigénétique du gène codant pour le brain-derived 
neurotrophic factor (BDNF) – un facteur de croissance impliqué dans la plasticité neuronale et 
développement du système nerveux central – serait un mécanisme clef dans la mise en place de la 
dépression et autres troubles de l’humeur.  
 
     Dans ce contexte, les travaux de recherche présentés dans cette thèse visent à explorer le rôle des 
régulations épigénétiques au niveau de la signalisation BDNF/TrkB dans la physiopathologie et 
traitement des troubles de l’humeur. 
 
     Les résultats montrent que les régulations épigénétiques au niveau de la signalisation BDNF/TrkB sont 
fortement impliquées dans la mise en place et maintenance de la plasticité neuronale. De plus, les 
variations environnementales, particulièrement au cours du développement, sont capables d’induire une 
reprogrammation épigénétique stable et persistante au niveau du complexe BDNF/TrkB ainsi qu’une 
altération de la neuroplasticité, conduisant à une augmentation de la vulnérabilité au stress et troubles de 
l’humeur. De manière intéressante, la signalisation du récepteur TrkB est nécessaire pour les effets 
neurobiologiques et comportementaux des antidépresseurs. De ce fait, une approche pharmocologique 
ciblée sur le complexe BDNF/TrkB et ses régulations épigénétiques sous-jacentes apparaît comme 
stratégie thérapeutique prometteuse pour le traitement des troubles de l’humeur tel que la dépression. 
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